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I. Abstract  
Hematopoietic stem cells (HSCs) reside at the top of a tightly regulated and hierarchically 
organized differentiation cascade. They are multipotent and able to self-renew, thereby 
ensuring life-long replenishment of mature blood cells. In-depth Omics analyses within the 
hematopoietic hierarchy, including analysis of HSCs and multipotent progenitor (MPP) cells, 
revealed not only differential expression of protein-coding genes, but also HSC-specific 
splicing variants and expression of long non-coding RNAs (lncRNAs) upon HSC commitment 
(Cabezas-Wallscheid et al., 2014; Klimmeck et al., 2014; Luo et al., 2015). Functional analyses 
revealed that non-coding RNAs and regulation of RNA biogenesis are crucial for HSC function 
and potency. In this thesis, the role of the lncRNA maternally expressed gene 3 (Meg3) in 
hematopoiesis is studied. In addition, I introduce the RNA regulatory mechanism alternative 
polyadenylation (APA) as a mechanism controlling HSC/MPP biology in homeostasis and 
during replicative stress response by extensive in silico, in vitro and in vivo analyses. 
Furthermore, I generated an inducible knockout mouse model, targeting the prominent APA 
regulator poly(A) binding protein 1 (Pabpn1). Thereby, I aimed to dissect the general role of 
lncRNAs and RNA regulatory mechanisms in hematopoiesis. 
Project 1: The role of the lncRNA Meg3 in HSCs 
The tumor suppressor lncRNA Meg3 is encoded in the imprinted Dlk1-Meg3 locus and 
expressed from the maternally inherited allele (Zhou et al., 2012). We and others found Meg3 
to be highly and specifically expressed in the HSC compartment compared to MPP cells. In 
this thesis, I crossed an inducible Meg3 flox mouse model (Klibanski et al., unpublished) to 
MxCre mice, generating MxCre Meg3 mat flox/pat wt mice. Cre-induction deleted the maternal allele 
in the hematopoietic compartment and thereby completely abrogated the expression of Meg3 
and its associated miRNA cluster in HSCs. Extensive in vivo and in vitro analyses of adult mice 
harboring a Meg3-deficient blood system surprisingly did not reveal any impairment of 
hematopoiesis or stem cell function. In addition, I performed serial transplantation assays to 
investigate the functional capacity of Meg3-deficient HSCs. Again, knockout cells did not 
exhibit altered blood contribution, even upon tertiary transplantation. Imprinting of the Dlk1-
Meg3 locus has recently been reported to regulate fetal liver HSC function (Qian et al., 2016). 
To analyze effects of the hematopoiesis-specific Meg3 knockout in the developing embryo, we 
generated VavCre Meg3 mat flox/pat wt mice. Cre+ offspring were born and developed normally. In-
depth analysis of adult animals revealed loss of Meg3 expression in HSCs, but again no 
hematopoietic impairments were detected. Next, I performed interferon-mediated stimulation 
in MxCre Meg3 mat flox/pat wt mice. During both activation and recovery phase, Meg3-deficient 
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adult HSCs responded highly similar compared to controls. Taken together, my work shows 
that the highly expressed, imprinted lncRNA Meg3 is dispensable for the function of HSCs 
during adulthood and embryonic development. In the adult system, loss of Meg3 does not 
impair the performance in serial reconstitution assays or response to stress mediators. 
(Sommerkamp et al., 2019) 
Project 2: HSC function, differentiation and activation are regulated by APA 
The majority of mammalian genes have multiple different polyadenylation sites. The RNA 
editing mechanism APA controls the selection of these sites, thereby altering 3’-UTR length 
and isoform expression. Thus, APA modulates RNA stability, localization, protein output and 
even protein localization (Di Giammartino et al., 2011; Tian and Manley, 2017). So far, the role 
of APA in the regulation of the adult HSC/MPP compartment has not been studied. In this 
thesis, I show that the APA regulator Pabpn1 is essential for HSCs, as knockdown (KD) of 
Pabpn1 led to decreased HSC function in vitro and in vivo. To analyze the prevalence of APA 
at the top of the hematopoietic hierarchy, I established an ultra-low input 3’-Seq approach and 
performed analysis of HSCs, MPP cells and HSCs activated by inflammation. Bioinformatic 
analysis revealed dynamic APA patterns in numerous genes between HSCs and MPPs as well 
as during inflammation-induced HSC stress response. We observed global 3’-UTR shortening 
both upon HSC differentiation towards MPPs and HSC activation. Further, 3’-Seq analysis of 
Pabpn1 KD cells revealed that PABPN1 regulates APA in the HSC/MPP compartment. We 
observed an APA-mediated glutaminase (Gls) isoform switch upon exit of HSCs from 
quiescence. Gls isoform switching led to enhanced relative expression of the highly active GLS 
GAC isoform and overall increased GLS protein levels. In line, small molecule-mediated 
inhibition of glutaminolysis in vitro enhanced HSC maintenance by limiting proliferation. I could 
show that Gls isoform switching leading to increased glutaminolysis is mediated by the APA 
regulator NUDT21 and in turn is required for proper HSC function. KD of Nudt21 led to 
inhibition of Gls isoform switching, impaired HSC function and a partial block in HSC 
differentiation. In summary, my results install differential employment of APA and associated 
glutamine metabolism adaptations as novel layers in the regulation of the HSC-controlled 
hematopoietic hierarchy. (Sommerkamp et al., under revision) 
Project 3: Generation of Pabpn1flox mice 
To enable in-depth in vivo analysis of the role of APA in different tissues and disease settings 
in the future, we generated an inducible Pabpn1flox mouse model. Here, we used the Easi-
CRISPR approach (Miura et al., 2018; Quadros et al., 2017) to generate transgenic animals. I 
performed extensive in vitro testing of various guide RNAs (gRNAs) to optimize recombination 
efficiency in vivo. Two different crRNA-tracrRNA:Cas9 complexes targeting upstream and 
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downstream genomic regions, respectively, were injected into one of the pronuclei of zygotes 
together with a long single-stranded DNA (ssDNA) template. By extensive genotyping, I 
identified 3 of 17 offspring animals to be correctly targeted. Homozygous offspring mice were 
successfully bred and can be used in the future to determine functionality of the Pabpn1flox 
mouse model and to functionally asses the role of APA in different biological settings.  
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II. Zusammenfassung 
Hämatopoetische Stammzellen (HSZs) befinden sich an der Spitze einer präzise regulierten, 
hierarchisch organisierten Differenzierungskaskade. Sie sind multipotent und können sich 
selbst erneuern, wodurch die lebenslange Generierung reifer Blutzellen sichergestellt wird. 
Detaillierte „Omics“-Analysen innerhalb der hämatopoetischen Hierarchie, einschließlich 
Analysen von HSZs und multipotenten Vorläuferzellen (MPPs), zeigten nicht nur eine 
differenzielle Expression von proteinkodierenden Genen, sondern auch von Isoformen die 
durch alternatives Spleißen entstehen und von langen nicht-kodierenden RNAs (lncRNAs) 
(Cabezas-Wallscheid et al., 2014; Klimmeck et al., 2014; Luo et al., 2015). Daher scheint die 
Expression von nicht-kodierenden RNAs und die Regulation der RNA-Biogenese 
entscheidend für die HSZ-Funktion und Potenz zu sein. In der vorliegenden Doktorarbeit habe 
ich die Rolle der lncRNA „maternally expressed gene 3“ (Meg3) in der Hämatopoese 
analysiert. Darüber hinaus habe ich die Rolle des RNA-Regulierungsmechanismus „alternative 
Polyadenylierung“ (APA) im HSZ/MPP-Kompartiment studiert und ein induzierbares Knockout-
Mausmodell des APA-Regulators „poly(A) binding protein 1“ (Pabpn1) generiert. Ziel meiner 
Arbeit war es, ein besseres Verständnis der Rolle von lncRNAs und RNA-
Regulationsmechanismen im Allgemeinen in der Hämatopoese zu entwickeln. 
Projekt 1: Die Rolle der lncRNA Meg3 in HSZs 
Die Tumorsuppressor lncRNA Meg3 ist im „imprinted“ Dlk1-Meg3-Locus kodiert und wird vom 
mütterlich vererbten Allel exprimiert (Zhou et al., 2012). Wir und andere Forschungsgruppen 
fanden heraus, dass Meg3, im Vergleich zu MPP-Zellen, sehr stark und spezifisch im HSZ-
Kompartiment exprimiert wird. In dieser Doktorarbeit habe ich ein induzierbares Meg3 flox-
Mausmodell (Klibanski et al., unveröffentlicht) verwendet und mit MxCre Tieren verpaart. 
Dadurch wurden MxCre Meg3 mat flox/pat wt Mäuse generiert. Die Cre-Induktion, welche zur 
Deletion des mütterlichen Allels führt, war ausreichend, um die Meg3-Expression und die 
Expression des zugehörigen miRNA-Clusters in HSZs vollständig zu hemmen. Umfangreiche 
in vivo und in vitro Analysen von adulten Mäusen mit einem Meg3-defizienten Blutsystem 
zeigten keine Beeinträchtigungen der Hämatopoese und Stammzellfunktion. Darüber hinaus 
habe ich serielle Transplantationsexperimente durchgeführt, um die Funktionsfähigkeit von 
Meg3-defizienten HSZs zu untersuchen. Auch hier konnte ich keine Beeinträchtigungen von 
Knockout-Zellen feststellen, selbst nicht in tertiären Transplantationsexperimenten. Vor 
Kurzem wurde gezeigt, dass korrektes „Imprinting“ des Dlk1-Meg3-Locus essentiell für die 
Funktion embryonaler Leber-HSZ ist (Qian et al., 2016). Um die Auswirkungen eines 
Hämatopoese-spezifischen Meg3-Knockout auf den sich entwickelnden Embryo zu 
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analysieren, habe ich VavCre Meg3 mat flox/pat wt Mäuse generiert. Cre+ Nachkommen wurden 
geboren und entwickelten sich normal. Eine eingehende Analyse der erwachsenen Tiere 
ergab, dass der Verlust der Meg3 Expression in HSZs auch in diesem Kontext nicht zu einer 
hämatopoetischen Beeinträchtigung führt. Darüber hinaus habe ich interferonvermittelte 
Stimulationsexperimente in MxCre Meg3 mat flox/pat wt Mäusen durchgeführt, die zu einer HSZ-
Aktivierung führen. Während der Aktivierungs- und Erholungsphase reagierten Meg3-
defiziente adulte HSZs sehr ähnlich wie Kontroll-HSZs. Zusammenfassend konnte ich zeigen, 
dass die stark exprimierte „imprinted“ lncRNA Meg3 für die Funktion von HSZs im adulten 
Stadium und in der Embryonalentwicklung nicht essenziell ist. Meine Ergebnisse zeigen, dass 
im adulten System der Verlust von Meg3 die Reaktion auf Stressmediatoren und die Funktion 
in seriellen Transplantationsexperimenten nicht beeinträchtigt. (Sommerkamp et al., 2019) 
Projekt 2: Hämatopoetische Stammzellfunktion, -differenzierung und -aktivierung 
werden durch APA reguliert. 
Für die meisten Säugetiergene existieren mehrere verschiedene Polyadenylierungsstellen. 
APA kontrolliert die Selektion der Polyadenylierungsstellen und ändert dadurch die 3'-UTR 
Länge und die Isoform Expressionsmuster. So moduliert APA die RNA-Stabilität, RNA-
Lokalisierung, Proteinproduktion und die Proteinlokalisierung (Di Giammartino et al., 2011; 
Tian and Manley, 2017). Die Rolle der APA bei der Regulation des adulten hämatopoetischen 
Systems ist derzeit unbekannt. In dieser Doktorarbeit zeigen wir, dass der APA-Regulator 
Pabpn1 für HSZs essenziell ist. Der „Knockdown“ (KD) von Pabpn1 führte zu einer 
verminderten HSZ-Funktion in vitro und in vivo. Um die Prävalenz von APA an der Spitze der 
hämatopoetischen Hierarchie zu analysieren, habe ich einen 3'-Sequenzierungsansatz für 
geringe RNA Mengen etabliert und HSZs, MPP-Zellen und durch Entzündungsmediatoren 
aktivierte HSZs analysiert. Die bioinformatische Analyse ergab dynamische APA-Muster in 
zahlreichen Genen von HSZs und MPPs und während der entzündungsinduzierten HSZ-
Stressreaktion. Wir konnten eine globale Verkürzung der 3'-UTR Länge beobachten, ausgelöst 
durch HSZ-Differenzierung und HSZ-Aktivierung. Weiterhin konnten wir durch die 3'-Seq-
Analyse von Pabpn1 KD-Zellen zeigen, dass Pabpn1 APA im HSZ/MPP-Kompartiment 
reguliert. Wir beobachteten eine APA-vermittelte Veränderung der Glutaminase (Gls) Isoform-
Expression nach HSZ Aktivierung. Die Veränderung der Gls Isoform-Expressionsmuster führte 
zu einer erhöhten relativen Expression der hochaktiven Gls Isoform GAC und zu insgesamt 
erhöhtem GLS Proteinlevel. Kurzfristige Hemmung der Glutaminolyse in vitro verbesserte die 
HSZ Kultivierung durch Begrenzung der Proliferation. Ich konnte zeigen, dass die veränderte 
Gls Isoform-Expression und die erhöhte Glutaminolyse durch den APA-Regulator NUDT21 
vermittelt wird und für eine einwandfreie HSZ-Funktion erforderlich ist. KD von Nudt21 hemmte 
das Umschalten des Gls Isoform-Expressionsmuster und führte damit zur Beeinträchtigung 
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der HSZ-Funktion und einer teilweisen Inhibition der Differenzierung. Zusammenfassend 
zeigen meine Daten, dass APA und die damit verbundenen Anpassungen des 
Glutaminstoffwechsels unterschiedlich zwischen HSZ und MPPs reguliert sind und diese 
Mechanismen einen Beitrag zur Regulation der hämatopoetischen Hierarchie darstellen. 
(Sommerkamp et al., in Revision) 
Projekt 3: Generierung von Pabpn1flox-Mäusen 
Um in der Zukunft eine eingehende Analyse der Rolle von APA in vivo in verschiedenen 
Geweben und Krankheitsbildern zu ermöglichen, haben wir ein induzierbares Pabpn1flox 
Mausmodell mittels Easi-CRISPR Ansatz generiert (Miura et al., 2018; Quadros et al., 2017). 
Ich habe umfangreiche in vitro Analysen zur Bestimmung der Effizienz verschiedener 
„guideRNAs“ (gRNAs) durchgeführt, um die Rekombinationseffizienz in vivo zu verbessern. 
Zwei verschiedene crRNA-tracrRNA:Cas9-Komplexe, die auf die vor und nach der 
entsprechenden Gensequenz lokalisierten genomischen Regionen abzielen, wurden 
zusammen mit einer langen einzelsträngigen DNA (ssDNA) Matrize in einen der Pronuclei der 
Zygoten injiziert. Durch umfangreiche Genotypisierung konnte ich 3 von 17 Nachkommen als 
korrekt modifiziert identifizieren. Homozygote Nachkommen konnten erfolgreich gezüchtet 
werden und können in der Zukunft verwendet werden, um die Funktionalität des Pabpn1flox 
Mausmodells zu bestimmen und APA in verschiedenen biologischen Fragestellungen 
funktionell zu untersuchen.  
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1 Introduction 
1.1 The hematopoietic system 
1.1.1 Stem cell hierarchies 
Development and growth of multicellular organisms ultimately depend on the constant 
production of terminally differentiated cells. During adulthood, production of new cells is vital 
to enable tissue maintenance and regeneration, as many terminally differentiated cells have a 
limited lifespan, for example mature cells in the gastrointestinal tract, in the skin and in the 
blood. The centerpiece of embryonic development, growth and tissue regeneration are stem 
cells. (Alberts, 2008) 
Mammalian development starts from a single totipotent zygote. This cell and its progeny cells 
in the early morula are able to give rise to all cell types found in the embryo and extraembryonic 
trophoblast cells. In the blastocyst state, the cells of the inner cell mass are pluripotent. They 
can give rise to all the three different germ layers, namely endoderm, mesoderm and ectoderm, 
but not to the outer trophoblast layer. Pluripotent embryonic stem cells (ESCs), which are 
widely used nowadays for in vitro stem cell research of potency and cell fate decisions, are 
derived from the inner blastocyst cell mass. During development, cells become increasingly 
more specified and their overall stem cell potential decreases. No pluripotent stem cells can 
be found in the adult organism. Thus, embryonic development in itself can serve as a 
paradigmatic example of hierarchical cellular organization. (Alberts, 2008) 
These hierarchical organization patterns are also omnipresent in the adult organism. 
Multipotent tissue stem cells generate progeny to ensure tissue function and regeneration 
throughout life (Fuchs and Chen, 2013). They can only differentiate into cell types of the 
respective tissue and are able to self-renew. Nowadays, in vitro reprogramming of these 
restricted multipotent adult stem cells and even of mature cell types into naïve, embryonic 
states is possible and led to the generation of induced pluripotent stem cells (iPSCs) 
(Takahashi et al., 2007; Takahashi and Yamanaka, 2006; Yu et al., 2007). Traditionally, life-
long self-renewal has been defined as a hallmark of tissue stem cells (Fuchs and Chen, 2013). 
It has become apparent that aging, reduced regenerative capacity and disease development 
are associated with tissue stem cell exhaustion (Ahmed et al., 2017; Ermolaeva et al., 2018). 
Thus, aging is intrinsically associated with a loss of stem cell potency and function.  
In general, tissue stem cells are thought to divide rather infrequently, giving rise to progenitor 
cells by asymmetric cell division (Morrison and Kimble, 2006). Asymmetric cell division allows 
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maintenance of the multipotent stem cell pool and at the same time enables production of a 
daughter progenitor cell (Morrison and Kimble, 2006). These progenitor cells divide rapidly and 
develop into short-lived oligopotent progenitor populations, which eventually give rise to 
terminally differentiated functional cells of the respective tissue (Orkin and Zon, 2008). This 
differentiation axis, stem cells – progenitor cells – differentiated cells, is the core of the classical 
hierarchical differentiation tree of cell production in the adult organism (Morrison and Spradling, 
2008). With differentiation, cells become increasingly more specified and at the same time 
progressively lose cellular potency (Morrison and Spradling, 2008). It has become apparent 
that this unidirectional hierarchical differentiation tree can serve as a model to study and 
describe stem cells, differentiation and cell fate decisions. However, shortcuts and return paths 
seem to exist in this hierarchy, indicating towards more flexible and less unidirectional 
differentiation pathways (Sanchez Alvarado and Yamanaka, 2014). In addition, stem cell 
differentiation and lineage commitment seem to be a continuous process rather than a 
stepwise generation of increasingly restricted progenitors and differentiated cells (Haas et al., 
2018).  
Many different mammalian tissue stem cells and associated differentiation hierarchies have 
been studied to date. Until now, however, hematopoietic stem cells (HSCs) remain the best 
characterized adult tissue stem cell population in the human and murine system. Classically, 
HSCs are defined as multipotent stem cells that are responsible for life-long production of all 
mature blood cells and are considered to represent the centerpiece of hematopoiesis (Orkin 
and Zon, 2008; Seita and Weissman, 2010; Weissman and Shizuru, 2008).  
1.1.2 Hematopoiesis 
Most mature blood cells are relatively short-lived. Mature erythrocytes, for example, have a 
limited lifespan of approximately 120 days (Shemin and Rittenberg, 1946). Thus, HSCs are 
essential to ensure lifelong replenishment of mature functional blood cells, including 
erythrocytes, megakaryocytes/platelets, myeloid cells like monocytes, macrophages and 
granulocytes, mast cells, dendritic cells (DCs) and lymphocytes like T cells, B cells and natural 
killer (NK) cells (Seita and Weissman, 2010). In the adult organism, HSCs mainly reside in the 
bone marrow (BM), where also the majority of blood and immune cell maturation takes place 
(Mendelson and Frenette, 2014; Morrison and Scadden, 2014). If not indicated otherwise, this 
introduction focusses on murine hematopoiesis.  
1.1.2.1 The hematopoietic hierarchy 
The hematopoietic system is hierarchically organized (Figure 1.1). HSCs are at the top of the 
hematopoietic hierarchy, are able to self-renew and give rise to all different lineages of the 
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blood (Orkin and Zon, 2008; Seita and Weissman, 2010; Weissman and Shizuru, 2008). 
Traditionally, HSCs are identified by their ability to serially repopulate the BM of lethally 
irradiated recipient mice generating life-long multilineage cellular output (Purton and Scadden, 
2007; Till and McCulloch, 1961). The classical hematopoiesis model is defined by 
unidirectional, binary cell-fate decisions and stable progenitor cell populations (Figure 1.1) 
(Haas et al., 2018). Multipotent HSCs beget multipotent progenitor 1 (MPP1) cells, which have 
slightly reduced stem cell capacity (Wilson et al., 2008; Wilson et al., 2007). This population 
differentiates into MPP2, MPP3 and MPP4 cells. These MPP populations are more proliferative 
than HSCs (Passegue et al., 2005; Wilson et al., 2008). However, their long-term engraftment 
in experimental settings is reduced, and they show a lineage-bias in transplantation 
experiments (Cabezas-Wallscheid et al., 2014; Pietras et al., 2015). MPP cells are traditionally 
thought to differentiate into oligopotent progenitor cells, namely common myeloid progenitors 
(CMPs), which give rise to the myeloid lineage, and common lymphoid progenitors (CLPs), 
which give rise to the lymphoid lineage (Akashi et al., 2000; Kondo et al., 1997). CMPs 
differentiate into more restricted oligopotent progenitors, the megakaryocyte-erythrocyte 
progenitors (MEPs) and the granulocyte-macrophage progenitors (GMPs) (Akashi et al., 
2000). MEPs are restricted to generation of cells belonging to the megakaryocyte and 
erythrocyte lineage, while GMPs give rise to the granulocyte and macrophage lineages (Akashi 
et al., 2000). Oligopotent progenitors are even more restricted in their potency and generate 
lineage-restricted progenitor cells, including megakaryocyte (Mk) and erythrocyte progenitors 
as well as Pro-DCs, Pro-T cells, Pro-NK cells and Pro-B cells (Seita and Weissman, 2010; 
Weissman and Shizuru, 2008). Pro-DCs are thought to be generated by CMPs as well as 
CLPs, representing a myeloid/lymphoid lineage cell population (Weissman and Shizuru, 2008). 
These restricted progenitors later differentiate into mature effector cells generating platelets, 
erythrocytes, granulocytes, macrophages, DCs, T cells, NK cells and B cells.  
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Figure 1.1: Classical hematopoietic hierarchy.  
The multipotent HSC sits at the top of the hierarchy giving rise to different MPP subsets (MPP1-4). Distinct 
branchpoints are identifiable between the erythrocyte-myeloid lineage and the lymphoid lineage. Oligopotent 
progenitor populations give rise to lineage-restricted progenitors, eventually differentiating into mature effector cells. 
Self-renewal capacity is highest in the HSC population and gradually decreases throughout the differentiation 
cascade. In contrast, the proliferative index increases from HSC towards MPP1-4. Mgk-P: megakaryocyte 
progenitor, E-P: erythrocyte progenitor. Redrawn and modified based on (Bryder et al., 2006). 
In recent years, the classical tree-like hematopoiesis model with defined stable progenitor 
populations harboring distinct potencies has been challenged (Haas et al., 2018). Limiting-
dilution and single-cell transplantation assays revealed intrinsic HSC lineage biases in murine 
as well as human HSCs (Dykstra et al., 2007; Morita et al., 2010; Muller-Sieburg et al., 2002; 
Yamamoto et al., 2013). Only a minority of HSCs found in the immunophenotypically defined 
HSC compartment exhibited unbiased multilineage engraftment upon transplantation. The 
majority of HSCs displayed lineage-biased engraftment, which is characterized by differences 
in reconstitution kinetics and lineage contribution. In addition, in silico barcoding and 
fluorescent tagging approaches confirmed lineage skewing of HSCs in the unperturbed 
hematopoietic system (Rodriguez-Fraticelli et al., 2018; Yu et al., 2016). Single-cell 
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transcriptional profiling revealed transcriptional lineage priming, further supporting the 
presence of a highly heterogenous human and mouse HSC and progenitor compartment 
(Grover et al., 2016; Guo et al., 2013; Moignard et al., 2013; Velten et al., 2017). In addition, 
transcriptional and functional in-depth analysis of oligopotent progenitor populations, e.g. 
CMPs, revealed that these populations are heterogenous and seem to consist of multiple 
lineage-committed progenitor populations (Karamitros et al., 2018; Paul et al., 2015). Further, 
lineage-committed HSCs have been identified. Within the phenotypically defined HSC 
compartment, Mk-restricted cells with high self-renewal capacity exist (Haas et al., 2015; 
Rodriguez-Fraticelli et al., 2018; Yamamoto et al., 2013). Thus, these recent experimental 
findings have changed our view of the hematopoietic hierarchy. Lineage-commitment does not 
seem to be acquired in stepwise binary cell fate decisions but rather in a continuous manner 
(Figure 1.2) (Haas et al., 2018). Today, we can use phenotypically identified HSCs and 
progenitor populations to perform functional and transcriptional analysis and use the tree-like 
hematopoietic hierarchy as a model. However, the intrinsic heterogeneity in these defined 
populations always has to be considered when interpreting results.  
 
Figure 1.2: Continuous model of HSC differentiation.  
In this model, no distinct subpopulations are defined. HSCs become increasingly more committed and lose self-
renewal capacity as well as multipotency. MPP, CMP and CLP states are transitory states during HSC 
differentiation. Redrawn and modified based on (Haas et al., 2018). 
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1.1.2.2 Murine embryonic hematopoiesis 
During murine embryonic development, distinct waves of hematopoietic activity occur in 
different anatomical sites (Galloway and Zon, 2003; Orkin and Zon, 2008). Primitive 
hematopoiesis, which primarily generates primitive erythrocytes, occurs in the yolk sac starting 
at embryonic day 7.5 (E7.5) (Galloway and Zon, 2003; Orkin and Zon, 2008). This initial wave 
of erythropoiesis is needed to meet the increasing demand of oxygen supply in the developing 
embryo and is characterized by the presence of embryonic globin proteins. From E9 on, 
definitive hematopoiesis can be detected, which gives rise not only to erythrocytes and 
macrophages but also to other myeloid and lymphoid cells (Galloway and Zon, 2003; Orkin 
and Zon, 2008). This next wave of hematopoiesis mainly takes place in the aorta-gonad-
mesonephros (AGM) region. While little HSC activity is detected in this region at E10.5, 
transplantable HSCs are present at E11 (Muller et al., 1994). The AGM region therefore seems 
to be the source of the first definitive HSCs. However, HSC activity has also been detected in 
the placenta, adding a potential additional site for HSC development (Gekas et al., 2005; 
Ottersbach and Dzierzak, 2005). Subsequently, HSCs are thought to colonize the fetal liver 
starting E11 (Galloway and Zon, 2003; Johnson and Moore, 1975; Muller et al., 1994), where 
they massively expand and differentiate. However, the liver is only a transient hematopoietic 
site, as hematopoiesis in the liver decreases shortly after birth (Galloway and Zon, 2003). 
During development, the spleen is colonized at E12, and hematopoiesis in the spleen starts 
around E16, aiding in the transition from fetal liver to BM hematopoiesis (Galloway and Zon, 
2003; Godin et al., 1999; Sasaki and Matsumura, 1988). HSCs migrate to the developing BM 
during embryogenesis, and B cell precursors are detected in the BM as early as E15 (Delassus 
and Cumano, 1996). Functional HSCs, however, are only identified in the BM starting E18 
(Galloway and Zon, 2003). After birth and during the lifespan of the murine organism, the BM 
remains the main site of definitive hematopoiesis.  
Fetal HSCs are able to engraft in long-term transplantation assays, are multipotent and able 
to self-renew. However, their intrinsic characteristics differ depending on the embryonic site of 
origin. In contrast to adult HSCs, for example, fetal liver HSCs are characterized by high 
proliferative activity (Bowie et al., 2006; Nygren et al., 2006; Wilson et al., 2008).  
1.1.2.3 Murine adult hematopoiesis 
In the adult organism, hematopoiesis mainly takes place in the BM, where HSCs reside and 
blood cells of all different lineages are produced, including myeloid as well as lymphoid cells. 
Most cells mature in the BM, including platelets, myeloid cells, B cells and reticulocytes, which 
advance to the erythrocyte stage in the blood (Seita and Weissman, 2010; Weissman and 
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Shizuru, 2008). T cell maturation, however, takes place in the thymus. After migration of 
lymphoid precursor cells to the thymus, T cell development and generation of different T cell 
lineages occurs (Alberts, 2008). In addition to the primary lymphoid organs, BM and thymus, 
where lymphoid cells are generated and mature, secondary lymphoid organs exist. These 
include lymph nodes, the spleen, tonsils, peyer’s patches and mucosa-associated lymphoid 
tissues. In these tissues, initial antigen contact takes place, leading to activation and expansion 
of lymphocytes (Murphy, 2008). Recently, additional tissues have been linked to 
hematopoiesis. For example, HSCs have been identified in the gut, and platelet production 
was observed in the lung (Fu et al., 2019; Lefrancais et al., 2017). Thus, hematopoiesis is also 
associated to and observed in other organs.  
1.1.3 Hematopoietic stem and multipotent progenitor cells 
Hematopoietic stem and multipotent progenitor cells (HSPCs) are at the top of the 
hematopoietic hierarchy. To enable analysis and characterization of HSPCs, HSCs and 
different MPP populations have been phenotypically and experimentally defined in the past.  
1.1.3.1 Identification of HSPCs by surface marker expression patterns 
In general, surface marker combinations are used to identify different HSPC populations, for 
example via flow cytometry analysis. All HSCs and MPP cells are contained in the lineage-
negative fraction. Lineage markers include cluster of differentiation (CD) 4, CD8, B220, Gr1, 
Ter119 and CD11b (Muller-Sieburg et al., 1988; Muller-Sieburg et al., 1986).  
Initially, it could be shown that multipotent HSC activity is restricted to the Lin- Sca-1+ c-Kit+ 
(LSK) compartment (Figure 1.3 A) (Ikuta and Weissman, 1992; Ogawa et al., 1991; Spangrude 
et al., 1988; Wilson et al., 2007). Later on, additional markers were identified by transplantation 
assays, including CD34, CD135 and the signal lymphocyte activating molecule (SLAM) 
receptors CD150 and CD48, leading to the identification of the murine LSK CD135- CD48- 
CD150+ CD34- HSC population (Adolfsson et al., 2005; Forsberg et al., 2006; Kiel et al., 2005; 
Osawa et al., 1996; Wilson et al., 2007). In the past, alternative assays, e.g. dye efflux, have 
been used to isolate and study HSCs (Purton and Scadden, 2007). Furthermore, additional 
HSC-specific genes including a-catulin, Hoxb5 and Fgd5 were recently identified and used to 
enrich for stem cell function by employing reporter mouse lines (Acar et al., 2015; Chen et al., 
2016; Gazit et al., 2014). The LSK CD135- CD48- CD150+ CD34- HSC surface marker code 
is, however, widely used and accepted.  
HSCs defined using these surface markers are extremely rare and only make up around 
0.0013% of all murine BM cells (Wilson et al., 2008). Nevertheless, these HSCs are extremely 
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potent as they can be serially transplanted, are multipotent and able to self-renew (Seita and 
Weissman, 2010; Weissman and Shizuru, 2008). In addition, they are highly quiescent, and 
less than 2% of all phenotypic HSCs are actively cycling. The majority of HSCs, up to 90%, 
reside in the G0 state of the cell cycle and can therefore be found in the Ki-67-negative 
compartment (Wilson et al., 2008). Presumably, this quiescent state protects HSCs from 
genetic damage (Flach et al., 2014; Walter et al., 2015). The resulting low mutational burden 
protects HSCs from malignant transformation and ensures lifelong production of mature blood 
cells (Trumpp et al., 2010).  
HSCs can be further subdivided into an active HSC (aHSC) and a dormant HSC (dHSC) 
compartment (Figure 1.3 B) (Cabezas-Wallscheid et al., 2017; Foudi et al., 2009; Wilson et al., 
2008). These subpopulations can be identified by label-retaining assays, for example using 
BrdU labeling approaches or the SCL-tTA:H2B-GFP transgenic mouse model (Wilson et al., 
2008). dHSCs retain the cellular label for up to 300 days, indicating a highly dormant cellular 
state. 25-35% of all phenotypic HSCs are dormant, as identified after a chase period of 70 to 
approximately 150 days. All dHSCs are in the G0 state of the cell cycle. Wilson et al. could 
show that only dHSCs, but not aHSCs, are serially transplantable, indicating that dHSCs 
harbor the majority of the multilineage long-term self-renewal capacity (Wilson et al., 2008). 
Mathematical modeling revealed that dHSCs divide only 4-5 times per mouse lifetime 
(approximately every 149-193 days), while aHSCs divide every 28-36 days (van der Wath et 
al., 2009). It has been proposed that dHSCs function as a backup HSC population that is 
protected from exhaustion and acquisition of mutations by their deeply dormant state (Trumpp 
et al., 2010; Wilson et al., 2009). In addition, label-retaining HSCs have been proposed to 
persist during aging (Bernitz et al., 2016). dHSCs become activated and contribute to 
hematopoiesis under stress conditions or upon injury. Cabezas-Wallscheid et al. further 
characterized dHSCs and aHSCs on a transcriptional level (Cabezas-Wallscheid et al., 2017). 
In this study, it was shown that dHSCs are characterized by a state of biosynthetic shutdown. 
In addition, GPRC5C was identified as a surface marker expressed on dHSCs.  
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Figure 1.3: HSC-MPP populations.  
(A) Surface marker codes of HSCs and MPP1-4 cells. CD34, CD48, CD150 and CD135 are used to identify the 
different HSPCs within the LSK population. (B) The HSC compartment can be further subdivided into a dHSC (~20-
30%) and an aHSC (~70-80%) compartment. dHSCs, in contrast to aHSCs, are characterized as label retaining 
cells (LRCs) exhibiting low CD34 mRNA levels and high HSC activity. Only dHSCs are serially transplantable. 
dHSCs become activated during hematopoietic stress responses and return to their dormant state during stress 
recovery. Redrawn and modified based on (Cabezas-Wallscheid et al., 2017; Cabezas-Wallscheid et al., 2014). 
In addition, HSC progeny cells, namely MPPs, have been described and functionally 
characterized (Cabezas-Wallscheid et al., 2014; Pietras et al., 2015; Wilson et al., 2007). 
Morrison et al. were one of the first to describe the reduced engraftment potential of MPP cells 
compared to HSCs (Morrison et al., 1997; Morrison and Weissman, 1994). Different surface 
marker combinations have been used to identify MPP cells (Wilson et al., 2008). MPPs can be 
found in the LSK compartment but, in contrast to HSCs, express CD34 (Osawa et al., 1996). 
It has been shown that increasing expression of the surface marker CD135 is accompanied 
by a decrease in self-renewal capacity (Adolfsson et al., 2005). In addition to CD135, the SLAM 
markers CD48 and CD150 are used to identify MPP subsets (Kiel et al., 2005). Wilson et al. 
used these markers to phenotypically identify four different MPP subsets (Figure 1.3 A) (Wilson 
et al., 2008). MPP1 cells are defined as LSK CD34+ CD48- CD150+ CD135-. MPP2 cells 
upregulate CD48 (LSK CD34+ CD48+ CD150+ CD135-) and MPP3 and MPP4 cells lose 
expression of CD150. They can be distinguished by CD135 expression patterns (MPP3: LSK 
CD34+ CD48+ CD150- CD135-; MPP4: LSK CD34+ CD48+ CD150- CD135+). To date, the 
MPP hierarchy is still controversially discussed and additional markers have been proposed 
(Oguro et al., 2013). Exact branch points could not be identified so far. Taking recent 
discoveries into account, it can be assumed that MPP subsets represent phenotypically 
identifiable populations that are part of a continuum-like developmental process from HSCs 
towards mature cells (Haas et al., 2018).  
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Functional assessment of different MPP populations was recently performed (Cabezas-
Wallscheid et al., 2014; Pietras et al., 2015). Cabezas-Wallscheid et al. could show that MPP2 
cells generate a large number of progeny cells of all different lineages, including B cells, T cells 
and myeloid cells, upon primary transplantation. MPP3 and MPP4 cells, in contrast, only 
generated little, but detectable progeny upon transplantation. Furthermore, MPP3 cells 
exhibited a myeloid and MPP4 cells a lymphoid lineage bias. In line, lymphoid-priming of MPPs 
has been linked to loss of expression of Mpl, which encodes for the thrombopoietin receptor 
(Luc et al., 2008). However, engraftment and lineage-contribution of MPP cells is always 
considered short-term compared to HSCs. In addition to engraftment potential and self-
renewal capacity, the cell cycle status of MPP cells was analyzed (Wilson et al., 2008). While 
HSCs are highly quiescent, MPP cells become progressively more active. Less cells are in the 
G0 state of the cell cycle and more cells are found in the S/G2/M state, supporting the 
hypothesis that MPP1-4 cells are the active drivers of hematopoiesis under homeostatic 
conditions. This is also supported by in situ fate-tracing approaches (Busch et al., 2015; Sun 
et al., 2014).  
1.1.3.2 The HSC bone marrow niche 
HSCs are highly dependent on a functional microenvironment. To date, it is still not possible 
to culture HSCs in vitro for long time periods. Within the BM, HSCs are localized in specialized 
niches providing soluble signaling molecules and direct cell-cell contacts, which maintain and 
regulate HSCs (Crane et al., 2017; Mendelson and Frenette, 2014; Morrison and Scadden, 
2014). Thereby, the niche mediates HSC self-renewal, quiescence, differentiation and stress 
response (Crane et al., 2017; Ehninger and Trumpp, 2011). In recent years, multiple studies 
have been performed to identify the cellular makeup and to precisely localize the HSC niches 
in the BM. However, the exact HSC location in the bone and identity of HSC niche cells are 
still under debate. In general, endosteal as well as perivascular HSC niches have been 
described (Crane et al., 2017). The majority of HSCs seems to be localized in perivascular 
niches, with around 80% being associated to sinusoidal blood vessels. Within the perivascular 
niche, only a minority of HSCs seems to be localized close to arterioles or within transition 
zone vessels (Acar et al., 2015; Crane et al., 2017). Multiple niche cells that are involved in 
HSC maintenance have been described, including megakaryocytes, monocytes and 
macrophages, neurons, Schwann cells, endothelial cells and leptin receptor-expressing, CXC-
chemokine ligand 12 (CXCL12)-abundant reticular (CAR) perivascular stromal cells (Crane et 
al., 2017; Mendelson and Frenette, 2014; Morrison and Scadden, 2014).  
Many different key factors in the HSC niche have been reported, including the soluble stem 
cell factor (SCF), which signals via the c-Kit receptor and is needed for HSC maintenance 
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(Barker, 1994; Crane et al., 2017; Czechowicz et al., 2007). In addition, CXCL12, signaling via 
CXC-chemokine receptor 4 (CXCR4), is an important soluble factor involved in retaining HSCs 
in the BM (Sugiyama et al., 2006; Zou et al., 1998). The CXCL12–CXCR4 signaling axis is 
also required for HSC homing to the BM upon transplantation by intravenous injection (Lai et 
al., 2014). Endothelial cells and leptin receptor-expressing, perivascular stromal CAR cells 
have been identified as the main sources of SCF and CXCL12 in the unperturbed young BM 
(Crane et al., 2017; Zhou et al., 2014). However, other sources have been reported as well. In 
addition, multiple other factors have been shown to be important or even essential for HSC 
maintenance in the niche, including thrombopoietin (TPO) (Crane et al., 2017). Overall, 
additional research is necessary to further analyze and better understand the organization, 
regulation and function of the HSC BM niche.  
1.1.3.3 Functional analysis of murine HSC activity 
Flow cytometry analysis of HSPCs alone cannot be used to investigate HSC capacity. To 
asses HSC function, self-renewal and potency, several in vitro and in vivo approaches have 
been established (Purton and Scadden, 2007). Today, the most common in vitro experiment 
is the colony forming unit (CFU) assay (Purton and Scadden, 2007). In this assay, total BM 
cells or sorted BM subsets are cultured in a semi-solid methyl-cellulose culture medium, which 
contains defined growth factors. Single cells are distributed in the medium, and during the 
incubation time of 5 to 14 days, colonies grow out depending on the initial potency of the given 
cell. The colony number can be quantified, and the lineage bias can be assessed. Depending 
on the cell type, different lineages are generated. Immature stem and progenitor cells form 
mixed colonies (CFU-GEMM), while restricted cell subsets give rise to myeloid (CFU-G/M/GM) 
or erythroid (CFU-E, BFU-E) colonies. Lymphoid potential cannot be assessed, as 
development depends on additional extrinsic factors and cell subsets not present in the culture 
conditions (Purton and Scadden, 2007). In primary platings of total BM cells, mainly the 
capacity of lineage-restricted progenitor cells and MPP cells is assessed. To investigate HSC 
capacity, serial CFU assays are needed, as HSCs primarily form colonies in the second and 
third round of the CFU assay. 
In vivo transplantation assays have long been established to identify HSCs and assess HSC 
capacity. Initially, so-called spleen colony forming unit (CFU-S) assays were used (Till and 
McCulloch, 1961). In these assays, macroscopic colony formation in the spleen is quantified 
approximately 2 weeks after intravenous transplantation into irradiated recipient animals. This 
assay mainly allows investigation of progenitor cell potential (Purton and Scadden, 2007). 
Nowadays, long-term transplantation assays are the gold standard to address functional 
potential. A prerequisite for successful transplantation approaches is the depletion of recipient 
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HSCs in the BM by irradiation or high-dose cytotoxic drug treatment (Kondo et al., 2003; 
Weissman and Shizuru, 2008). Thereby, vacant HSC niches are created that can be taken 
over by the transplanted HSCs.  
In general, transplantation assays rely on the identification of transplanted cells and progeny 
cells in the recipient mouse. Therefore, congenic mice differing in the expression of allelic 
variants of the Ly5 antigen (CD45) are widely used (Purton and Scadden, 2007). CD45.1, 
CD45.2 and CD45.1/.2 mice exist, and HSCs, MPPs and mature cells can be identified in the 
BM and the peripheral blood (PB) by surface antigen expression. Platelet and erythrocyte 
contribution in the PB cannot be assessed, as CD45 is not expressed on these cellular entities. 
Potency is analyzed by quantifying PB contribution over time and engraftment of HSCs and 
MPPs in the BM (Purton and Scadden, 2007).  
Transplantation of whole BM is used to generate full chimeras and thereby asses general HSC 
function. In contrast, competitive transplantations can be set up by mixing BM cells with 
competitor BM cells. These assays are used to analyze HSC performance and potency. HSCs 
that exhibit minor impairments might engraft and perform normally in full chimeras, however 
their reduced potency becomes apparent in competitive settings. Fully functional HSCs will 
outperform impaired HSCs in such conditions. For HSC quantification, limiting-dilution assays 
can be performed. Recently, more and more single-cell transplantation assays have been used 
to analyze single cell HSC potency, lineage-skewing and -priming (Dykstra et al., 2007; Morita 
et al., 2010; Muller-Sieburg et al., 2002; Yamamoto et al., 2013). In these assays, however, 
co-transplantation of supportive BM cells is needed to ensure survival of the recipient mouse.  
Transplantation experiments revealed that HSCs, MPP1 and MPP2 cells are capable of 
balanced multilineage reconstitution (Cabezas-Wallscheid et al., 2014). MPP1 cells, however, 
only contribute to the PB of recipient mice for a limited timeframe. Subsequently, contribution 
significantly declines. Only transplanted HSCs contribute to the PB for the whole lifetime of the 
mouse. MPP2 cells also exhibit multilineage engraftment, while PB contribution of MPP3 and 
MPP4 cells is reduced and exhibits a lineage-bias (Cabezas-Wallscheid et al., 2014; Pietras 
et al., 2015). However, only dHSCs can be serially transplanted and are therefore thought to 
represent the HSC subset with the highest long-term self-renewal capacity (Wilson et al., 
2008). Over the years, different transplantation approaches have been used to increase the 
purity of the phenotypically defined HSC and MPP populations. In addition, functional 
properties on the single cell level have become apparent. 
It has to be kept in mind that, in transplantation settings, HSC potential is always analyzed in 
stressed hematopoietic situations, as the recipient animals have undergone inflammation-
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inducing, HSC-depleting therapies, which enable donor HSC engraftment. Alternative 
conditioning methods allowing transplantation without the need of myeloablative therapies 
have been established, including dietary valine depletion and transgenic mouse models, e.g. 
c-Kit mutant mice (Taya et al., 2016; Waskow et al., 2009). In addition, in situ fate tracing 
approaches that make use of HSC labeling or barcoding can be used to assess HSC PB 
contribution and function in homeostatic and stress conditions in a more physiological setting 
(Busch et al., 2015; Rodriguez-Fraticelli et al., 2018; Sun et al., 2014; Yu et al., 2016).  
1.1.3.4 Cell cycle status and activation of HSCs  
In situ cell fate tracing approaches and cell cycle analysis revealed that HSCs do not seem to 
be the main drivers of hematopoiesis under steady state conditions but rather remain in a 
highly quiescent, protective, cellular state with up to 90% of HSCs residing in the G0 cell cycle 
phase (Busch et al., 2015; Rodriguez-Fraticelli et al., 2018; Sun et al., 2014; Wilson et al., 
2008). This quiescent state protects HSCs from genetic damage, potentially creating a cellular 
backup resource for times of hematopoietic stress (Pietras et al., 2011; Trumpp et al., 2010). 
In line, deeply quiescent HSCs are activated in response to stress and injury signals, including 
inflammation, chemotherapy and blood loss (Trumpp et al., 2010; Wilson et al., 2009). During 
infection, the organism is in need of an increased production of immune cells to combat 
invading pathogens. Upon chemotherapy or blood loss, depleted mature cells need to be 
replaced. In response, HSCs exit the G0 cell cycle state, actively proliferate and increase 
cellular output. This activation is also apparent in MPP cells, which exhibit increased cell cycle 
activity potentially to sustain the HSC emergency response.  
HSC activation occurs for example in the presence of lipopolysaccharide (LPS) or 
inflammatory mediators like IFN-gamma and IFN-alpha (Baldridge et al., 2010; Esplin et al., 
2011; Essers et al., 2009; Walter et al., 2015; Zhao et al., 2013). Experimentally, 
polyinosinic:polycytidylic acid (pIC), a synthetic dsRNA analog, can be used to activate HSCs 
(Essers et al., 2009). pIC triggers an IFN-alpha response, which signals via the IFN-alpha 
receptor. Using genetic knockout mouse models, Essers et al. could show that downstream 
JAK-STAT signaling in HSCs leads to exit of the G0 cell cycle state. In addition, upregulation 
of the stem cell marker and interferon response gene Sca-1 on HSCs and different Lin- cell 
populations was reported. Activation of HSCs by pIC is only transient, the response peaks 16h 
after intraperitoneal pIC injections and subsequently declines. Four days after induction, a 
partial return to the quiescent state is observed, and after 8 days, the homeostatic status within 
the HSPC compartment is restored. Interestingly, Essers et al. could show that chronic 
activation of HSCs by interferon-signaling impairs HSC function and eventually leads to loss 
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of HSCs. These observations support the notion that the intrinsic quiescent status of HSCs is 
a prerequisite for lifelong maintenance of this highly potent stem cell population.  
Intriguingly, recent studies have suggested that lineage-skewed HSCs and progenitor cells are 
functionally important in stress hematopoiesis. For example, emergency-megakaryopoiesis 
seems to be driven by Mk-restricted progenitors that can be found in the phenotypic HSC 
compartment (Haas et al., 2015). These novel observations in stress hematopoiesis support 
the theory of a rather heterogenous HSC compartment with lineage-biased HSCs (Haas et al., 
2018).  
1.1.3.5 The metabolic state of HSCs 
Under steady-state conditions, HSCs are highly quiescent. They are characterized by a 
biosynthetic shutdown, a low proliferative index and low protein translation activity (Cabezas-
Wallscheid et al., 2017; Signer et al., 2014; Wilson et al., 2008). Studies on human HSCs have 
confirmed the quiescent state of the most potent HSCs, which are characterized by low CDK6 
levels (Laurenti et al., 2015). Thus, HSCs also seem to be metabolically dormant. Multiple 
knockout and functional studies have been performed to better understand the metabolic 
status of HSCs, including deletion of essential metabolic enzymes and regulators (Ito and Ito, 
2018; Ito and Suda, 2014). This introduction focusses on the reported metabolic requirements 
for HSC self-renewal and maintenance.  
Interestingly, HSCs are localized in hypoxic niches in the BM (Ito and Suda, 2014; Suda et al., 
2011). This hypoxic niche promotes HSC maintenance, inhibits differentiation and protects 
HSCs from reactive oxygen species (ROS), which potentially induce DNA damage (Ito and 
Suda, 2014; Suda et al., 2011). HSCs have been reported to express high levels of hypoxia-
inducible factor (HIF1) a (Figure 1.4 A) (Simsek et al., 2010; Takubo et al., 2010). Under 
normoxic conditions, prolyl hydroxylases (PHD) are activated by oxygen and subsequently 
hydroxylate HIF1a (Semenza, 2010). HIF1a is then bound by the E3 ligase von Hippel-Lindau 
(VHL) factor, leading to HIF1a degradation by the ubiquitin-proteasome system. Under hypoxic 
conditions, as observed in HSCs, HIF1a is stable and forms a complex with HIF1b. This 
complex then drives expression of glycolytic genes. In addition, the pyruvate dehydrogenase 
kinase (PDK) is activated. This kinase suppresses the pyruvate dehydrogenase (PDH) 
complex. Thereby, pyruvate oxidation is inhibited and mitochondrial oxidative phosphorylation 
(OXPHOS) is limited (Ito and Ito, 2018; Ito and Suda, 2014). Thus, HSCs highly depend on 
anaerobic glycolysis via production of lactate from pyruvate by the lactate dehydrogenase 
enzyme (Figure 1.4 A) (Ito and Suda, 2014; Takubo et al., 2013). High HIF1a levels, which are 
caused by HSC residency in the hypoxic niche, prevent engagement of the tricarboxylic acid 
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(TCA) cycle and subsequent OXPHOS. Limiting OXPHOS is essential for HSCs to remain in 
an undifferentiated multipotent state. HIF1a deletion, for example, leads to decreased 
glycolysis and increased metabolism, ultimately leading to HSC exhaustion (Takubo et al., 
2010). In line, chemical mitochondrial uncouplers can be used to lower mitochondrial activity 
in HSCs in vitro, thereby increasing HSC maintenance (Vannini et al., 2016). Keeping HSCs 
in this metabolically dormant state is important to limit cell cycle activity and production of ROS. 
Excessive ROS generation induces HSC apoptosis presumably to prevent spreading of ROS-
induced DNA mutations throughout the hematopoietic system (Ito and Suda, 2014). In addition 
to anaerobic glycolysis and inhibition of OXPHOS, HSCs seem to actively remove functional 
mitochondria by autophagy to reduce oxidative metabolism (Ho et al., 2017; Ito and Ito, 2018). 
In sum, quiescent HSCs rely on anaerobic glycolysis and actively limit the TCA cycle and 
OXPHOS. 
While maintaining a quiescent metabolic state is beneficial for HSCs under homeostatic 
conditions when progeny cell production from the HSC subset is not required, HSCs need to 
enter the cell cycle and divide in hematopoietic stress conditions (Figure 1.4 B). This response 
is accompanied by metabolic adaptations that are necessary to meet the increased demand 
for amino acids, fatty acids and nucleotides to generate biomass in the form of proteins, lipids 
and DNA/RNA. Activated HSCs switch to OXPHOS to enhance energy production (Ito and Ito, 
2018; Ito and Suda, 2014). Increase in OXPHOS is mediated by growth factor signaling via 
the PI3K-AKT pathway, leading to activation of mTOR signaling (Ito and Suda, 2014). mTOR 
signaling, in turn, enhances cell growth and proliferation. In addition, PI3K-AKT signaling leads 
to forkhead box protein O (FOXO) phosphorylation and translocation out of the nucleus, 
leading to reduced HSC quiescence (Ito and Suda, 2014; Yamazaki et al., 2006). FOXO 
proteins usually drive expression of enzymes that are required for ROS detoxification and of 
quiescence-promoting genes and have been shown to be important for stem cell maintenance 
(Miyamoto et al., 2007; Tothova and Gilliland, 2007; Tothova et al., 2007). Thereby, growth 
factor signaling leads to metabolic adaptations in HSCs and ultimately enhanced cell cycle 
progression.  
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Figure 1.4: HSC metabolism during homeostasis and in response to stress.  
(A) Under homeostatic conditions, HSCs rely on anaerobic glycolysis. In the hypoxic niche, HIF1a is stable and not 
hydroxylated by PHD, which induces HIF1a degradation by the ubiquitin-proteasome system. Active HIF1a 
promotes glycolysis and activates PDK. PDK inhibits PDH, thereby limiting Acetyl-CoA synthesis and in turn the 
TCA cycle and OXPHOS. Anaerobic glycolysis leads to the production of lactate from glucose for energy production. 
(B) During HSC stress response and division, metabolic adjustments take place. Growth factors activate PI3K-AKT 
signaling, leading to activation of mTOR. mTOR in turn enhances glycolysis and inhibits the FOXO-mediated stress 
response, usually inhibiting ROS. HIF1a is degraded via the PHD-VHL axis. Thereby, PDH inhibition by HIF1a-
induced PDK activation is released. During stress response, the metabolic mode of HSCs switches from anaerobic 
glycolysis to OXPHOS. In addition, the PML-PPARd axis promotes FAO. In cycling HSCs FAO controls cell fate 
decisions and limits oxidative stress. Proteins are shown in red, processes are shown in green. LDH: lactate 
dehydrogenase, FASN: fatty acid synthase. Redrawn and modified based on (Ito and Suda, 2014). 
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While entry into the cell cycle and HSC differentiation are crucial in emergency hematopoiesis, 
the HSC stress-response has to be balanced to maintain functional HSCs throughout life (Ito 
and Ito, 2018; Ito and Suda, 2014). Recently, fatty acid metabolism has been linked to stem 
cell self-renewal (Figure 1.4 B) (Ito et al., 2012; Ito et al., 2016). Fatty acid metabolism supports 
the biosynthetic and bioenergetic requirements of proliferation that are necessary during HSC 
activation (Ito and Ito, 2018; Ito and Suda, 2014). Activation of the promyelocytic leukemia 
protein (PML)-peroxisome proliferator-activated receptor (PPAR) d axis leads to increased 
expression of genes involved in fatty acid oxidation (FAO) (Ito et al., 2012). The PPARd 
signaling axis also enhances mitophagy via the E3 ubiquitin ligase subunit PARKIN and the 
PTEN-induced putative protein kinase 1 (PINK1) (Ito et al., 2016). By increasing mitophagy, 
oxidative stress is minimized, and HSC division under stress conditions is enabled. In addition, 
FAO might also act as a source for NADPH, which counteracts oxidative stress (Ito and Suda, 
2014; Pike et al., 2011). Thus, FAO seems to be a key metabolic adaptation during HSC 
activation, enabling HSC division while minimizing ROS and subsequent DNA mutations.  
Glutamine is an important energy source for proliferating cells, fueling the TCA cycle and 
thereby contributing to OXPHOS metabolism (Figure 1.5) (Yang et al., 2017). Glutamine (Gln) 
is taken up by cells and can be used to synthesize nucleotides. Deamination of Gln by the 
enzyme glutaminase (GLS) leads to production of glutamate (Glu). Glu can be converted into 
a-ketoglutarate (a-KG) by glutamate dehydrogenase or aminotransferases. a-KG is then fed 
into the TCA cycle, ultimately fueling OXPHOS. In addition, glutaminolysis supports the 
production of glutathione, which is produced from Glu and protects cells from oxidative stress. 
Furthermore, transaminases use Glu and a-keto acids to produce a-KG and the corresponding 
amino acids. Interestingly, glutaminolysis is regulated via c-Myc. It has been shown that c-Myc 
transcriptionally suppresses the microRNA (miRNA) miR-23, which targets the Gls mRNA 
(Gao et al., 2009). Thus, an increase in c-Myc activity is associated with increased 
glutaminolysis.  
Little is known about the role of glutaminolysis in HSCs and during HSC activation (Ito and 
Suda, 2014). Interestingly, HSC activation has been linked to increased c-Myc levels (Ehninger 
et al., 2014). Thus, glutaminolysis could be enhanced in activated HSCs. In addition, HSCs 
could benefit from using glutaminolysis as an energy source, as it fuels the TCA cycle, thereby 
increasing energy production. At the same time, glutaminolysis enables production of 
antioxidants (Yang et al., 2017), e.g. glutathione, which might protect HSCs from DNA damage 
during the transient activation phase. However, further investigation is needed to better 
understand the role of glutaminolysis in HSC biology.  
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Figure 1.5: Glutaminolysis.  
Glutamine is transported into cells via the ASCT2 transporter, where it can be used to synthesize nucleotides and 
amino acids. GLS converts glutamine to glutamate, which is then used to for glutathione (GSH) or amino acid (AA) 
production. Alternatively, glutamate is converted to a-KG, which is used in the TCA cycle fueling OXPHOS.   
1.1.4 Knockout mouse models used in hematopoietic research 
More than 100 knockout (KO) mouse models have been used to investigate the role of different 
proteins for HSC function, maintenance and regulation (Rossi et al., 2012). BM, PB and 
secondary lymphoid organ analysis can be performed in these mice. In addition, functional in 
vitro and in vivo assays can be executed. Originally, straight KO models were used. In these 
animals, expression of the respective gene is disabled in all tissues independent of the 
developmental stage. Thus, it is difficult to distinguish primary from secondary effects in HSCs. 
For example, KO of an important niche component will reduce HSC number or function. 
However, the respective gene is not intrinsically needed for HSC maintenance. To circumvent 
false interpretation of results, inducible and tissue-specific KO mouse models have been 
established. 
1.1.4.1 The Cre/loxP system: using MxCre and VavCre mice in hematopoietic research 
Different site-specific recombination systems exist, including the Cre/loxP system, which is 
widely used (Orban et al., 1992; Sauer, 1987; Sauer and Henderson, 1988). The Cre 
recombinase can be expressed under the control of a tissue-specific and/or inducible 
promoter. The genomic sequence of interest is flanked by two loxP sites, each consisting of a 
34 bp sequence. Depending on the orientation of the loxP sites, Cre activity either leads to 
excision of the flanked sequence (same orientation) or inversion of the flanked sequence 
(opposing orientation). Thus, Cre activation can lead to KO induction in the targeted cell 
entities and, for example, excision of one or multiple exons. 
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In hematopoietic research, multiple Cre driver mouse lines have been established. One widely 
used inducible Cre line is MxCre (Kuhn et al., 1995). Cre expression is controlled by the 
interferon-response promoter Mx1. In healthy mice, this promoter is silent. pIC injections can 
be used to activated Cre expression under the Mx1 promoter, leading to efficient deletion of 
the floxed allele mainly in liver, spleen and hematopoietic cells. Thus, MxCre mice can be 
crossed to floxed mouse lines, enabling inducible KO of the target gene in the hematopoietic 
system by pIC injection. As recombination also takes place in other tissues, transplantation 
approaches can be used to generate chimeras, which only harbor the MxCre transgene and 
the floxed alleles in the hematopoietic compartment.  
MxCre driver mice are used for inducible deletion in adult mice. For hematopoietic deletion of 
floxed alleles in the embryonic stage, the VavCre mouse model can be used (Georgiades et 
al., 2002). This model is not inducible, and recombination is observed in hematopoietic cells, 
endothelial cells and germ cells during embryogenesis. Chen et al. reported VavCre-mediated 
deletion in E11.5 CD45+ AGM and fetal liver cells (Chen et al., 2009). In their study, deletion 
occurred in all cells expressing Vav1, leading to deletion of the floxed allele after the 
endothelial-cell-to-HSC transition during embryogenesis. Controversially, deletion in 
endothelial cells was not observed in this study (Chen et al., 2009).   
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1.2 Long non-coding RNAs 
1.2.1 Function of RNA molecules 
For decades, RNA was regarded as a pure messenger molecule, acting as a template to 
transfer information from stable DNA to chemically functional polypeptides (Brenner et al., 
1961; Fatica and Bozzoni, 2014; Morris and Mattick, 2014; Quinn and Chang, 2016). However, 
rRNAs were identified as functionally important parts of ribosomes and tRNAs were discovered 
to act as adaptor molecules to enable polypeptide synthesis (Hoagland et al., 1958; Palade, 
1955). Nonetheless, mRNA, rRNA and tRNA were considered to enable flow of information 
from the DNA to the protein level. For years, research was focused on protein function and 
transcription factor-mediated regulation of gene expression (Morris and Mattick, 2014). This 
DNA/protein-centric view also affected disease research, as the main focus was laid on 
mutations in coding DNA regions and impaired protein functions. While these studies are of 
high importance, investigation of additional functional and regulatory roles of RNA was 
missing.  
Besides mRNA, rRNA and tRNA, small RNAs were discovered relatively early. However, the 
function of these molecules was not well understood. Later, these RNAs were termed small 
nuclear RNAs (snRNAs), which were shown to be involved in RNA splicing, small nucleolar 
RNAs (snoRNAs) and cajal-body specific RNAs (scaRNAs), involved in RNA editing, including 
methylation and pseudouridylation (Butcher and Brow, 2005; Dreyfuss et al., 1988; Henras et 
al., 2004; Jady et al., 2004; Maxwell and Fournier, 1995; Meier, 2005; Morris and Mattick, 
2014).  
In the 1980s, Gilbert postulated the so-called RNA-world hypothesis (Gilbert, 1986). Discovery 
of enzymatically active RNA, so-called ribozymes, led to the idea that RNA was the molecule 
used to store information and to catalyze reactions, originally (Guerrier-Takada et al., 1983; 
Kruger et al., 1982). According to this hypothesis, DNA and proteins evolved later to enable 
more stable information storage and higher catalytic activities. The underlying discoveries and 
this new hypothesis opened the door to further research focusing on the function and 
regulatory abilities of RNA.  
1.2.2 Non-coding RNAs 
Detailed analysis of the cellular RNA content and refined methods led to the discovery of the 
so-called non-coding RNA (ncRNA) world. Different ncRNA subclasses have been discovered 
and functionally characterized in the last 30 years (Fatica and Bozzoni, 2014; Morris and 
Mattick, 2014; Quinn and Chang, 2016). In total, two thirds of the genomic DNA are 
 Introduction  
 21 
transcribed, while less than 2% are translated into proteins (Djebali et al., 2012; Maeda et al., 
2006). These observations indicate that RNA molecules play important functional roles in 
cellular systems.  
MiRNAs, for example, are small, ~22 nt long ncRNAs that influence RNA translation and 
degradation (Fabian and Sonenberg, 2012; Lee et al., 1993; Morris and Mattick, 2014; 
Wightman et al., 1993). Pri-miRNAs are synthesized as dsRNA hairpin molecules in the 
nucleus by RNA polymerase II (Pol II). So-called pre-miRNAs are generated after cleavage by 
Drosha (Shukla et al., 2011). These molecules are exported into the cytoplasm by Exportin 5, 
where Dicer processes them to generate small (21-24 nt) dsRNA moieties. One strand of this 
dsRNA molecule is loaded onto the Argonaute (AGO) protein, which is a part of the multiprotein 
RNA-induced silencing complex (RISC). This complex binds to target mRNAs by base-pairing, 
using the miRNA molecule as the complementary strand (Shukla et al., 2011). miRNAs mainly 
exhibit incomplete homology with their target sequence, leading to translational repression of 
the targeted mRNA by RISC (Morris and Mattick, 2014). The majority of mRNA molecules, but 
also other ncRNAs, exhibit multiple miRNA target sites, and at the same time most miRNAs 
target multiple mRNAs. Thus, the RNA interference pathway is a complex process, fine-tuning 
RNA stability and translation. miRNAs are involved in many different physiological processes, 
including stem cell potency and cellular differentiation (Leonardo et al., 2012; Rakoczy et al., 
2013). In addition to miRNAs, small interfering RNAs (siRNAs) were described, mainly in plants 
(Morris and Mattick, 2014). By perfect base-pairing, these molecules induce RNA degradation 
via AGO-mediated cleavage of target RNAs. Today, siRNAs and artificial short hairpin RNAs 
(shRNAs) are used to silence target gene expression in experimental settings.  
In addition to miRNAs, other ncRNAs have been described. These include the telomerase 
RNA (TR, TER or TERC), which acts as a template for the synthesis of telomeric DNA, and 
PIWI-associated RNA (piRNA), which is involved in epigenetic transposon silencing, 
particularly in male germline cells (Feng et al., 1995; Siomi et al., 2011). Novel sequencing 
approaches led to the discovery of additional small ncRNA entities, namely transcription 
initiation RNAs (tiRNAs) and splice site RNAs (spliRNAs) (Taft et al., 2009; Taft et al., 2010). 
The exact function of these molecules needs to be unraveled, but they seem to be involved in 
nucleosome positioning and chromatin organization.  
In addition to the discovery of small ncRNAs, array-based and sequencing-based analysis of 
the transcriptome revealed the presence of thousands of lncRNA transcripts (Morris and 
Mattick, 2014). The ENCODE project provided evidence that lncRNAs are highly common and 
broadly expressed (Derrien et al., 2012; Rosenbloom et al., 2012). In general, lncRNAs are 
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defined as non-protein-coding RNAs that are longer than 200 nt (Quinn and Chang, 2016). 
Like mRNAs, most lncRNAs are transcribed by Pol II and undergo 5’-capping, splicing and 
polyadenylation. LncRNAs are encoded in intronic, antisense or intergenic regions, and their 
expression is controlled by promoters that can be regulated by transcription factors. Like many 
other genes, lncRNAs often undergo alternative splicing. In general, expression levels of 
lncRNAs are lower compared to mRNAs, and primary sequence conservation between species 
is lower. However, it has been suggested that secondary structures are conserved and 
important for lncRNA function. LncRNAs exhibit tissue-specific and stage of development-
specific expression patterns (Quinn and Chang, 2016). 
1.2.3 LncRNA function 
The function of distinct lncRNA molecules has been analyzed (Fatica and Bozzoni, 2014; 
Morris and Mattick, 2014; Quinn and Chang, 2016) but lncRNA function seems to be highly 
versatile. lncRNAs can form secondary structures and interact with proteins, leading to 
assembly of ribonucleoproteins (RNPs). By complementary base-pairing, lncRNAs can 
additionally interact with DNA and RNA molecules. Thus, multiple modes of action are possible 
(Figure 1.6).  
Nuclear lncRNAs are involved in guiding epigenomic modifiers, thereby recruiting for example 
DNMT3, PRC2 and H3K9 methyltransferases to certain gene loci (Nagano et al., 2008; Pandey 
et al., 2008; Zhao et al., 2008). In general, epigenetic roles of lncRNAs have mainly been 
associated with transcriptional repression. However, transcriptional activation by lncRNAs has 
also been observed, e.g. by recruiting H3K4 methyltransferases (Bertani et al., 2011; Wang et 
al., 2011). Besides directing epigenetic regulators to certain gene loci, lncRNAs can also act 
as scaffold molecules for other chromatin remodelers, epigenetic regulators and transcription 
factors (Tsai et al., 2010). In epigenetic regulation, lncRNAs can act in cis as well as in trans 
(Fatica and Bozzoni, 2014), but their mode of action is poorly understood. In addition, lncRNAs 
have been reported to control alternative splicing (Morris and Mattick, 2014). Furthermore, 
lncRNAs exhibit enhancer properties by guiding the physical looping between enhancers and 
promoters (Orom et al., 2010). Additionally, lncRNAs can affect transcription by acting as 
decoy molecules, for example for transcription factors (Morris and Mattick, 2014). Thus, 
lncRNAs can execute versatile functions in the nucleus depending on the respective mode of 
action.  
One of the most widely and longest known lncRNAs functioning in the nucleus is X-inactive 
specific transcript (Xist) (Fatica and Bozzoni, 2014). In female cells, Xist is transcribed from 
one of the two X chromosomes and acts in cis to initiate the formation of heterochromatin partly 
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by tethering PRC2 to the respective X chromosome (Zhao et al., 2008). Thereby, transcription 
is silenced and gene overdosage in female cells is prevented.  
In the cytoplasm, lncRNAs can function as miRNA sponges, sequestering miRNAs. Especially 
circular RNAs (circRNAs) have a long half-life and mainly act as miRNA decoy molecules 
(Fatica and Bozzoni, 2014). In addition, lncRNAs have been shown to control translation and 
mRNA stability by recruiting regulator proteins to target mRNAs (Fatica and Bozzoni, 2014).  
 
Figure 1.6: LncRNA functions.  
Different modes of action have been reported for lncRNAs. In the nucleus, lncRNAs target epigenetic remodelers 
to certain gene loci. In addition, they act as scaffold molecules for chromatin remodelers. By interacting with proteins 
and DNA, lncRNAs activate or repress gene expression and guide enhancer-promoter interactions. lncRNAs have 
also been shown to mediate splicing and function as transcription factor sponges. In the cytoplasm, lncRNAs 
sequester miRNAs and act as translational regulators by recruiting specific regulatory proteins. Redrawn and 
modified based on (Malik and Feng, 2016).   
Interestingly, many lncRNAs have been associated with imprinted regions (Fatica and Bozzoni, 
2014; Morris and Mattick, 2014; Quinn and Chang, 2016). Imprinting leads to a parent-of-
origin-specific gene expression pattern. During male and female gametogenesis, the 
respective imprinting control regions are epigenetically silenced by DNA or histone methylation 
in a sex-dependent manner. In the embryo and adult organism, either the paternal or the 
maternal regions are epigenetically silenced, leading to distinct gene expression patterns from 
the maternal and paternal allele, respectively. lncRNAs are often transcribed from these 
regions and have been reported to act in cis. The paternally expressed lncRNA Airn, for 
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example, is encoded antisense to the Igf2r gene (Latos et al., 2012; Quinn and Chang, 2016; 
Sleutels et al., 2002; Wutz et al., 1997). The maternal allele exhibits hypermethylated CpG 
islands, leading to silencing of Airn and expression of protein-coding genes, including Igf2r. 
On the paternal allele, however, CpG islands are not methylated, and the lncRNA Airn is 
expressed instead of the protein-coding genes. Loss of full-length Airn expression leads to loss 
of imprinting, namely hypermethylation of the paternal CpG islands and reactivation of Igf2r 
expression from the paternal allele. Thus, active transcription and/or production of the mature 
lncRNA are important to maintain imprinting patterns, as lncRNAs act in cis (Quinn and Chang, 
2016). One of many lncRNAs expressed from an imprinted locus is maternally expressed gene 
3 (Meg3), also known as gene trap locus 2 (Gtl2) (Benetatos et al., 2011; Zhou et al., 2012). 
1.2.4 The imprinted Dlk1-Meg3 locus  
Meg3 is a lncRNA encoded in the imprinted Dlk1-Meg3 gene locus (Figure 1.7 A) (Schuster-
Gossler et al., 1998). Imprinted alleles are usually differentially methylated. So-called 
imprinting control regions (ICRs) are methylated on the paternally or maternally inherited allele, 
leading to allele-specific expression patterns (Benetatos et al., 2011). Uniparental disomy 
(upd) in humans, which leads to the presence of either two copies of the paternally or 
maternally inherited allele or chromosome, is associated with developmental abnormalities 
and an increased risk of cancer development in the case of maternal upd (Irving et al., 2010; 
Ogata et al., 2008; Tuna et al., 2009). Thus, correct expression patterns in the Dlk1-Meg3 
gene locus and regulation of gene-dosage effects seem to be of high importance. In the Dlk1-
Meg3 locus, three protein-coding genes, Dlk1, Rtl1 and Dio3, are expressed from the 
paternally inherited allele. In contrast, multiple ncRNAs are expressed from the maternally 
inherited allele, including the lncRNA Meg3 and multiple snoRNAs and miRNAs, which are 
organized in multiple clusters (da Rocha et al., 2008). Expression is controlled by two different 
intergenic differentially methylated regions (IG-DMRs), namely IG-DMR and Meg3-DMR (da 
Rocha et al., 2008). Methylation patterns of the IG-DMR are established in the germline cells 
(Kagami et al., 2008; Lin et al., 2007; Lin et al., 2003; Takada et al., 2002). IG-DMR is localized 
13 kb upstream of the Meg3 promoter. Tandem repeats are methylated in male germline cells, 
but they remain unmethylated in female germline cells. IG-DMR regulates methylation of the 
downstream Meg3-DMR (Kagami et al., 2010; Lin et al., 2003). Meg3-DMR methylation 
patterns are established respectively to the IG-DMR status in postfertilized states, indicating 
that methylation patterns of DMRs of the Dlk1-Meg3 locus are hierarchically organized. The 
Meg3-DMR starts approximately 1.5 kb upstream of the Meg3 promoter and extends into the 
first intron of Meg3 (Paulsen et al., 2001; Takada et al., 2002). How these patterns are 
established, however, remains elusive (da Rocha et al., 2008). In summary, Meg3 and its 
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associated ncRNA clusters are expressed from the unmethylated maternally inherited allele, 
while protein-coding genes are expressed from the methylated paternally inherited allele.  
Eleven isoforms of Meg3 in mice are currently annotated in Ensembl (Zerbino et al., 2018). 
Structural as well as functional studies showed that Meg3 indeed acts as a lncRNA, rather 
than by generating protein output (Zhang et al., 2010b; Zhou et al., 2007). Interestingly, for 
human Meg3 transcripts, it has been shown that the secondary folding structure of the different 
isoforms is comparable, and that the 3D-structure is more important for Meg3 function than 
the nucleotide sequence (Zhang et al., 2010b). 
 
Figure 1.7: The Meg3-Dlk1 locus.  
(A) Schematic representation of the Dlk1-Meg3 locus. On the maternally inherited allele, IG-DMR and Meg3-DMR 
are unmethylated, leading to expression of Meg3 and the associated miRNA/snoRNA clusters. The paternally 
inherited allele exhibits methylated CpG islands. From this allele, protein-coding genes like Dlk1 are expressed. 
Redrawn and modified based on (Kameswaran and Kaestner, 2014). (B) Overview of different previously published 
KO mouse models of the Dlk1-Meg3 locus. Targeting strategy and phenotypes are represented.  
1.2.5 Meg3 function 
Many studies have focused on the broader role of the Dlk1-Meg3 locus, including the function 
of the different protein-coding genes in the locus, using different mouse models (da Rocha et 
al., 2008). For example, the transmembrane glycoprotein Dlk1 has been associated with 
cellular differentiation (Carlsson et al., 1997; Laborda, 2000; Moon et al., 2002). In addition, 
studies on IG-DMR and Meg3 KO mice have also shed light on the role of the maternally 
A
B
Deletion Model Targeting Strategy Phenotype Maternal KO Phenotype Paternal KO Publication
IG deletion IG-DMR loss of imprinting
lethal after E16
no loss of imprinting
viable
Lin et al., 2003
Meg3-DMR/exon1-5 deletion Meg3-DMR + Exon 1-5
lethal 4 weeks after birth
no loss of imprinting 
50% die perinatally 
25% die few days after birth
25% show growth retardation
Takahashi et al., 2009
Meg3-partDMR/exon1-5 partial deletion Meg3-DMR + Exon 1-5 loss of imprinting
pre-/perinatal death 
no loss of imprinting
growth retardation
Zhou et al., 2010
no loss of imprinting 
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expressed lncRNA Meg3 and the associated ncRNAs (Figure 1.7 B) (Lin et al., 2003; 
Takahashi et al., 2009; Zhou et al., 2010). 
Lin et al. generated a mouse strain with a 4.15 kb deletion covering the IG-DMR (Lin et al., 
2003). At E16, heterozygous animals were detected in the expected ratios. Later in embryonic 
development, the number of heterozygous live embryos was reduced in animals with maternal 
inheritance of the deleted IG-DMR. In these animals, bidirectional loss of imprinting on both 
alleles was observed in the locus, leading to loss of expression of the maternally expressed 
genes and gain of expression of the paternally expressed genes. These deregulations 
potentially lead to the observed lethality after E16. In contrast, offspring that inherited the 
targeted deletion from the father did not exhibit any phenotype, and no loss of imprinting was 
observed. In line, the model of Zhou et al. showed a highly similar phenotype (Zhou et al., 
2010). Here, a 5 kb deletion covering part of the Meg3 promoter, part of the Meg3-DMR and 
exon 1-5 was generated. Paternal deletion did not lead to loss of imprinting or deregulated 
expression patterns from the maternal or paternal allele. Maternal deletion, however, was 
associated with loss of imprinting and reactivation of paternal expression patterns, leading to 
loss of maternal genes and bi-allelic expression of paternal genes. Consequently, mice died 
perinatally and presented skeletal muscle defects. In contrast, a mouse model generated by 
Takahashi et al. exhibited a different phenotype (Takahashi et al., 2009). Deletion of a 10 kb 
region including the Meg3-DMR, the Meg3 promoter and exon 1-5 was performed. Mice with 
maternal deletion died 4 weeks after birth, but only loss of Meg3 expression was observed. 
ncRNAs from the maternal locus were still moderately expressed. In contrast, mice inheriting 
the deletion from the father mostly died perinatally. In these mice, expression of the paternal 
protein-coding genes was reduced, while ncRNAs from the maternal allele, but not Meg3, were 
upregulated. In addition, no loss of imprinting was observed, independently of deletion 
inheritance. Zhou et al. speculated that, in the model of Takahashi et al., the Neomycin 
promoter from the resistance cassette, which is oriented in the same direction as Meg3, leads 
to moderate expression of the ncRNA cluster in maternal deletion mice (Takahashi et al., 2009; 
Zhou et al., 2010). In line, this promoter would drive ncRNA expression from the paternal allele, 
leading to the observed upregulation of maternal ncRNAs in the paternal deletion mice 
(Takahashi et al., 2009; Zhou et al., 2010). In summary, Meg3 itself seems to be important to 
control imprinting of the Dlk1-Meg3 locus. In addition, the different phenotypes observed in 
these mouse models highlight the importance of study design and result interpretation.  
Studies in different cancer entities revealed that Meg3 might act as a tumor suppressor 
(Benetatos et al., 2011; Zhou et al., 2012). Zhang et al. could show that Meg3 expression was 
reduced in nonfunctioning pituitary tumors (Zhang et al., 2003). Re-expression of the lncRNA 
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in cancer cells led to inhibition of cellular proliferation. Loss of Meg3 expression has also been 
reported in meningioma, renal cell carcinoma, leukemia, neuroblastoma, pheochromocytoma 
and Wilms’ tumors (Astuti et al., 2005; Benetatos et al., 2008; Benetatos et al., 2010; 
Kawakami et al., 2006; Khoury et al., 2010; Zhang et al., 2010a). Interestingly, loss of Meg3 
expression in cancer is not caused by mutations or genomic deletions but mainly by 
methylation of IG- or Meg3-DMR, leading to silencing of the associated maternal locus and 
reactivation of paternal expression patterns (Benetatos et al., 2011; Zhou et al., 2012). In 
summary, Meg3 acts as a tumor suppressor gene and is epigenetically silenced in different 
tumor entities.   
In multiple myeloma (MM), myelodysplastic syndrome (MDS) and acute myeloid leukemia 
(AML) patients, aberrant methylation patterns of DMRs in the Meg3 locus were reported 
(Benetatos et al., 2008; Benetatos et al., 2010; Khoury et al., 2010). No association was 
observed between methylation patterns and AML subtypes. However, an increase in Meg3 
promoter methylation was associated with decreased overall survival of AML patients. 
Furthermore, an increase in Dlk1 expression, which is linked to silencing of the maternal 
expression patterns, was observed in the majority of AML patients (Khoury et al., 2010). In 
addition, acquired upd of the Dlk1-Meg3 locus has been shown to promote clonal 
hematopoiesis (Chase et al., 2015). Thus, Meg3 and the Meg3 locus harbor important tumor 
suppressor functions in the hematopoietic lineage.  
Different functional studies have been performed to identify the mode of action of Meg3, mostly 
in human tumor cell lines (Benetatos et al., 2011). In general, Meg3 seems to suppress Mdm2 
expression, leading to an increase in p53 levels (Zhou et al., 2007). Recently, Lyu et al. could 
show that Meg3 reduces AML cell proliferation via a p53-dependent but also a p53-
independent mechanism, presumably by downregulation of DNMT3a (Lyu et al., 2017). They 
also reported epigenetic silencing of the maternal locus, leading to loss of Meg3 expression. 
Interestingly, they could show that TET2 activates the Meg3 locus via WT1. Thus, TET2 
mutations, which are common in AML, could lead to silencing of Meg3. In addition, Meg3 
seems to suppress Rb phosphorylation directly and via activation of p16INK4A, which negatively 
regulates Cdk4/6-cyclin D complexes (Zhang et al., 2010c). Thus, in line with the observed 
tumor suppressor function, Meg3 acts as an inhibitor of cell cycle. Meg3 is also involved in 
regulating angiogenesis via vascular endothelial growth factor (VEGF) signaling (Zhou et al., 
2012). An increase in brain blood vessel development in Meg3 KO mice supports the 
hypothesis that Meg3 seems to inhibit the VEGF axis, thereby limiting angiogenesis (Gordon 
et al., 2010). In summary, Meg3 acts as a tumor suppressor by regulating p53 and Rb, thereby 
inhibiting proliferation, and by inhibition of VEGF, leading to a decrease in angiogenesis.  
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Meg3 expression is stimulated by cAMP response element binding protein (CREB) family 
activation and binding to cAMP response elements (CRE) located in the Meg3 proximal 
promoter (Zhao et al., 2006). Overall, care has to be taken when analyzing Meg3 function. 
Silencing of the maternally expressed genes does not only affect the lncRNA Meg3 but also 
the other ncRNAs encoded in this locus. In addition, methylation of IG- and Meg3-DMR leads 
to reactivation of the paternal expression patterns and therefore a 2-fold increase in protein 
levels of DLK1, RTL2 and DIO3. Thus, it is very difficult to distinguish between primary and 
secondary effects of Meg3 loss, especially as most studies are correlative and mainly analyze 
consequences of Meg3 silencing. However, no real mechanistic studies have been performed 
on how Meg3 is supposed to exert its multiple functions. As lncRNA functions are highly 
versatile, a better understanding of the mode of action of Meg3 is needed.  
1.2.6 The lncRNA Meg3 in hematopoiesis 
Different studies showed that specific lncRNAs play important roles in normal and malignant 
hematopoiesis, for example Lnc-HSC-2, H19 and Xist (Alvarez-Dominguez and Lodish, 2017; 
Luo et al., 2015; Venkatraman et al., 2013; Yildirim et al., 2013). Qian et al. focused on the 
role of the Dlk1-Meg3 locus in hematopoiesis (Qian et al., 2016). They showed that Meg3 is 
highly expressed in fetal liver as well as adult murine HSCs. Using the maternal IG-DMR KO 
mice (Lin et al., 2003), they observed reduced fetal liver HSC numbers and reduced fetal liver 
HSC long-term reconstitution capacity in adult recipient mice. They also reported a comparable 
phenotype using the mouse model generated by Takahashi et al. (Takahashi et al., 2009). 
Functionally, Qian et al. showed that loss of imprinting leads to hyperactivation of the PI3K-
mTOR pathway due to reduced expression of the Meg3 miRNA cluster. This hyperactivation 
causes an increase in mitochondrial metabolic activity in HSCs, causing elevated ROS levels 
and potentially HSC apoptosis. Qian et al. could show that global deregulation of the Meg3-
Dlk1 locus in the murine embryo leads to impairment of fetal liver HSCs. However, it remains 
elusive if these effects are of primary or secondary nature due to the whole-body deletion 
approach and the broad deregulation induced in their mouse model. In addition, fetal liver 
HSCs greatly differ from adult HSCs, as they are actively cycling and expanding (Bowie et al., 
2006; Nygren et al., 2006; Wilson et al., 2008). Thus, the role of Meg3 and the Meg3-Dlk1 
locus in adult HSCs remains to be determined.   
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1.3 The mechanism of alternative polyadenylation 
The majority of mRNA and lncRNA molecules undergo co-transcriptional polyadenylation in 
the nucleus. This process is important for nuclear export, mRNA stability and translation (Elkon 
et al., 2013; Tian and Manley, 2017). Polyadenylation involves endonucleolytic cleavage of the 
pre-mRNA strand and addition of the poly(A) tail to the 3’-UTR. In recent years, it has become 
apparent that the process of polyadenylation itself is an RNA regulatory mechanism influencing 
gene expression (Di Giammartino et al., 2011). More than 70% of mammalian mRNA-encoding 
genes harbor more than one functional cleavage site, and differential usage of these sites is 
termed alternative polyadenylation (APA) (Tian and Manley, 2017). APA regulates isoform 
expression and 3’-UTR length, which in turn influences translation efficiency, mRNA 
localization and stability and even protein localization (Di Giammartino et al., 2011; Mayr, 2017; 
Tian and Graber, 2012; Tian and Manley, 2017). 
1.3.1 Polyadenylation 
Pol II, a large protein complex consisting of multiple subunits, synthesizes all eukaryotic 
mRNAs and multiple ncRNAs with the exception of replication-dependent histone-encoding 
transcripts. This process is tightly regulated, and transcription initiation requires, for example, 
binding of multiple transcription factors as well as histone- and chromatin-modifying processes. 
In addition to its DNA-dependent RNA polymerase activity, Pol II acts as a platform and 
recruits, among others, epigenetic remodelers. It is also involved in RNA maturation by 
recruiting RNA capping, splicing and 3’-end processing factors (Gruber et al., 2014a).  
All RNA maturation processes mostly occur co-transcriptionally. Polyadenylation is an 
essential RNA maturation step, and all mRNAs, except for histone mRNAs, and many lncRNA 
molecules undergo polyadenylation (Elkon et al., 2013; Gruber et al., 2014a). In 1960, 
Edmonds et al. first described the enzymatic addition of a sequence of adenylate units to RNA 
(Edmonds and Abrams, 1960). Today, it is well known that the process of polyadenylation is a 
prerequisite for RNA nuclear export, stability and efficient translation (Elkon et al., 2013). 
Polyadenylation consists of two steps: endonucleolytic cleavage of the growing RNA strand 
and addition of the poly(A) tail. Hence, polyadenylation is regulated by the interaction of 
specific sequence motifs in the RNA and numerous different multiprotein complexes (Figure 
1.8) (Tian and Graber, 2012). The cleavage site is surrounded by different sequence motifs. 
For example, the so-called polyadenylation signal (PAS) is localized around 20 nt upstream of 
the respective cleavage site (Proudfoot and Brownlee, 1976; Tian and Graber, 2012). The two 
most common PAS variants are AAUAAA (~55%) and AUUAAA (~16%) (Beaudoing et al., 
2000; Tian et al., 2005). However, multiple other conserved PAS motifs have been described 
 Introduction  
  
 30 
 
(Beaudoing et al., 2000). In addition to the upstream PAS, downstream sequence motifs have 
been identified, including the U/GU-rich region (Hu et al., 2005; Hutchins et al., 2008). 
Upstream of the PAS, so-called UGUA motifs and U-rich elements are localized (Hu et al., 
2005; Hutchins et al., 2008). Important protein complexes mediating cleavage and 
polyadenylation are cleavage and polyadenylation specificity factor (CPSF), which binds to the 
polyadenylation signal AAUAAA and its variants, and the cleavage stimulatory factor (CstF), 
which interacts with U/GU-rich regions (Davis and Shi, 2014; Gruber et al., 2014a; Mandel et 
al., 2008). Cleavage factor Im (CFIm) binds to UGUA motifs upstream of the PAS and cleavage 
site. Interaction of these protein complexes leads to recruitment of the cleavage factor IIm 
(CFIIm) and poly(A) polymerase (PAP), initiating transcription termination, cleavage and 
polyadenylation. Moreover, other factors like Symplekin, which mediates CPSF-CstF 
interaction, and poly(A) binding protein 1 (PABPN1), which stabilizes and regulates the length 
of the poly(A) tail, are important. The C-terminal domain of Pol II acts as an assembly platform 
for these different multiprotein complexes (Davis and Shi, 2014; Gruber et al., 2014a; Mandel 
et al., 2008). Interaction of RNA motifs and different protein complexes leads to RNA cleavage 
at the cleavage site and addition of the poly(A) tail. Multiple different cleavage sites and the 
associated motifs exist in most pre-mRNAs, allowing APA.  
 
Figure 1.8: The cleavage and polyadenylation complex.  
Specific motifs in the RNA strand and different protein complexes mediate RNA cleavage and polyadenylation. 
Redrawn and modified based on (Gruber et al., 2014a).  
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1.3.2 Alternative polyadenylation 
Multiple PASs exists for most genes. Differential usage of these sites is termed APA and is 
regulated in tissue-, development-, and disease-specific patterns. APA seems to be an 
evolutionary conserved RNA regulatory mechanism, as the number of PASs for a given gene 
is conserved between species (Di Giammartino et al., 2011; Mayr, 2017). APA has been shown 
to influence mRNA stability, translation efficiency, nuclear export, and mRNA as well as protein 
localization (see 1.3.4). 
1.3.2.1 Genome-wide analysis of APA 
One of the first examples of functional APA was the discovery of the APA-mediated switch 
from the membrane-bound to the secreted form of IgM in B cells (Takagaki and Manley, 1998; 
Takagaki et al., 1996). Later, global analysis of APA was feasible by using expressed 
sequence tag (EST) databases and microarray approaches (Beaudoing et al., 2000; Gautheret 
et al., 1998; Sandberg et al., 2008; Tian et al., 2005). However, these approaches only allow 
limited analysis: EST library preparation does not enable analysis of all APA sites, and 
microarray analysis is based on previously identified sites for probe design (Elkon et al., 2013). 
Thus, early studies using these techniques underestimated the prevalence of APA and 
detected APA in not more than 60% of murine and human genes (Elkon et al., 2013). With the 
technical progress in RNA-seq, global analysis of APA sites and de novo discovery was 
simplified (Pickrell et al., 2010; Wang et al., 2008). In addition, novel bioinformatic analysis 
pipelines streamlined PAS prediction and APA analysis. However, it also became apparent 
that standard generation of RNA-seq libraries is disadvantageous for APA analysis (Chen et 
al., 2017; Elkon et al., 2013; Sun et al., 2012; Wilkening et al., 2013). Only few reads are 
localized in the 3’-UTR region, and only a limited number thereof is localized directly upstream 
of PAS, which are needed for bioinformatic prediction of APA patterns. Furthermore, during 
library amplification and sequencing, polymerase slippage leads to desynchronized, not 
analyzable reads within one cluster. This slippage is caused by residual parts of the poly(A) 
tail, which are present in libraries as A/T-stretches due to the oligo(dT)-priming step. All of 
these limitations hinder an in-depth analysis of APA using standard RNA-seq datasets (Chen 
et al., 2017; Wilkening et al., 2013). Thus, novel, specific sequencing approaches were 
developed to enable global APA analysis. In general, these are called 3’-enriched RNA-seq 
and include PAS-Seq, 3’-Seq and 3’READS (Chen et al., 2017; Elkon et al., 2013). All these 
methods use different strategies to specifically generate libraries that cover 3’-UTR regions 
and cleavage sites, for example fragmentation followed by oligo(dT)-priming or custom 
sequencing primers extending through the poly(A) tail part in sequencing libraries. Reliability 
of these methods has increased significantly during the last years, and today it is possible to 
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generate libraries for 3’-Seq analysis that enable global de novo APA analysis with high 
reliability (Chen et al., 2017; Elkon et al., 2013). In the dissertation at hand, a sequencing 
approach using a custom sequencing primer was used. Thus, read1 is derived from the 
terminal end of the utilized 3’-UTR, and no bioinformatic reconstitution of PAS usage is 
needed. The start of the read corresponds to the utilized cleavage site.  
Using these novel sequencing approaches, it has become apparent that at least 70% of all 
mammalian mRNA-encoding genes undergo APA (Derti et al., 2012; Hoque et al., 2013; Wang 
et al., 2018). Thus, APA is a widely used RNA regulatory mechanism, eventually influencing 
gene expression patterns.  
1.3.2.2 Modes of action of APA 
Two general modes of action are known for APA (Figure 1.9) (Di Giammartino et al., 2011). 
The so-called coding region APA (CR-APA) leads to the generation of different protein 
isoforms. The different PASs are localized in 3’-UTR regions, introns or sometimes even in 
exon structures. In CR-APA, the upstream coding sequence exon of the different PASs differs. 
Therefore, selection of different PASs does not only influence mRNA isoform expression but 
also protein isoform expression (Di Giammartino et al., 2011). Thus, CR-APA influences gene 
expression qualitatively. This process is tightly connected to alternative splicing, and 
competition between APA and splicing has been described.  
 
Figure 1.9: CR-APA and UTR-APA.  
By using PASs associated with different coding-sequence exons, CR-APA leads to the generation of mRNA 
isoforms encoding different protein isoforms. UTR-APA leads to the presence of mRNA isoforms varying only in the 
length of the 3’-UTR, depending on the selection of proximal versus distal PASs. The encoded protein isoform is 
identical, but differences in 3’-UTR length influence targeting by miRNAs and RNA-binding proteins (RBPs), thereby 
affecting RNA localization, stability and translation efficiency. Redrawn and modified based on (Di Giammartino et 
al., 2011). 
In addition, so-called untranslated region APA (UTR-APA) occurs. In this case, the protein 
isoform that is encoded is identical, only the length of the 3’-UTR differs (Di Giammartino et 
al., 2011). Depending on the selection of a more proximal or more distal PAS, the 3’-UTR can 
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be shorter or longer. For example, short 3’-UTRs have a median length of 249 nt, while long 
3’-UTRs have a median length of 1773 nt (Hoque et al., 2013). In general, it is thought that 
differences in 3’-UTR length enable fine-tuning of gene expression and protein localization, as 
the 3’-UTR provides an interaction platform (Di Giammartino et al., 2011; Elkon et al., 2013; 
Tian and Manley, 2017). The 3’-UTR contains miRNA-target sites, protein binding sites and 
regulatory sequences. By 3’-UTR choice, presence of these regulatory sequences is 
determined. Thereby, RNA stability, protein output as well as RNA and protein localization can 
be controlled (Di Giammartino et al., 2011; Elkon et al., 2013; Tian and Manley, 2017). In 
general, longer 3’-UTRs harbor more miRNA target sequences and destabilizing sequences, 
leading to lower stability of these mRNA transcripts (Di Giammartino et al., 2011). However, 
this hypothesis is still under debate. It has to be kept in mind that multiple PASs are present in 
most genes and PASs are localized in introns and in the annotated 3’-UTR regions. Thus, CR- 
and UTR-APA occur jointly, influencing the fate of the encoded mRNAs and proteins in multiple 
ways. 
1.3.3 PAS selection 
Today, we know that the majority of genes undergo APA, leading to the expression of different 
protein isoforms or to the regulation of 3’-UTR length. It is still not well understood how APA is 
regulated and how different cleavage sites are selected. Multiple layers of regulation seem to 
act synergistically (Di Giammartino et al., 2011; Elkon et al., 2013; Tian and Manley, 2017). In 
general, different PASs as well as up- and downstream motifs have varying strength in 
recruiting the cleavage and polyadenylation machinery. Some PAS motifs, for example, are 
stronger (e.g. AAUAAA) than others (e.g. CAUAAA), leading to intrinsic differences in motif 
selection (Hu et al., 2005; Tian et al., 2005). Generally, PASs that are more proximal to the 
coding sequence exon or localized in introns are considered weaker than those located further 
downstream (Di Giammartino et al., 2011; Elkon et al., 2013; Tian and Manley, 2017). Usage 
of stronger versus weaker sites is tightly regulated.  
1.3.3.1 APA regulation by 3’-end factors, RNA-binding proteins and splicing factors 
Different 3’-end factors have been shown to be involved in the regulation of APA. In general, 
higher levels of 3’-end factors have been associated with shorter 3’-UTRs. It is thought that 
higher levels of these processing factors enable recruitment to weaker sites, leading to usage 
of, for example, cryptic or less strong intronic or more proximal cleavage sites (Di Giammartino 
et al., 2011; Elkon et al., 2013; Tian and Manley, 2017). One prominent example occurs during 
B cell maturation. CstF64, a subunit of the CstF complex, is upregulated during the maturation 
process, leading to usage of a weaker upstream intronic PAS in the IgM heavy transcript. As 
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a consequence, IgM is no longer membrane-bound but secreted (Takagaki and Manley, 1998; 
Takagaki et al., 1996). In line, CstF64 silencing has recently also been shown to induce 3’-
UTR lengthening in HeLa cells, and its upregulation in different cancer entities is linked to 
global 3’-UTR shortening (Xia et al., 2014; Yao et al., 2013). Another example is the CPSF 
subunit Fip1, which upon knockdown leads to 3’-UTR lengthening (Lackford et al., 2014; Li et 
al., 2015). 
Vice versa, downregulation of Nudt21, a component of the CFIm complex, leads to shortening 
of 3’-UTRs (Gruber et al., 2012; Martin et al., 2012). These observations contradict the general 
hypotheses that downregulation of 3’-end factors is generally associated with 3’-UTR 
lengthening (Tian and Manley, 2017). However, how Nudt21 regulates APA is still not 
understood. In addition, Pabpn1 has been identified as an APA regulator that enhances usage 
of distal PASs. Pabpn1 knockdown leads to global 3’-UTR shortening (de Klerk et al., 2012; 
Jenal et al., 2012). Overall, the role of 3’-UTR factors in regulating 3’-UTR length and PAS 
choice seems to be highly versatile. While some seem to promote proximal PASs, others seem 
to enhance usage of distal PASs. In addition, changes in expression levels of some 3’-UTR 
factors did not affect APA patterns at all (Tian and Manley, 2017).  
Besides 3’-UTR factors, RNA-binding proteins, including hnRNP H and Elav family members, 
as well as splicing factors have been shown to regulate APA (Di Giammartino et al., 2011; 
Elkon et al., 2013; Tian and Manley, 2017). Alternative splicing and APA are tightly connected. 
For example, alternative splicing and CR-APA seem to compete regarding the usage of intronic 
cleavage sites (Tian et al., 2007). Alternative splicing leads to exclusion of intronic structures 
harboring PASs, which in turn cannot be used for APA. In line, inhibition of splicing leads to an 
increase in intronic polyadenylation levels (Li et al., 2015). Thus, it remains to be determined 
if splicing factors directly or rather indirectly control APA. For example, the splicing factor 
Nova2 seems to directly control APA. Nova2 has been shown to inhibit PAS usage by binding 
in close proximity, while binding distantly from the PAS enhances respective PAS usage 
(Licatalosi et al., 2008).  
In summary, the availability of different protein factors, including 3’-UTR processing factors, 
RNA-binding proteins and splicing factors, influence APA. These proteins can either enhance 
usage of weaker PASs or repress usage of stronger PASs. These proteins exhibit versatile 
modes of action, and the mechanism of how these proteins regulate APA is still poorly 
understood. 
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1.3.3.2 Chromatin status and epigenetic modifications influence APA 
Interestingly, accessibility of PASs has been linked to APA. For example, nucleosome 
depletion is observed in PAS regions and is more pronounced at the site of and downstream 
of strong PAS (Spies et al., 2009). Thus, nucleosome positioning seems to influence APA by 
regulating accessibility of specific PASs. However, current studies are purely correlative, and 
experimental validation of these hypotheses is needed.  
In addition to nucleosome positioning, genomic imprinting and thus specific DNA methylation 
patterns have been linked to APA regulation (Wood et al., 2008). Proximal as well as distal 
PAS clusters have been identified in the imprinted gene H13. These PAS clusters are 
separated by CpG islands. On the maternal allele, these CpG islands are methylated, and 
usage of the distal PASs is promoted. On the paternal allele, in contrast, the CpG island is not 
methylated, and usage of the proximal PASs is observed (Wood et al., 2008).  
Overall, nucleosome positioning as well as DNA methylation patterns influence APA (Di 
Giammartino et al., 2011; Elkon et al., 2013; Tian and Manley, 2017). The mechanisms, 
however, are still not understood. In addition, it remains to be determined if, for example, 
histone modifications also play a role in APA regulation.  
1.3.3.3 APA regulation by transcription 
APA is also regulated by transcription. A kinetic coupling between the Pol II elongation rate 
and distinct APA patterns has been reported (Elkon et al., 2013; Tian and Manley, 2017). Using 
Drosophila models, it was shown that slower elongation rates lead to usage of more proximal 
PASs (Pinto et al., 2011). The idea is that a slower Pol II leads to a longer holding time of the 
3’-end processing complex at the proximal PASs, leading to increased usage of these sites 
(Elkon et al., 2013; Tian and Manley, 2017). Again, detailed mechanistic insights into these 
processes are still missing. 
In addition, the transcription rate and transcription-activating factors have been shown to 
influence APA (Elkon et al., 2013; Tian and Manley, 2017). Higher gene expression levels 
have been linked to shorter 3’-UTR length, and certain transcription-activating factors have 
been shown to promote usage of distinct PASs (Ji et al., 2011; Nagaike et al., 2011; Rosonina 
et al., 2003). In summary, the transcription process itself regulates APA patterns and is 
important for 3’-UTR choice. 
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1.3.3.4 Different layers of regulation control APA 
Many different layers of APA regulation have been discovered in recent years, including 
regulation by RNA-binding proteins, 3’-end processing factors, chromatin and epigenetic 
regulators as well as transcription itself. However, detailed mechanistic studies on most of 
these processes are still lacking. In addition, novel layers of regulation are constantly 
described, including, for example, RNA modifications and RNA secondary structures (Di 
Giammartino et al., 2011; Elkon et al., 2013; Tian and Manley, 2017). Additional functional and 
mechanistic studies are needed to facilitate a deeper understanding of APA regulation.  
1.3.4 Biological functions of APA  
1.3.4.1 APA influences mRNA stability and translation 
Biological functions of APA are versatile. Previous studies have shown the relevance of APA 
in several biological processes, such as cellular quiescence and stress responses, using cell 
lines (Chang et al., 2015; Elkon et al., 2012; Hollerer et al., 2016). Sandberg et al. reported in 
2008 that activation of CD4+ T cells leads to an increased usage of proximal PASs, causing 
global 3’-UTR shortening (Sandberg et al., 2008). Forced expression of the long 3’-UTR 
versions led to a reduction in protein expression levels, presumably by miRNA targeting. 
Conclusively, Sandberg et al. showed that T cell activation is accompanied by 3’-UTR 
shortening, which in turn leads to an increase in protein expression. This is the first study in 
which an increase in proliferative status was linked to 3’-UTR shortening and in turn increased 
protein expression. In line with these reports, shortening of 3’-UTRs and increased protein 
expression has been reported in other immune cells, including for example macrophages (Jia 
et al., 2017; Pai et al., 2016). Further, Zheng et al. could show that cellular stress leads to a 
reduction in 3’-UTR length (Zheng et al., 2018). In contrast, Gruber et al. reported that 3’-UTR 
shortening in proliferating cells is not associated with changes in protein levels (Gruber et al., 
2014b). In line, Spies et al. reported a slightly higher translational efficiency of mRNAs with 
longer 3’-UTRs (Spies et al., 2013). Novel studies, however, partially contradict these findings. 
Fu et al. could show in 2018 that mRNAs with shorter 3’-UTRs are enriched in the polysome-
bound RNA fraction in most cell lines, indicating higher translation efficiency (Fu et al., 2018). 
However, they confirmed the findings of Spies et al. using the NIH3T3 cell line from the original 
study. Due to these inconsistent findings, Fu et al. performed additional analyses and could 
show that the cell cycle status of NIH3T3 cells is different from most other cell lines, with the 
majority of NIH3T3 cells in the G0/G1 state of the cell cycle due to contact inhibition. Using 
cells in different cell cycle phases, they could show that higher protein expression due to 
enhanced ribosome binding of short 3’-UTRs seems to be a property of actively proliferating 
cells in the G2/M phase. These findings at least resolve some of the contradictory results of 
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different studies. 3’-UTR length itself is not always an indicator of translation efficiency. The 
influence on protein expression seems to be dependent on the intrinsic cellular status of the 
cells. Actively proliferating cells exhibit shortened 3’-UTRs, in many cases leading to an 
increase in protein output from these transcripts, most likely due to evasion of miRNA targeting. 
Interestingly, mediators of cellular activation, like E2F transcription factors and mTOR, lead to 
3’-UTR shortening and an increase in protein output (Chang et al., 2015; Elkon et al., 2012).  
The 3’-UTR choice does not only influence translation and miRNA-targeting but also RNA-
stability. In general, long 3’-UTRs are thought to be less stable due to destabilizing sequences 
present in the extended 3’-UTR and due to nonsense-mediated mRNA decay (Elkon et al., 
2013). However, these hypotheses have been challenged by publications showing that longer 
3’-UTRs are only slightly less stable than their shorter counterparts, presumably due to 
stabilizing sequences present in the longer 3’-UTR version (Elkon et al., 2013; Spies et al., 
2013). As for 3’-UTR length and translation efficiency, regulation of mRNA stability by APA 
seems to be more complex than initially expected and appears to be influenced by the cellular 
status. 
1.3.4.2 APA mediates mRNA and protein localization 
APA has been shown to influence nuclear export efficiency and cytoplasmic mRNA localization 
(Elkon et al., 2013). While the role of APA for nuclear export is only poorly understood, several 
studies focused on the influence of 3’-UTR choice on subcellular mRNA localization, mainly in 
neurons. In these studies, it was shown that mRNA transcripts with the longer 3’-UTR version 
of a gene are transported to dendrites, while the transcripts with the shorter 3’-UTR version 
are retained in the cellular bodies (An et al., 2008; Andreassi and Riccio, 2009). It is thought 
that this mechanism is used to increase the protein concentration in certain sites by targeting 
the encoding mRNAs to the respective locations (Martin and Ephrussi, 2009).  
Recently, it was also observed that APA can influence protein localization. In a comprehensive 
study, Berkovits and Mayr could show that UTR-APA regulates CD47 localization (Berkovits 
and Mayr, 2015). CD47 protein translated from transcripts with the shorter 3’-UTR is localized 
in the ER. The longer 3’-UTR version acts as a scaffold molecule, recruiting RNA-binding 
proteins ELAVL1 and SET to the site of translation, which in turn mediate localization of the 
newly synthesized CD47 protein to the surface membrane by binding of SET to the cytoplasmic 
CD47 domain. The group could extend their findings to additional proteins, indicating that 
protein localization can be determined by 3’-UTR length variation without taking the detour of 
altering mRNA localization. 
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1.3.4.3 APA in health and disease 
Many studies have investigated the role of APA in different cellular systems, mostly in vitro, 
and in disease settings (Di Giammartino et al., 2011; Elkon et al., 2013; Tian and Manley, 
2017). For example, the role of APA during embryonic development and its prevalence in 
mature cellular populations, including testis, muscle and brain tissue as well as mature immune 
cells, was analyzed in vivo (Boutet et al., 2012; Jereb et al., 2018; Ji et al., 2009; Jia et al., 
2017; Lau et al., 2010; Mueller et al., 2016; Singh et al., 2018). In the hematopoietic field, 
mutations in PASs and deregulated intronic APA have been linked to hematological diseases, 
including thalassemia (Curinha et al., 2014) and leukemia (Lee et al., 2018). Furthermore, 
distinct individual genes undergoing APA and having functional consequences in the 
hematopoietic system and during hematopoietic cellular transformation have been reported 
(Cesana et al., 2018; Park et al., 2016). Here, I want to highlight some of the recent findings 
regarding the function of APA in health and disease.  
Interestingly, specific APA patterns were detected in immune cells and linked to certain 
activation states. As previously mentioned, Sandberg et al. could show that T cell activation in 
vitro is associated with 3’-UTR shortening (Sandberg et al., 2008). In line, Gruber et al. 
observed similar changes in human and murine T cells (Gruber et al., 2014b). Recent studies 
focusing on immune cells could confirm these findings. In 2016, Pai et al. could show that 
bacterial infection of macrophages in vitro leads to 3’-UTR shortening and thereby evasion of 
miRNA-mediated degradation and inhibition (Pai et al., 2016). These findings were further 
supported by a report of Jia et al., who showed that vesicular stomatitis virus infections also 
lead to 3’-UTR shortening in human and murine macrophages in vitro (Jia et al., 2017). All 
these studies show that immune cell activation is linked to a global shortening of 3’-UTRs, and 
most studies show that these changes lead to evasion of miRNA regulation and an increase 
in protein output (see also 1.3.4.1). In 2018, Singh et al. published an important report, showing 
that APA is also differentially regulated in immune cells in vivo (Singh et al., 2018). They 
performed 3’-Seq of primary human immune cells, among others, and could show that intronic 
polyadenylation is common, leading to generation of truncated proteins. Thus, immune cells 
exhibit different APA patterns and seem to actively regulate and depend on differential APA, 
especially upon activation.  
In addition, APA has been studied in different cancer entities (Tian and Manley, 2017). 
Exemplarily for many other studies, Xia et al. detected global 3’-UTR shortening in seven 
different tumor types (Xia et al., 2014). This leads to escape from miRNA targeting, and certain 
APA events can even be used as prognostic factors. By now, it has been acknowledged that 
cellular transformation is accompanied by changes in APA patterns, mainly 3’-UTR shortening. 
One could speculate that this is a consequence of the increased cellular proliferation, which 
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has also been linked to 3’-UTR shortening. However, we do not yet know if differential APA is 
a cause, a consequence or a prerequisite for cellular transformation. Notably, Lee et al. 
showed that intronic polyadenylation is increased in chronic lymphocytic leukemia (CLL) (Lee 
et al., 2018). This increase causes production of truncated proteins, leading to inactivation of 
tumor suppressor genes. For some of the affected genes, truncation did not only cause loss 
of tumor suppressor activity but also induced oncogenic potential. This was a landmark study, 
as it extends our current knowledge of APA in cancer and during cellular transformation, which 
had been characterized by mainly descriptive and correlative studies.  
In recent years, APA has also been analyzed in different developmental stages, in embryonic 
stem cells and other stem cell populations (Mueller et al., 2013). For example, progressive 
lengthening of 3’-UTRs was observed during the embryonic development of mice (Ji et al., 
2009). The authors hypothesized that this lengthening process enables increased fine-tuning 
of transcripts by a higher accessibility to post-transcriptional regulation, like miRNAs, in mature 
cells. Interestingly, reprogramming of differentiated cells towards the induced pluripotent stem 
cell (iPSC) state is accompanied by global 3’-UTR shortening (Ji and Tian, 2009). Lackford et 
al. could show that Fip1, a 3’ processing factor, is essential for embryonic stem cell (ESC) self-
renewal and somatic cell reprogramming (Lackford et al., 2014). Fip1 promotes stem cell 
maintenance and activates ESC-specific APA profiles. Upon differentiation, Fip1 
downregulation is accompanied by changes in APA profiles and 3’-UTR lengthening. In ESCs, 
Fip1 promotes usage of proximal PASs, leading to globally shortened 3’-UTRs. In addition to 
Fip1, other APA mediators have been identified to be important for ESC function, including 
NUDT21 (Brumbaugh et al., 2018). 
Studies on adult stem cells have mainly focused on muscle stem cells and neural development 
(Boutet et al., 2012; Lau et al., 2010; Mansfield and Keene, 2012; Mueller et al., 2016). In these 
studies, APA events affecting specific genes have been functionally studied. However, a global 
in-depth analysis of APA in stem cell hierarchies is still lacking. To date, we do not know how 
global differential APA is affected by and affects stem cell differentiation, activation and 
quiescence in vivo (Mueller et al., 2013). The hematopoietic system with its very well defined 
quiescent stem cell and active progenitor populations presents a model system that can be 
used to study these questions and to draw conclusions that could be representative for other 
stem cell hierarchies in vivo. Studies focusing on changes in polyadenylation patterns of the 
gene Hmga2 in HSCs and Atg7 in MDS and leukemia hint that APA could indeed be a 
mechanism that plays an important functional role in hematopoiesis and within the 
hematopoietic hierarchy (Cesana et al., 2018; Park et al., 2016). In summary, the global role 
of APA in functional stem cell hierarchies remains elusive.  
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1.4 Generation of genetic mouse models using CRISPR/Cas9 
1.4.1 Transgenic mouse models 
Transgenic mouse models have been developed to study gene function in vivo. For example, 
global or tissue-specific knockout and overexpression models are available. In addition, these 
mouse models can also be designed to be inducible, for example by using tamoxifen-
dependent Cre recombinases. Furthermore, specific mutations can be introduced, enabling 
the study of these mutations in disease settings. For studying gene expression patterns in 
different tissues and identification of cells expressing the respective genes, fluorescent 
reporter mice can be generated. These are only some of the possibilities to employ transgenic 
animals to better understand complex processes in vivo in health and disease.  
Many different techniques have been developed to generate transgenic mouse models. Most 
commonly, homologous recombinant ESC clones are used to generate transgenic mice. ESCs 
can be cultured in vitro and can be genetically modified. A targeting vector is used to introduce 
the transgene by homologous recombination. Subsequently, successfully edited clones are 
selected, e.g. by resistance against a specific selection agent. These clones are analyzed in 
depth to ensure correct targeting of the sequence of interest and can then be injected into 
blastocysts, leading to the generation of chimeric animals, which can subsequently be used to 
generate homogenous transgenic animals by crossing. (Bouabe and Okkenhaug, 2013; Miao, 
2013) 
This approach is, however, highly time-consuming. Today, transgenic animal models can be 
generated in an efficient and convenient way using the CRISPR/Cas9 system. 
1.4.2 The CRISPR/Cas9 system 
The clustered regularly interspaced short palindromic repeat (CRISPR) system was first 
discovered as an antiviral mechanism in bacteria, where it cleaves foreign nucleic acids 
(Fineran and Charpentier, 2012; Wiedenheft et al., 2012). This system has been adapted to 
enable sequence-specific induction of DNA double-strand breaks (DSB) for targeted genome 
editing (Jinek et al., 2012).  
In this system, a so-called single-molecule guide RNA (gRNA) is used to direct a nuclease, 
namely Cas9 (derived from S. pyogenes), to a specific target DNA sequence (Figure 1.10) 
(Sander and Joung, 2014). The gRNA is a fusion of the CRISPR RNA (crRNA), which directs 
the Cas9 to the target site, and the transactivating CRISPR RNA (tracrRNA), which is bound 
by Cas9. However, nowadays some systems start using the two-molecule crRNA:tracrRNA 
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hybrids as originally detected in bacteria, since this approach seems to be more efficient than 
single-molecule gRNAs. By complementary base-pairing, the gRNA-Cas9 complex is 
specifically directed to the target site. A prerequisite for this target site is the presence of a 
protospacer adjacent motif (PAM) immediately downstream of the target sequence. The 
canonical PAM signal is NGG, thus the Cas9 complex can be targeted to any N20-NGG DNA 
sequence. Today, additional Cas9 nucleases from bacteria have been detected that utilize 
other PAM sequences. Therefore, the number of genomic regions that can be targeted is 
steadily increasing. (Sander and Joung, 2014) 
After binding to the target site, the Cas9 complex cleaves the DNA, generating a DNA DSB. 
This introduces insertion-deletion (indel) mutations by non-homologous end-joining. These 
mutations can lead to amino acid deletions in the encoded proteins, insertions or frameshift 
mutations causing premature stop codons within the open reading frame (ORF) of the targeted 
gene, eventually leading to a gene knockout. By providing template DNA strands, the Cas9-
induced DSB can be used for homology-directed repair (HDR). Thereby, specific gene 
sequences, like point mutations or even fluorescent reporter sequences, can be introduced. 
Furthermore, so-called dead Cas9 (dCas9), which has no nuclease activity, has been fused to 
activation or effector domains. With the help of the gRNA, the complex is targeted to a specific 
region, where it leads to gene activation or changes of chromatin or DNA modifications using 
the additional domains. (Sander and Joung, 2014) 
In summary, the CRISPR/Cas9 approach is a highly flexible method to target and edit specific 
genomic sequences. Adaptations of this system extended its usage beyond the initial 
introduction of relatively simple indel mutations. However, care has to be taken during gRNA 
design to minimize off-target cleavage events.  
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Figure 1.10: The CRISPR/Cas9 system.  
The crRNA:tracrRNA hybrid assembles by base pairing (green box). The crRNA is complementary to the DNA 
target site, and the tracrRNA is important for complex formation with the Cas9 nuclease. Alternatively, a single-
molecule gRNA can be used (orange box). In both cases, a crRNA-tracrRNA/gRNA:Cas9 complex assembles. This 
complex is directed to the target site by base pairing. The presence of a PAM sequence is a prerequisite for 
CRISPR/Cas9 targeting. The Cas9 nuclease induces a DNA DSB at the target site. Redrawn and modified based 
on (Sander and Joung, 2014). 
1.4.3 Easi-CRISPR 
Different approaches have been used to employ CRISPR/Cas9-mediated genome editing to 
generate knockout mice and targeted transgenic mice (Burgio, 2018; Liu et al., 2017). Here, I 
aim to introduce one of the many described systems for creating knock-in mice using 
CRISPR/Cas9, namely efficient additions with ssDNA inserts-CRISPR (Easi-CRISPR) (Miura 
et al., 2018; Quadros et al., 2017).  
In this method, crRNA and tracrRNA molecules are precomplexed with Cas9. Long single-
stranded DNA (ssDNA) donor molecules with short homology arms of only around 100 bp are 
used as templates (Figure 1.11). This method can for example be used to introduce loxP sites 
or other knock-in alleles. For introduction of loxP sites, two different crRNA-tracrRNA:Cas9 
complexes are employed that cut upstream and downstream of the region of interest, 
respectively. The ssDNA template contains a short upper homology arm, the upper loxP site, 
the target exon, the lower loxP site and a short lower homology arm. The crRNA-
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tracrRNA:Cas9 complexes are microinjected into one of the pronuclei of a zygote together with 
the long ssDNA template. The offspring can then be genotyped to identify founder animals. 
Using this technique, inserts of up to 1.5 kb can be introduced, and targeting efficiency is 
usually between 30-60%. As all custom-made components needed for the injection mix can 
be purchased, Easi-CRISPR allows fast generation of transgenic knock-in mice in only ~3 
months of time.  
 
Figure 1.11: Schematic representation of Easi-CRISPR.  
For introduction of loxP sites, 2 crRNA-tracrRNA:Cas9 complexes are precomplexed, targeting the upper and the 
lower integration site, respectively. In addition, a ssDNA template is provided that harbors short (~100 bp) upper 
and lower homology arms, the loxP sites and the target exon. These components are injected into one of the 
pronuclei of a zygote. In the pronucleus, the Cas9 complexes induce two DSBs and the template sequence 
containing the loxP sites is integrated via HDR. Redrawn and modified based on (Quadros et al., 2017). 
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2 Aim of the thesis 
Omics analyses have recently been applied to HSCs and MPP populations to further 
investigate regulatory processes. The results revealed that not only proteins but also splicing 
variants and lncRNAs show differential expression (Cabezas-Wallscheid et al., 2014; 
Klimmeck et al., 2014; Luo et al., 2015). These observations suggest that expression of non-
coding RNAs and regulation of RNA biogenesis could be crucial for a functional hematopoietic 
system. In this thesis, I aimed to uncover the role of lncRNAs and RNA regulatory mechanisms 
in HSCs and hematopoiesis. 
The role of lncRNAs in different biological systems is attracting increasing attention (Morris 
and Mattick, 2014). Specific lncRNAs have been shown to be essential for HSC function and 
hematopoiesis (Alvarez-Dominguez and Lodish, 2017; Luo et al., 2015; Yildirim et al., 2013). 
Cabezas-Wallscheid et al. showed that the lncRNA Meg3 is highly and specifically expressed 
in the HSC compartment (Cabezas-Wallscheid et al., 2017; Cabezas-Wallscheid et al., 2014). 
Therefore, we hypothesized that Meg3 plays an important regulatory role in hematopoiesis. 
Recently, Qian et al. reported that the Dlk1-Meg3 locus has important functions in fetal 
hematopoiesis (Qian et al., 2016). Using fetal liver HSCs, they showed that long-term 
repopulation capacity of these cells is impaired upon loss of imprinting of the maternally 
inherited Meg3 allele. As fetal liver HSCs greatly differ from adult HSCs (Bowie et al., 2006; 
Nygren et al., 2006; Wilson et al., 2008), the role of Meg3 and the Dlk1-Meg3 locus in adult 
HSCs remains elusive. Thus, I aimed to uncover the function of Meg3 in the adult 
hematopoietic compartment (Figure 2.1, blue part). To this end, I analyzed the hematopoietic 
system of induced MxCre Meg3 mat flox/pat wt mice. To assess HSC functionality, I performed in 
vitro CFU assays and BM transplantations. In addition, I intended to uncover the role of Meg3 
upon acute inflammatory stress and after recovery. 
In recent years, regulation of DNA methylation, gene expression, enhancer regions, protein 
translation as well as alternative splicing have been shown to be crucial for HSC self-renewal, 
function and differentiation (Bahr et al., 2018; Cabezas-Wallscheid et al., 2014; Goldstein et 
al., 2017; Ji et al., 2010; Lipka et al., 2014; Signer et al., 2014). We know that multiple layers 
of regulation act synergistically to tightly control HSC fate and function. Perturbations in those 
tightly regulated systems can lead to stem cell failure or even development of hematologic 
malignancies. An additional regulator of cells is the newly discovered RNA regulatory 
mechanism APA (Tian and Manley, 2017). It is still poorly understood if APA is functionally 
important for stem cells in vivo. In addition, it is not known if differential APA is essential for 
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stem cell differentiation and activation. In this thesis, I aimed to investigate if APA is functionally 
important for hematopoiesis and HSCs (Figure 2.1, yellow part). By using lentiviral knockdown 
of APA regulators, I analyzed the functional role of this process in hematopoiesis. In addition, 
I intended to perform 3’-Seq on homeostatic and activated HSPCs to investigate global APA 
changes upon HSC differentiation and activation. In the following, I aimed to functionally 
validate differential APA hits. This included APA-mediated activation of glutaminolysis in the 
HSC compartment upon HSC activation and differentiation. In addition, I aimed to establish a 
transgenic mouse model using CRISPR/Cas9 that would enable inducible knockout of the 
prominent APA regulator Pabpn1 in vivo (Figure 2.1, green part).  
 
Figure 2.1: Visual summary of study aims.  
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3 Results 
3.1 The lncRNA Meg3 is dispensable for HSCs 
3.1.1 Meg3 expression is specifically upregulated in the HSC compartment 
Previous studies found the lncRNA Meg3 to be very highly and specifically expressed in HSCs 
(Cabezas-Wallscheid et al., 2017; Cabezas-Wallscheid et al., 2014; Klimmeck et al., 2014). 
To confirm this expression pattern, we sorted HSCs and MPP cells gating for lineage-negative 
(CD4, CD8, B220, Ter119, CD11b, Gr1) cells using cKit, Sca-1, CD150, CD48 and CD34 as 
markers and isolated total RNA (Figure 3.1 A-B). Analysis of previously generated RNA-seq 
data showed Meg3 to be exclusively expressed in HSCs compared to progenitor cells (Figure 
3.1 C). We could validate this expression pattern by quantitative real-time PCR (qPCR) 
analysis (Figure 3.1 D). In addition, analysis of Meg3 expression in HSCs in different 
developmental stages was performed (Figure 3.1 E). We observed a significant decrease in 
Meg3 levels in adult HSCs (8-12 weeks old mice) compared to fetal liver HSCs (E13.5; CD48- 
CD41+ cKit+ CD34+). However, no significant decrease in Meg3 levels in the HSC 
compartment upon aging of adult mice was detected (24 months old mice). Thus, Meg3 is 
highly and specifically expressed in HSCs independently of the developmental stage, but a 
slight reduction in overall levels is observed during development and aging.  
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Figure 3.1: Meg3 expression is specifically upregulated in the HSC compartment.  
(A) Surface marker profiles of HSCs and MPPs used in flow cytometry analysis and sorting of BM cells. CD135 was 
only included for analysis in Fig. 1 C and 1 E (Panel A), for all other experiments Panel B was used. (B) 
Representative flow cytometry dot plots showing the gating strategy for HSCs and MPP1-4 cells using Lin, c-Kit, 
Sca-1, CD48, CD150 and CD34 as markers. (C) Analysis of Meg3 expression by RNA-seq. Data derived from 
(Cabezas-Wallscheid et al., 2014). N = 3-4. (D) Analysis of Meg3 expression by qPCR. N = 3, one-way ANOVA. 
(E) qPCR-based Meg3 expression analysis in fetal liver (FL) at E13.5, adult BM and aged BM HSCs. N = 3, student’s 
t-test. For all panels: *p < 0.05, **p < 0.01, ***p < 0.001, ns: not significant; N indicates number of biological 
replicates; 3 independent experiments were performed; mean + SD is shown. Figure is adapted from (Sommerkamp 
et al., 2019). 
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3.1.2 Loss of Meg3 expression does not impair adult homeostatic 
hematopoiesis 
3.1.2.1 Successful deletion of Meg3 in MxCre Meg3 mat flox/pat wt mice after Cre induction 
Previously, the Dlk1-Meg3 locus has been shown to be essential for fetal liver HSC function 
(Qian et al., 2016). Fetal liver HSCs and adult BM HSCs exhibit differences in cellular 
properties, for example fetal liver HSCs are actively cycling in contrast to adult BM HSCs 
(Bowie et al., 2006; Nygren et al., 2006; Wilson et al., 2008). Thus, after confirming Meg3 
expression patterns in the adult HSC/MPP compartment, we aimed to investigate the role of 
Meg3 in adult hematopoiesis. To this end, we utilized Meg3 mat flox/pat flox mice kindly provided by 
the laboratory of Dr. Klibanski, Boston. In these mice, exon 1 to 4 of the Meg3 gene are floxed. 
As the Meg3 locus is imprinted and Meg3 is only expressed from the maternally inherited allele 
harboring unmethylated DMRs, we crossed male MxCre driver mice to female Meg3 mat flox/pat 
flox mice, thereby generating MxCre Meg3 mat flox/pat wt mice (from now on called Meg3 KO) (Figure 
3.2 A). Meg3 KO mice and MxCre+ control mice were repeatedly injected with pIC 6 to 18 
weeks after birth to induce expression of Cre (Figure 3.2 B). pIC injections lead to an 
inflammatory response activating the Mx1 promoter, which controls Cre expression in 
hematopoietic cells (Kuhn et al., 1995). Analysis was performed after 7 to 12 weeks, allowing 
recovery of the hematopoietic system to a homeostatic state. First, we aimed to validate loss 
of Meg3 expression in induced Meg3 KO mice. Hence, we sorted HSCs from control and KO 
animals, isolated RNA and performed qPCR analysis (Figure 3.2 C). We observed complete 
loss of Meg3 expression in induced MxCre Meg3 KO animals, confirming the efficiency of our 
KO approach. Deletion of Meg3 and loss of Meg3 transcription has been shown to abolish 
expression of the downstream maternally expressed miRNA cluster (Lin et al., 2003; Zhou et 
al., 2010). To analyze expression of the miRNA cluster in our KO model, we performed small 
RNA-seq analysis using LSK SLAM cells (LSK CD150+ CD48-) (Figure 3.2 D). In total, around 
49 miRNAs are associated with the Meg3 cluster (Seitz et al., 2004; Winter, 2015). In our 
control dataset, we only observed 9 miRNAs of this cluster to be stably expressed. 
Presumably, detection of the other miRNAs of the cluster was not possible due to limited 
sequencing depth. Strikingly, we detected only 11 miRNAs to be differentially expressed in 
Meg3 KO compared to control cells, with 9 of these miRNAs being the initially identified Meg3 
cluster miRNAs. All of these miRNAs were strongly downregulated. In summary, we 
successfully deleted Meg3 expression and expression of the associated miRNA cluster by 
targeting the maternal allele in the adult hematopoietic compartment.  
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Figure 3.2: Successful deletion of Meg3 in MxCre Meg3 mat flox/pat wt mice after Cre induction.  
(A) Schematic representation of the Dlk1-Meg3 locus. (B) Workflow of pIC-mediated Cre induction in control and 
MxCre Meg3 mat flox/pat wt mice and consecutive analysis. (C) Analysis of Meg3 expression in sorted control and Meg3 
mat KO HSCs. N = 7, unpaired student’s t-test. (D) Differential mature miRNA expression analysis by small RNA-
seq in sorted LSK CD150+ CD48- cells (LSK SLAM). Adjusted p-value <0.1 is shown. For all panels: *p < 0.05, **p 
< 0.01, ***p < 0.001, ns: not significant; N indicates number of biological replicates; 3 independent experiments 
were performed; mean + SD is shown. Figure is adapted from (Sommerkamp et al., 2019). 
3.1.2.2 Production and frequency of mature blood cells in primary and secondary 
hematopoietic organs is not affected by loss of Meg3 expression 
First, we aimed to investigate the effects of Meg3 KO in the hematopoietic system on the 
frequency of mature blood cells. Seven to twelve weeks after deletion, peripheral blood was 
analyzed by flow cytometry (Figure 3.3 A). We did not observe changes in the frequency of 
mature B cells (B220+), T cells (CD4/8+) and myeloid cells (Gr1+ CD11b+) (Figure 3.3 B). In 
addition, we analyzed mature cell frequencies and B cell maturation in the BM by using IgM 
expression as an additional marker (pre/pro B cells: B220low IgM-; immature B cells: B220low 
IgM+; mature B cells: B220high IgM+) (Figure 3.3 C). Again, we did not observe major 
differences (Figure 3.3 D). Only the frequency of immature B cells was slightly increased in 
Meg3 KO animals. Analysis of secondary hematopoietic organs also did not exhibit any 
changes upon loss of Meg3 expression, as mature cell frequencies in the spleen and T cell 
maturation in the thymus were unaffected (Figure 3.3 E-F). T cell maturation was analyzed by 
investigating the CD4- CD8- compartment using CD25 and CD44 to identify DN1-DN4 
populations. In conclusion, mature cell frequencies in hematopoietic organs and the peripheral 
blood are not perturbed by loss of Meg3 and the associated miRNA cluster in the hematopoietic 
system. 
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Figure 3.3: Production and frequency of mature blood cells in primary and secondary hematopoietic organs 
is not affected by loss of Meg3 expression.  
(A) Representative flow cytometry dot plots of PB analysis. (B) Flow cytometry-based analysis of mature cells in 
the peripheral blood. N = 12-18, unpaired student’s t-test. (C) Representative flow cytometry dot plots showing 
analysis of differentiated BM cells. (D) Flow cytometry-based analysis of B cell maturation and mature cells in the 
BM compartment. N = 12-18, unpaired student’s t-test. (E) Flow cytometry-based analysis of mature cells in the 
spleen. N = 12-18, unpaired student’s t-test. (F) Flow cytometry-based analysis of T cell maturation in the thymus. 
N = 9-13, unpaired student’s t-test. For all panels: *p < 0.05, **p < 0.01, ***p < 0.001, ns: not significant; N indicates 
number of biological replicates; 3 independent experiments were performed; mean + SD is shown. Figure is adapted 
from (Sommerkamp et al., 2019). 
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3.1.2.3 HSPC frequencies are unchanged upon hematopoietic deletion of Meg3 
To investigate direct effects of Meg3 loss on the HSC/MPP compartment, we performed flow 
cytometry analysis of BM cells using Lin, cKit, Sca-1, CD150, CD48 and CD34 as markers 
(see 3.1.1). The BM frequency of HSCs and MPP1-3/4 cells was unchanged (Figure 3.4 A). 
Furthermore, we aimed to analyze the cell cycle status of control and KO cells, as Meg3 has 
been described to inhibit proliferation (Braconi et al., 2011; Wang et al., 2012; Zhang et al., 
2010a; Zhang et al., 2003; Zhou et al., 2007). We used intracellular Ki-67 staining and the DNA 
dye Hoechst 33342 to analyze the cell cycle status of HSCs and MPP cells (G0: Ki-67- 1-
chromatide chromosomes (1-C-C); G1: Ki-67+ 1-C-C; S/G2/M: Ki-67+ 2-C-C) (Figure 3.4 B). 
As previously described, HSC control cells were highly quiescent and mainly in the G0 state 
of the cell cycle (>80%; Figure 3.4 C) (Wilson et al., 2008). As expected, MPP cells became 
increasingly more activated, with MPP2 cells exhibiting the highest frequency of cells in the 
S/G2/M phase (>20%) (Wilson et al., 2008). Meg3 KO HSCs did not exhibit any alterations in 
the cell cycle status. However, we detected slightly increased cellular quiescence in MPP1-3/4 
cells. To analyze the molecular profile of HSCs in response to Meg3 KO, we again sorted 
control and KO HSCs and performed qPCR analysis (Figure 3.4 D). We analyzed expression 
patterns of previously described HSC-specific genes and HSC regulatory genes (Cabezas-
Wallscheid et al., 2017). Except for a minor reduction in Cdk6 levels, we did not observe any 
deregulated expression of HSC key regulatory genes upon loss of Meg3. Collectively, no major 
changes in the HSC/MPP compartment in Meg3 KO animals were detected. In addition, the 
molecular profile of HSCs remained unchanged. 
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Figure 3.4: HSC and MPP frequencies are unchanged upon hematopoietic deletion of Meg3.  
(A) Flow cytometry-based analysis of the HSC/MPP compartment in the BM. Percentage of BM HSCs/MPPs is 
shown. N = 11–16, unpaired student’s t-test. (B) Representative flow cytometry zebra plots (including outliers) 
showing cell cycle analysis of BM HSC/MPP populations. (C) Analysis of cell cycle status in HSCs/MPPs. Relative 
percentage within each cell cycle phase is depicted. N = 9–15, two-way ANOVA. Shaded in orange: Meg3 KO (D) 
qPCR-based analysis of HSC signature gene expression in sorted control and Meg3 mat KO HSCs. N = 3, unpaired 
student’s t-test. For all panels: *p < 0.05, **p < 0.01, ***p < 0.001, ns: not significant; N indicates number of biological 
replicates; 3 independent experiments were performed; mean + SD is shown. Figure is adapted from (Sommerkamp 
et al., 2019). 
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3.1.2.4 HSC function in vitro and long-term engraftment in vivo is not impaired upon 
loss of Meg3 expression 
Hematopoietic defects in the HSC/MPP compartment might not become apparent in adult mice 
7 to 12 weeks after Meg3 deletion, as contribution to mature cellular output is low and 
production of blood cells can be maintained by more committed progenitors for a limited 
timeframe (Busch et al., 2015; Sun et al., 2014). To asses HSC function, we performed in vitro 
CFU assays and in vivo transplantation experiments (Figure 3.5 A). Functional HSCs are able 
to form colonies in vitro in primary and secondary platings. In vivo, they engraft in lethally 
irradiated recipient mice and contribute to peripheral blood production even in tertiary 
transplants (Purton and Scadden, 2007). Nine weeks after Meg3 deletion, total bone marrow 
cells were isolated, and colony forming capacity was investigated. Control as well as KO cells 
formed colonies in primary and secondary CFU assays, and no significant differences were 
observed (Figure 3.5 B). To generate full chimeras, 1x106 control or KO total BM cells 
(CD45.2+) were transplanted into lethally irradiated recipients (CD45.1+) by intravenous 
injection. The allelic variants of CD45 (CD45.1 and CD45.2) can be distinguished in flow 
cytometry analysis using specific antibodies and allow differentiation between cellular 
contribution of recipient and donor (Figure 3.5 C) (Purton and Scadden, 2007). Analysis of the 
peripheral blood exhibited equal contribution of control as well as KO BM cells to mature 
cellular output in primary recipients (Figure 3.5 D). Serial transplantation was performed by 
retransplanting 3x106 BM cells into lethally irradiated recipient mice. In secondary and tertiary 
recipients, we again did not observe any functional defects in Meg3 KO HSCs (Figure 3.5 D). 
Analysis of mature cellular lineages, including B cells, T cells and myeloid cells, did not exhibit 
any defects of Meg3 KO cell contribution to mature lineage output in primary, secondary and 
tertiary recipient mice over time (Figure 3.5 E-G).  
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Figure 3.5: HSC function in vitro and long-term engraftment in vivo is not impaired upon loss of Meg3.  
(A) Workflow depicting Cre induction by pIC and functional analysis by CFU assays and generation of full chimeras. 
(B) Serial CFU assays. N = 5–6, unpaired student’s t-test. (C) Representative flow cytometry dot plots showing PB 
analysis of full chimeras. (D) Flow cytometry-based analysis of serial full transplantation experiments. CD45.2% 
outcome is shown. N = 9, two-way ANOVA. (E-G) Flow cytometry-based analysis of serial full transplantation 
experiments. CD45.2% outcome is shown for T cells (E), B cells (F) and myeloid cells (G). N = 7-9, two-way ANOVA. 
For all panels: *p < 0.05, **p < 0.01, ***p < 0.001, ns: not significant; N indicates number of biological replicates; B: 
2 independent experiments were performed; D-G: 1 independent experiment was performed; mean + SD is shown. 
Figure is adapted from (Sommerkamp et al., 2019). 
In addition to peripheral blood, we also performed analysis of BM and spleen cells of recipient 
animals. Here, analysis of primary recipients is shown exemplary (Figure 3.6). First, we 
investigated the frequency of transplanted HSCs and MPP cells by using HSC/MPP markers 
and analyzing CD45.2 contribution (Figure 3.6 A). We did not observe any changes in 
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engrafted HSCs and MPP cells did not display significant changes in cycling activity in KO 
cells (Figure 3.6 B). Only MPP3 KO cells showed a slight increase in G1 and a slight decrease 
in S/G2/M. To confirm persistent Meg3 deficiency, we sorted CD45.2+ HSCs of primary 
recipients and analyzed Meg3 expression by qPCR analysis (Figure 3.6 C). No Meg3 
expression was detected in transplanted KO HSCs, verifying stability of our KO approach. In 
addition, we analyzed cellular contribution in the BM and spleen (Figure 3.6 D-E). Again, we 
did not observe changes in CD45.2+ contribution in hematopoietic organs. The same analysis 
of BM HSC/MPP and mature BM and spleen cells was also performed using material derived 
from secondary and tertiary recipients (data not shown). In line, no changes were observed in 
response to loss of Meg3 expression. In summary, in vitro function as well as long-term 
engraftment potential of HSCs is not affected upon KO of Meg3 and loss of expression of the 
associated miRNA cluster. 
 
Figure 3.6: HSC long-term engraftment in vivo is not impaired upon loss of Meg3.  
(A) Flow cytometry-based analysis of BM of primary recipients 18 weeks after transplantation showing the 
HSC/MPP compartment. CD45.2% outcome is shown. N = 9, unpaired student’s t-test. (B) Cell cycle analysis of 
transplanted CD45.2+ HSCs/MPPs. Relative percentage within each cell-cycle phase is shown. N = 6–9, two-way 
ANOVA. Shaded in orange: Meg3 KO (C) Analysis of Meg3 expression by qPCR in sorted CD45.2+ control and 
Meg3 mat KO HSCs from primary recipient animals. N = 5-6, unpaired student’s t-test. (D) Flow cytometry-based 
analysis of mature cells in the BM of primary recipients 18 weeks after transplantation. CD45.2% outcome is shown. 
N = 9, unpaired student’s t-test. (E) Flow cytometry-based analysis in the spleen of primary recipients 18 weeks 
after transplantation. Mature cells were analyzed. CD45.2% outcome is shown. N = 9, unpaired student’s t-test. For 
all panels: *p < 0.05, **p < 0.01, ***p < 0.001, ns: not significant; N indicates number of biological replicates; 1 
independent experiment was performed; mean + SD is shown. Figure is adapted from (Sommerkamp et al., 2019). 
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3.1.2.5 Loss of Meg3 expression does not impair the competitive potential of HSCs 
If HSC function is only slightly impaired or HSC expansion kinetics are affected, defects might 
not become apparent in full chimera transplantation experiments (see 3.1.2.4). To ensure that 
we do not overlook minor changes in HSC potential upon loss of Meg3 expression, we 
additionally set up competitive transplantation experiments. 2x105 control or KO BM cells 
(CD45.2) were mixed with 2x105 competitor BM cells (CD45.1/.2) and transplanted into lethally 
irradiated recipients (CD45.1) (Figure 3.7 A). Analysis of the peripheral blood was performed 
approximately every 4 weeks (Figure 3.7 B), and secondary and tertiary recipients were 
generated and analyzed over time (3x106 BM cells). Analysis of the peripheral blood 
contribution of CD45.2+ cells in long-term serial competitive chimeras did not exhibit loss of 
HSC engraftment upon deletion of the maternal Meg3 allele (Figure 3.7 C). In addition, we also 
analyzed contribution in defined mature cell populations, including T cells, B cells and myeloid 
cells in serial transplantation experiments (Figure 3.7 D-F). Again, we did not observe any 
impairments in lineage output upon transplantation of Meg3 KO cells. Collectively, our data 
shows that, even in highly competitive serial long-term transplantation experiments, Meg3 KO 
HSCs do not exhibit decreased stem cell potential in comparison to control HSCs.  
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Figure 3.7: Loss of Meg3 expression does not impair the competitive potential of HSCs.  
(A) Workflow showing Cre induction and functional analysis by generation of competitive chimeras. (B) 
Representative flow cytometry dot plots showing PB analysis of competitive chimeras. (C) Flow cytometry-based 
analysis of serial competitive transplantation experiments. CD45.2% outcome is shown. N = 7-9, two-way ANOVA. 
(D-F) Flow cytometry-based analysis of serial competitive transplantation experiments. CD45.2% outcome is shown 
for T cells (D), B cells (E) and myeloid cells (F). N = 7-9, two-way ANOVA. For all panels: *p < 0.05, **p < 0.01, ***p 
< 0.001, ns: not significant; N indicates number of biological replicates; 1 independent experiment was performed; 
mean + SD is shown. Figure is adapted from (Sommerkamp et al., 2019). 
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3.1.3 Meg3 is dispensable for embryonic hematopoietic cells expressing Vav1 
A previous study focused on the role of the Dlk1-Meg3 locus in fetal liver HSCs (Qian et al., 
2016). In these studies, straight knockout models were used, leading to deletion of the locus 
in all embryonic cells. Thus, observed hematopoietic phenotypes might represent secondary 
effects generated by, for example, defective HSC niches in the developing embryos. As we 
did not observe any relevant biological effects in adult HSCs upon Meg3 KO, we aimed to 
analyze the effects of hematopoietic specific KO of the locus in the embryo. Male VavCre driver 
mice were crossed to female Meg3 mat flox/pat flox mice, generating VavCre Meg3 mat flox/pat wt mice. 
Cre is expressed under the control of the Vav1 promoter, leading to Cre expression in CD45+ 
AGM and CD45+ fetal liver cells starting at E11.5 (Chen et al., 2009). Thus, Meg3 is deleted 
in all hematopoietic cells after the endothelial-cell-to-HSC transition, allowing embryonic 
deletion of Meg3 in the hematopoietic lineage. Cre+ animals were born and appeared healthy. 
Analysis of hematopoiesis was performed 9 to 15 weeks after birth, Cre- littermates were used 
as controls (Figure 3.8 A). First, we confirmed Meg3 KO by qPCR analysis of sorted control 
and Meg3 KO HSCs (Figure 3.8 B). No expression of Meg3 was detected in adult HSCs upon 
deletion of Meg3 in the embryonic stage. Second, we analyzed peripheral blood, BM and 
spleen of control and KO animals. Analysis of peripheral blood did not exhibit any defects in 
the B cell, myeloid cell or T cell lineages (Figure 3.8 C). In line, we did not observe any changes 
in B cell maturation (pre/pro B cells, immature B cells, mature B cells) and the myeloid and T 
cell lineages in the adult BM upon embryonic loss of Meg3 expression (Figure 3.8 D). 
Furthermore, no impairments in mature hematopoietic cell lineages in the spleen were 
detected (Figure 3.8 E). Conclusively, we performed analysis of the HSC/MPP compartment 
in VavCre Meg3 mat flox/pat wt mice and did not observe any changes in cell frequencies compared 
to controls (Figure 3.8 F). Collectively, our data demonstrates that Meg3 and the associated 
miRNA cluster are not only dispensable in the established adult hematopoietic hierarchy but 
also in the embryo after the endothelial-cell-to-HSC transition step. 
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Figure 3.8: Meg3 is dispensable for embryonic hematopoietic cells expressing Vav1. 
(A) Workflow showing analysis of control and VavCre Meg3 mat flox/pat wt mice. (B) qPCR-based analysis of Meg3 
expression in sorted HSCs. N = 3, unpaired student’s t-test. (C) Flow cytometry-based analysis of mature cells in 
the peripheral blood compartment. N = 5, unpaired student’s t-test. (D) Flow cytometry-based analysis of B cell 
maturation and mature cells in the BM compartment. N = 5, unpaired student’s t-test. (E) Flow cytometry-based 
analysis of mature cells in the spleen. N = 5, unpaired student’s t-test. (F) Flow cytometry-based analysis of 
HSCs/MPPs in the BM. Percentage of BM HSCs/MPPs is shown. N = 5, unpaired student’s t-test. For all panels: 
*p < 0.05, **p < 0.01, ***p < 0.001, ns: not significant; N indicates number of biological replicates; B: 1 independent 
experiment was performed; C-F: 2 independent experiments were performed; mean + SD is shown. Figure is 
adapted from (Sommerkamp et al., 2019). 
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3.1.4 Lack of Meg3 expression marginally affects interferon-mediated HSC 
stress response 
Meg3 has been reported to decrease cell proliferation (Braconi et al., 2011; Wang et al., 2012; 
Zhang et al., 2010a; Zhang et al., 2003; Zhou et al., 2007). HSCs are highly dormant, and 
inflammation-induced interferon signaling leads to activation of HSCs and exit from the G0 cell 
cycle state (Baldridge et al., 2010; Essers et al., 2009). This inflammatory response can be 
induced by pIC injections. We questioned if the return to quiescence in HSCs might be affected 
by loss of Meg3. We treated control and Meg3 KO mice with pIC 6-12 weeks after deletion and 
analyzed the immediate cellular response in the HSC/MPP compartment using Ki-67/Hoechst 
33348 staining 16 hours, 4 days and 8 days after proliferation induction (Figure 3.9 A). As 
expected, control HSCs and MPP cells became activated 16 hours after pIC injection and 
exited G0 (Figure 3.9 B). A gradual return to the intrinsic cell cycle status was observed after 
4 and 8 days following cellular activation. Meg3 KO HSCs and MPP cells did not exhibit 
changes in activation and return to quiescence. Only MPP1 KO cells showed slightly increased 
return to quiescence after 4 days and at the same time a slightly decreased return to 
quiescence after 8 days. In addition to cell cycle status, we analyzed BM frequencies (Figure 
3.9 C). As expected, the proliferative response induced by pIC led to an increase of HSC and 
MPP frequencies 16 hours after injections. This increase was not affected by lack of Meg3 
expression. After 4 days, cell frequencies started to decrease again and reached homeostatic 
levels after 8 days. This response pattern was observed in control as well as Meg3 KO animals. 
However, slightly increased HSC and MPP1 frequencies were observed in KO animals 8 days 
after injections.  
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Figure 3.9: Lack of Meg3 expression marginally affects interferon-mediated HSC stress response.  
(A) Workflow showing pIC-mediated Cre induction and interferon-mediated stress induction. (B) Flow cytometry-
based cell cycle analysis of HSCs/MPPs. Relative percentage within each cell cycle phase is shown. N = 4-11, two-
way ANOVA. (C) HSC, MPP1, MPP2 and MPP3/4 frequencies as determined by flow cytometry analysis. 
Percentage of BM HSCs/MPPs is shown. N = 4-18, one-way ANOVA. For all panels: *p < 0.05, **p < 0.01, ***p < 
0.001, ns: not significant; N indicates number of biological replicates; 1-4 independent experiments were performed; 
mean + SD is shown. Figure is adapted from (Sommerkamp et al., 2019). 
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To understand if this increase is of biological relevance, we decided to perform functional CFU 
assays using total BM cells derived from pIC-treated animals (Figure 3.10 A). We used cells 
derived from mice 16 hours and 8 days after pIC injection and performed serial plating 
experiments. CFU potential was not affected by Meg3 KO. Even though we observed slightly 
increased HSC/MPP1 frequencies 8 days after pIC treatment, these changes did not lead to 
significantly altered colony formation capacity. This indicates that the changes observed are 
not of major biological relevance. To further strengthen this hypothesis, we performed long-
term (LT) stress experiments. Ten weeks after Meg3 deletion, mice were injected with pIC 
twice a week for a period of 4 weeks and analyzed after an 8-week recovery phase (Figure 
3.10 B). As previously reported, LT stress leads to an overall decrease of HSC/MPP 
frequencies in control mice (Essers et al., 2009). In Meg3 KO mice, this decrease in BM 
frequencies was comparable. Overall, Meg3 does not seem to play an essential role in 
mediating HSC activation and return to quiescence following interferon-mediated inflammatory 
stress.  
In summary, we performed extensive in vitro and in vivo characterization of Meg3 KO mice 
harboring a specific deletion of Meg3 in hematopoietic cells. Adult mice were analyzed, and 
Meg3 is dispensable for functional hematopoiesis independently of the deletion time point 
(embryonic stage 11.5 or in the adult animal).  
 
Figure 3.10: Lack of Meg3 expression does not functionally affect interferon-mediated HSC stress 
response.  
(A) Functional analysis of BM derived from pIC-treated mice by serial CFU assays. N = 5, one-way ANOVA. (B) 
HSC, MPP1, MPP2 and MPP3/4 frequencies as determined by flow cytometry analysis in LT stress experiments. 
Percentage of BM HSCs/MPPs is shown. N = 2-3, unpaired student’s t-test. For all panels: *p < 0.05, **p < 0.01, 
***p < 0.001, ns: not significant; N indicates number of biological replicates; 1 independent experiment was 
performed; mean + SD is shown. Figure is adapted from (Sommerkamp et al., 2019). 
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3.2 HSC function, differentiation and activation are regulated by APA 
3.2.1 The APA regulator Pabpn1 is an important regulator of HSC function 
In addition to lncRNAs, our lab identified RNA regulatory mechanisms like alternative splicing 
to be differentially regulated between HSCs and MPP cells, potentially playing an important 
role in hematopoiesis (Cabezas-Wallscheid et al., 2014). Not only alternative splicing but also 
the RNA regulatory mechanism APA attracts increasing attention in different cellular entities 
and model systems (Di Giammartino et al., 2011; Tian and Manley, 2017). We aimed to identify 
if this process is functionally important for HSCs and if APA pattern changes occur upon HSC 
differentiation or activation. First, we investigated the functional relevance of APA in HSCs by 
targeting APA regulators.  
3.2.1.1 Pabpn1 is differentially expressed in HSCs and MPP cells 
We screened RNA-seq datasets (Cabezas-Wallscheid et al., 2014) to identify differentially 
expressed APA key regulators in HSCs and MPP cells. One of these key regulators was 
Pabpn1, which had previously been reported to regulate APA in cell lines and murine disease 
models (Jenal et al., 2012). In our RNA-seq dataset, we observed Pabpn1 to be upregulated 
in HSCs compared to MPP cells (Figure 3.11 A). Expression of Pabpn1 was especially low in 
MPP2 cells. This is interesting, as APA has been linked to changes in the cell cycle state and 
MPP2 cells are the most proliferative MPP subset (Tian and Manley, 2017; Wilson et al., 2008). 
We confirmed differential expression of Pabpn1 by sorting HSC and MPP subsets and 
performing qPCR analysis (Figure 3.11 B). 
 
Figure 3.11: Pabpn1 is differentially expressed in HSCs and MPP cells.  
(A) RNA-seq-based expression analysis (Cabezas-Wallscheid et al., 2014) of Pabpn1 in HSCs/MPPs (gated using 
LSK CD150+/- CD48+/- CD34+/- CD135+/-). Normalized relative expression values. N = 3-4, DeSeq analysis, #: 
significant compared to HSCs. (B) qPCR-based Pabpn1 expression analysis in HSCs/MPPs (gated using LSK 
CD150+/- CD48+/-CD34+/-). Normalized relative expression values. N = 3, unpaired student’s t-test between HSCs 
and MPP cells. For all panels: *p < 0.05, **p < 0.01, ***p < 0.001, ns: not significant; N indicates number of biological 
replicates; 3 independent experiments were performed; mean + SD is shown. 
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3.2.1.2 Establishing shRNA-mediated Pabpn1 KD in LSK cells  
To investigate the functional role of the APA mediator Pabpn1 in hematopoiesis, we aimed to 
perform knockdown (KD) of Pabpn1 in primary hematopoietic cells, namely LSK cells, and to 
perform subsequent in vitro and in vivo analyses (Figure 3.12 A). Plasmids for shRNA or Scr 
control RNA expression were purchased, and lentiviral particles were produced. After titration 
of viruses, primary LSK cells from C57Bl6/J mice were sorted by fluorescence-activated cell 
sorting (FACS) and transduced in vitro with an MOI of 35. Successfully transduced cells 
express the shRNA/Scr control RNA and a GFP reporter under the control of the murine EF1a 
promoter. 48 h and 72 h after transduction, cells were harvested and GFP+ cells were sorted 
by FACS (Figure 3.12 B). Up to 85% of cells were successfully transduced. Expression of the 
target gene Pabpn1 was analyzed in GFP+ cells by qPCR analysis 48 h after transduction 
(Figure 3.12 C). Using two independent shRNAs, gene expression was reduced by 
approximately 50% compared to Scr control conditions (Figure 3.12 C). In addition to RNA 
expression, protein levels were assessed (Figure 3.12 D-E). GFP+ cells were sorted 48 h and 
72 h after transduction and intracellular PABPN1 staining was performed to subsequently 
analyze expression levels by flow cytometry. A significant reduction in PABPN1 protein levels 
was observed. Reduction was higher 72 h after transduction, and protein levels were halved 
compared to Scr control conditions.   
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Figure 3.12: Establishing shRNA-mediated Pabpn1 KD in LSK cells.  
(A) Workflow of shRNA-mediated Pabpn1 KD and subsequent in vitro and in vivo analyses. (B) Representative flow 
cytometry dot plots showing GFP expression of control and transduced LSK cells. (C) qPCR analysis of Pabpn1 
expression in Scr control and KD cells after 48 h. LSK cells were sorted and transduced, and GFP+ cells were 
resorted and analyzed. N = 9-12, unpaired student’s t-test. (D) Representative flow cytometry histograms showing 
PABPN1 expression in resorted GFP+ control and KD cells after 48 h and 72 h. (E) Flow cytometry-based analysis 
of PABPN1 protein levels in Scr control and KD cells (48 h and 72 h). LSK cells were sorted and transduced, and 
GFP+ cells were resorted and analyzed. Fold change (FC) of the mean fluorescent intensity (MFI) is shown. 
Normalized to Scr control. N = 3-6, unpaired student’s t-test, one independent experiment for KD shRNA_3. For all 
panels: Significance levels compared to Scr Ctrl, *p < 0.05, **p < 0.01, ***p < 0.001, ns: not significant; N indicates 
number of biological replicates; equal to or more than 3 independent experiments were performed unless otherwise 
indicated; mean + SD is shown. 
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3.2.1.3 shRNA-mediated Pabpn1 KD in LSK cells does not affect cellular viability or 
differentiation 48 h after lentiviral transduction 
We aimed to perform functional assays using Scr control and Pabpn1 KD cells 48 h after 
transduction. These assays are highly sensitive and if the KD approach would alter viability or 
cellular composition already 48 h after transduction, this might influence functional assays, as 
Pabpn1 KD stem cells might already be affected and harbor cellular disadvantages. Thus, we 
performed viability analysis by 7AAD/Annexin staining (Figure 3.13 A). Annexin binds to 
phosphatidylserine, which is presented on cells undergoing apoptosis (Koopman et al., 1994). 
7AAD/Annexin double negative cells are viable, 7AAD- Annexin+ cells undergo apoptosis, 
while 7AAD/Annexin double positive cells are no longer viable. Pabpn1 KD did not affect cell 
viability 48 h after transduction. In addition, we performed flow cytometry analysis of GFP+ 
cells (Figure 3.13 B). 48 h after transduction, initially sorted LSK cells had partially 
differentiated into Lin+ Sca-1- c-Kit+ (LS-K) cells, consisting of different progenitor populations 
(CMP, GMP, MEP), in GFP+ Scr control samples. Analysis of Pabpn1 KD cells did not exhibit 
any changes in these differentiation patterns. In summary, no changes in cell viability and 
differentiation were observed in Pabpn1 KD cells 48 h after transduction, allowing unbiased 
functional analysis. 
 
Figure 3.13: shRNA-mediated Pabpn1 KD in LSK cells does not affect cellular viability or differentiation 48 
h after lentiviral transduction.  
(A) Flow cytometry-based viability analysis upon Pabpn1 KD. N = 6. (B) Flow cytometry-based analysis of 
subpopulations in GFP+ cells. Percent of GFP+ cells is shown. N = 5-6. For all panels: N indicates number of 
biological replicates; equal to or more than 3 independent experiments were performed; mean + SD is shown. 
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3.2.1.4 Pabpn1 KD cells exhibit reduced CFU capacity in vitro but unchanged homing 
potential in vivo 
To investigate the stem cell potential of Pabpn1 KD cells, we first performed in vitro CFU 
assays (Figure 3.14 A). Interestingly, colony forming potential was reduced in primary and 
secondary platings using two independent shRNAs targeting Pabpn1. Thus, HSCs lacking the 
APA regulator Pabpn1 exhibit decreased stem cell potential. In further experiments, we aimed 
to analyze stem cell capacity of KD cells in vivo. To this end, we performed in vivo 
transplantation experiments. A prerequisite to assess peripheral blood contribution is homing 
of the transplanted cells to the BM after i.v. injection. If the intrinsic homing capacity of the 
experimental cellular subject in question is already affected, this changes cellular performance 
in transplantation assays, leading to potential misinterpretation of results. To prevent this, we 
performed homing experiments using Scr control and KD cells (Figure 3.14 B). LSK cells were 
sorted and transduced, and 48 h later GFP+ cells were resorted. 30,000 GFP+ cells (CD45.2) 
were transplanted per lethally irradiated recipient mouse (CD45.1). Mice were sacrificed after 
48 h, and homing was quantified by flow cytometry analysis of BM cells. CD45.2+ GFP+ cells 
were gated, and BM frequency of this cell population was determined (Figure 3.14 C-D). No 
difference in homing potential was observed in Pabpn1 KD cells, enabling long-term 
transplantation experiments without an intrinsic bias in the experimental setup. Collectively, 
Pabpn1 KD impairs HSC capacity in vitro, but does not affect in vivo homing capacity.   
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Figure 3.14: Pabpn1 KD cells exhibit reduced colony forming unit capacity in vitro but unchanged homing 
potential in vivo.  
(A) CFU assay of Scr control and Pabpn1 KD cells showing fold change (FC) in colony numbers for first and second 
plating. N = 4-5, unpaired student’s t-test. (B) Workflow showing homing assay analysis. (C) Representative flow 
cytometry dot plots of homing assay analysis. BM samples are shown. (D) Analysis of HSC homing. BM frequency 
of total CD45.2+ GFP+ cells is indicated. N = 6, unpaired student’s t-test. For all panels: *p < 0.05, **p < 0.01, ***p 
< 0.001, ns: not significant; N indicates number of biological replicates; equal to or more than 2 independent 
experiments were performed; A: mean + SD is shown; D: mean ± 95% CI is shown. 
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3.2.1.5 Engraftment and peripheral blood contribution of Pabpn1 KD cells in vivo is 
decreased 
The gold standard to investigate HSC potential is transplantation, as only HSCs show serial 
multilineage engraftment. To asses HSC potential of Pabpn1 KD cells in vivo, we generated 
full chimeras by transplanting either 30,000 GFP+ Scr control or 30,000 GFP+ Pabpn1 KD 
(shRNA_2) cells (all CD45.2) into lethally irradiated recipient mice (CD45.1) (Figure 3.15 A). 
The proportion of CD45.2+ GFP+ cells in the peripheral blood was analyzed approximately 
every 4 weeks by flow cytometry analysis (Figure 3.15 B-C). Pabpn1 KD cells exhibited 
significantly reduced contribution to the peripheral blood already in primary recipients at the 
first analysis time point (4 weeks). This decreased contribution was observed over time in 
primary as well as secondary recipients. In addition to overall peripheral blood contribution, we 
also analyzed contribution to the T cell, B cell and myeloid cell lineage by determining the 
proportion of CD45.2+ GFP+ cells in the respective population (Figure 3.15 D). Most strikingly, 
we did not observe CD45+ GFP+ T cells in the peripheral blood of Pabpn1 KD recipient mice 
(Figure 3.15 E). We performed analysis of thymus cells to analyze T cell maturation using CD4, 
CD8, CD25 and CD44 as markers of different T cell development steps (Figure 3.15 F). We 
were not able to detect CD45.2+ GFP+ T cell populations in Pabpn1 KD recipients. Hence, the 
APA regulator Pabpn1 seems to be essential for T cell development, as successful T cell 
maturation is completely abrogated upon reduced Pabpn1 expression. Contribution of Pabpn1 
KD cells to peripheral B cell levels was also significantly reduced, while myeloid cells were less 
affected (Figure 3.15 G-H). Further, we analyzed HSC/MPP engraftment in the BM (Figure 
3.15 I). Engraftment of CD45.2+ GFP+ Pabpn1 KD HSCs was reduced in primary and 
secondary recipients. Collectively, the APA regulator Pabpn1 is essential for HSC function in 
vivo affecting all lineages, while the T cell lineage exhibits the most severe phenotype.   
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Figure 3.15: Decreased engraftment and peripheral blood contribution of Pabpn1 KD cells in vivo.  
(A) Workflow showing generation of full chimeras. (B) Representative flow cytometry dot plots of PB analysis are 
shown. (C) CD45.2+ GFP+ outcome in PB analysis of full chimeras is shown. N = 10-12, two-way ANOVA. (D) 
Representative flow cytometry dot plots of gating of mature cells in PB analysis are shown. (E) CD45.2+ GFP+ 
outcome in PB analysis for T cells of full chimeras is shown. N = 10-12, two-way ANOVA. (F) CD45.2+ GFP+ 
outcome in thymus of full chimeras is shown. N = 10-12, unpaired student’s t-test. DP: double positive (CD4+ 
CD8+), DN: double negative (CD4- CD8-) (G) CD45.2+ GFP+ outcome in PB analysis for B cells of full chimeras is 
shown. N = 10-12, two-way ANOVA. (H) CD45.2+ GFP+ outcome in PB analysis for myeloid cells of full chimeras 
is shown. N = 10-12, two-way ANOVA. (I) First and second endpoint analysis of BM of full chimeras. Gated on LSK 
CD150+/- CD48+/- CD34+/-. CD45.2+ GFP+ outcome is shown. N=10-12, unpaired student’s t-test. For all panels: 
Significance levels compared to Scr Ctrl, *p < 0.05, **p < 0.01, ***p < 0.001, ns: not significant; N indicates number 
of biological replicates; 2 independent experiments were performed; mean ± 95% CI is shown. 
3.2.1.6 Pabpn1 KD cells exhibit competitive disadvantage in transplantation 
experiments in vivo 
We generated 50/50 chimeras to analyze the competitive potential of Pabpn1 KD 
hematopoietic cells. Therefore, we mixed 15,000 Scr control (CD45.2 or CD45.1/.2) with 
15,000 Pabpn1 KD (CD45.1/.2 or CD45.2) cells and transplanted the cells into lethally 
irradiated recipients (CD45.1) (Figure 3.16 A). Thus, mice were either transplanted with a 
mixture of Scr control CD45.2/Pabpn1 KD CD45.1/.2 cells or Scr control CD45.1/.2/Pabpn1 
KD CD45.2 cells. This setup is necessary, as CD45.2 cells exhibit an intrinsic advantage in 
engraftment (Jafri et al., 2017). For analysis of peripheral blood contribution, frequencies of 
CD45.2+ GFP+ Pabpn1 KD cells of one setup were compared to frequencies of CD45.2+ 
GFP+ Scr control cells of the other setup (Figure 3.16 B). In competitive settings, Scr control 
cells outperformed Pabpn1 KD cells in serial transplantation assays (Figure 3.16 C). Analysis 
of mature lineages in the peripheral blood confirmed our in vivo results generated by full 
chimera analysis. Again, we observed decreased production of B cells, T cells and myeloid 
cells, with T cells being most affected (Figure 3.16 D-F). Results were confirmed by setting up 
additional competitive transplantation experiments using the independent shRNA_3 to 
generate Pabpn1 KD cells (Figure 3.16 G). Competitive engraftment potential of HSCs and 
MPP cells in the BM was analyzed by flow cytometry (Figure 3.16 H). Again, we observed 
reduced engraftment of HSCs and MPP cells in primary recipients. Analysis of secondary 
recipients was challenging, as only few GFP+ HSCs and MPP cells could be detected 16 
weeks after retransplantation. In general, we observed the tendency that Pabpn1 KD 
HSC/MPP cells showed reduced engraftment in secondary recipients in competitive settings. 
In summary, Pabpn1 KD cells do not only exhibit reduced engraftment potential in full chimeras 
but are also outperformed in competitive transplantation settings.  
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Figure 3.16 Pabpn1 KD cells exhibit competitive disadvantage in transplantation experiments in vivo.  
(A) Workflow showing generation of competitive chimeras. (B) Representative flow cytometry dot plots of PB 
analysis are shown. (C) PB analysis of competitive chimeras. Frequency of CD45.2+ cells in the GFP+ compartment 
is represented. N = 13-18, two-way ANOVA. (D-F) PB analysis showing frequency of CD45.2+ cells in the GFP+ 
compartment of B cells (D), T cells (E) and myeloid cells (F). N = 13-18, two-way ANOVA. (G) PB analysis of 
competitive chimeras using shRNA_3. Frequency of CD45.2+ cells in the GFP+ compartment is represented. N = 
6, two-way ANOVA, one independent experiment. (H) First and second endpoint analysis of BM of competitive 
chimeras. Gated on LSK CD150+/- CD48+/- CD34+/-. Frequency of CD45.2+ cells in the GFP+ compartment is 
represented. N=10-12, unpaired student’s t-test. For all panels: Significance levels compared to Scr Ctrl, *p < 0.05, 
**p < 0.01, ***p < 0.001, ns: not significant; N indicates number of biological replicates; 3 independent experiments 
were performed unless otherwise indicated; mean ± 95% CI is shown. 
3.2.2 3’-Seq analysis reveals distinct APA patterns in hematopoietic stem and 
progenitor populations 
3.2.2.1 Establishing ultra-low input 3’-Seq 
After showing that the APA regulator Pabpn1 is essential for hematopoiesis, we aimed to 
analyze the prevalence of APA in HSCs and MPP cells. Standard RNA-seq data can hardly 
be used to analyze APA patterns, as complex bioinformatic reconstruction of cleavage site 
usage has to be performed (Chen et al., 2017; Wilkening et al., 2013). In addition, only few 
reads are localized in the 3’-UTR region to perform bioinformatic analysis. Thus, to enable in-
depth analysis of APA in the hematopoietic hierarchy, we aimed to perform 3’-Seq analysis. 
To this end, we sorted HSC and MPP1-4 cells under homeostatic conditions and isolated total 
RNA (Figure 3.17 A-B). Lin, cKit, Sca-1, CD135, CD150, CD48 and CD34 were used as 
markers. Around 10,000 cells were sorted by FACS in quadruplicates in independent 
experiments.  
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Figure 3.17: Establishing ultra-low input 3’-Seq – gating strategy.  
(A) Workflow and study design of 3’-Seq analysis of homeostatic HSCs/MPPs. (B) Representative flow cytometry 
dot plots of HSC/MPP sorting approach. 
Isolated RNA was used for library generation using the QuantSeq 3’-mRNA Library Prep Kit 
REV (Lexogen) (Figure 3.18 A). First, RNA quality was confirmed using an Agilent Bioanalyzer. 
The RNA integrity number (RIN) resembles RNA quality and integrity (Schroeder et al., 2006). 
Only high-quality samples with a RIN value higher than 9 were processed. During 
establishment of the protocol for ultra-low inputs, we started to include an RNA denaturation 
step to enable library preparation (see methods section). 3 ng of total RNA were reverse 
transcribed using oligo(dT)-priming. Residual RNA was digested, and random priming was 
used to generate double-stranded cDNA. PCR amplification was performed and during this 
step, adapter sequences for Illumina sequencing and barcodes for sample identification were 
introduced. The cycle number for amplification was determined to be 19 cycles with the help 
of PCR Add-on Kit for Illumina (Lexogen). Library quality was checked using the Agilent 
Bioanalyzer, and only samples with an average size below 450 bp and a molarity of at least 2 
A
H
SC
M
PP
1
M
PP
2
M
PP
3
M
PP
4
C57Bl6/J
CD34 - 
CD48 -
CD150+ 
CD135- 
CD34 + 
CD48 -
CD150+ 
CD135- 
CD34 + 
CD48 +
CD150+ 
CD135- 
MPP1 HSC MPP2 
MPP4 MPP3
LSK
BM Isolation and FACS
RNA Isolation 
3‘-Seq Library Generation
Multiplexed Illumina HiSeq V4
Paired-End Sequencing
CD34 + 
CD48 +
CD150- 
CD135- 
CD34 + 
CD48 +
CD150- 
CD135+ 
FSC-A
SS
C-
A
FSC-A
FS
C-
W
FSC-A
Li
n-
PE
/C
y7
Sca-1-APC/Cy7
cK
it-
AP
C
CD34-FITC
CD
13
5-
PE
0 50K 100K 150K 200K 250K
0
50K
100K
150K
200K
250K
singlets
96.5%
0 50K 100K 150K 200K 250K
0
50K
100K
150K
200K
250K
4.42%
0-10 3 10 3 10 4 10 5
0
-10 3
10 3
10 4
10 5 CD34+ CD135+
48.8%
CD34- 
CD135-
5.51%
0-10 3 10 3 10 4 10 5
0
-10 3
10 3
10 4
10 5
lin neg
53.3%
0 50K 100K 150K 200K 250K
0
-10 3
10 3
10 4
10 5
LSK
CD48-PB
CD
15
0-
PE
/C
y5
CD48-PB
CD
15
0-
PE
/C
y5
CD48-PB
CD
15
0-
PE
/C
y5
66.9%
0-10 3 10 3 10 4 10 5
0
-10 3
10 3
10 4
10 5
30.9% 13.5%
22.9%
0-10 3 10 3 10 4 10 5
0
-10 3
10 3
10 4
10 5
60.8
0-10 3 10 3 10 4 10 5
0
-10 3
10 3
10 4
10 5
MPP4MPP3
HSC MPP2MPP1
B
CD34+ 
CD135-
27.4%
Cells
39.3%
 Results  
 
 76 
 
nM were used. Successfully generated libraries were pooled, and multiplexed paired-end 
sequencing was performed on a HiSeq 2000 device. In this sequencing approach, read1 was 
generated using a custom sequencing primer provided with the QuantSeq 3’-mRNA Library 
Prep Kit REV (Lexogen, 5’ CCCTACACGACGCTCTTCCGATCTTTTTTTTTTTTTTTTTTT 3’). 
Read1 is derived from the terminal end of the utilized 3’-UTR, providing the advantage that no 
bioinformatic reconstruction of PAS selection is needed. The start of the read corresponds to 
the utilized cleavage site. In general, two different datasets were generated: paired-end read 
data, which can be used for analysis of differentially expressed genes, and single-end read 
data, which can be used for analysis of APA.  
 
Figure 3.18: Establishing ultra-low input 3’-Seq – library generation and QC.  
(A) 3’-Seq workflow of library generation and sequencing. (B) 3’-Seq bioinformatic analysis workflow. (C) PCA of 
the HSC/MPP 3’-Seq dataset using paired-end data. (D) Venn diagram of DEGs identified in MPP2 cells vs HSCs 
using standard RNA-seq (Cabezas-Wallscheid et al., 2014) or 3’-Seq analysis. 1594 shared DEGs representing 
58% of DEGs detected by 3’-Seq were identified. For all panels: 3’-Seq data is derived from libraries generated in 
4 independent experiments, representing 4 biological replicates per cell population, respectively.  
For bioinformatic analysis (Figure 3.18 B), we collaborated with Sandro Altamura (Heidelberg 
University Medical Center). Initially, raw reads were demultiplexed, FastQC was performed 
and adapter sequences were trimmed. In addition, a prefiltering step was included. Paired-end 
read data was used to asses quality of our newly generated 3’-Seq dataset. As we established 
this sequencing approach for low inputs, we aimed to validate the reliability and robustness of 
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our data. Paired-end data was aligned using STAR, and principal component analysis (PCA) 
was performed (Figure 3.18 C). We observed robust clustering of independently generated 
biological HSC and MPP1-4 replicates, indicating high reliability of our 3’-Seq dataset. In 
addition, we performed analysis of differentially expressed genes (DEGs) using DESeq2 (Love 
et al., 2014). We identified 2,741 genes that were differentially expressed in HSCs and MPP2 
cells. Comparison of our dataset with an RNA-seq dataset previously published by our lab 
revealed a strong overlap of DEGs, further supporting the quality of our generated dataset 
(Figure 3.18 D). Overall, we established an ultra-low RNA input 3’-Seq approach and 
confirmed the high quality and robustness of our dataset.   
3.2.2.2 Identification of high confidence PASs using single-end read data from 3’-Seq 
analysis 
In a next step, we aimed to use the newly generated 3’-Seq resource of primary HSCs and 
MPP cells to analyze APA patterns in the distinct subpopulations. To this end, we made use 
of the single-end read data generated using the custom sequencing primer. This allowed us to 
address: I) PAS usage, II) 3’-UTR length and III) associated exons for each detected peak. 
Reads were aligned using Bowtie, and polyadenylation peaks were identified and filtered for 
the presence of conserved PAS and absence of downstream internal poly-A stretches to only 
include peaks originating from pre-mRNA cleavage enabling high-fidelity APA analysis (Figure 
3.19 A-B). As expected, analysis of peak annotation revealed that the majority of peaks is 
annotated in the 3’-UTR region in contrast to standard RNA-seq datasets in which almost 90% 
of reads are localized in coding sequence exons (Figure 3.19 C). Interestingly and in line with 
previous reports (Elkon et al., 2013), we also identified APA in introns, intergenic and 
downstream regions. Analysis of overall representation of the different conserved PASs did 
not reveal any differences between HSCs and MPP cells (Figure 3.19 D). The most common 
canonical PAS AAUAAA was used in over 50% of polyadenylation events. This observation 
further substantiates the quality and reliability of our APA analysis, as this PAS usage pattern 
was previously described (Tian and Graber, 2012). In line, we observed a distance of ~15-30 
bp between the read start site, which corresponds to the cleavage site, and the conserved 
PAS (Figure 3.19 E) (Tian and Graber, 2012). Collectively, we were able to identify high 
confidence polyadenylation sites using our generated 3’-Seq analysis. Quantification of PAS 
usage in our dataset can subsequently be used to identify and analyze APA.  
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Figure 3.19: Identification of high-confidence PASs using single-end read data from 3’-Seq analysis.  
(A) Workflow of peak identification in 3’-Seq data. (B) Peak annotation before and after filtering of the 3’-Seq dataset. 
Number of peaks per population is shown. (C) Read classification after mapping and filtering. Exemplary RNA-seq 
and 3’-Seq datasets are shown. (D) Usage of different conserved PASs in HSCs and MPP cells. Percentage of 
PAS usage is shown. (E) Representative distribution of distance from the conserved PAS to the read start site. 
Number of peaks is shown. For all panels: 3’-Seq data is derived from libraries generated in 4 independent 
experiments, representing 4 biological replicates per cell population, respectively.  
3.2.2.3 Analysis of APA patterns in HSCs and MPP1-4 cells 
After confirming the reliability of our PAS identification strategy, we continued with the analysis 
of APA patterns in primary HSC/MPP cells. First, we compared peak annotations between the 
different populations (Figure 3.20 A). As expected, the majority of polyadenylation events was 
identified in annotated 3’-UTRs. Interestingly, however, HSCs exhibited a significant, ~2-fold, 
increase in the intronic polyadenylation frequency compared to MPP1-4 cells. In addition, 
HSCs showed a significant increase in the total number of genes using more or equal to 3 
polyadenylation sites compared to MPP cells (Figure 3.20 B). Polyadenylation patterns seem 
to be more variable in the stem cell compartment compared to progenitors with regard to 
localization of PASs and PAS usage per gene. 
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Figure 3.20: Analysis of APA patterns in HSCs and MPP1-4 cells – read localization and PAS number per 
gene.  
(A) Read localization in percent of HSCs and MPP cells in the analyzed 3’-Seq dataset. Chi-square test. (B) PAS 
number per gene in percent for HSCs and MPP cells. Chi-square test. For all panels: 3’-Seq data is derived from 
libraries generated in 4 independent experiments, representing 4 biological replicates per cell population, 
respectively. 
Next, we aimed to identify statistically significant differentially used APA sites (DAPAS) 
between populations. A stringent bioinformatic pipeline was established on the basis of 
DEXSeq (Anders et al., 2012). As DAPAS are defined as differentially used PASs of a given 
gene, analysis can only be performed for genes expressed in both cell populations. Hits can 
include CR-APA, affecting protein isoform expression, UTR-APA, affecting only 3’-UTR length, 
or a combination of both. In a first step, we called DEGs and DAPAS between HSCs and 
MPP1-4 cells (Figure 3.21 A). In total, we identified between 657 and 2,872 genes to be 
differentially expressed between HSCs and the different MPP populations. As expected and 
previously described, most DEGs were identified between the highly proliferative MPP2 subset 
and deeply dormant HSCs. DAPAS analysis revealed a similar pattern with 113 DAPAS hits 
identified in HSCs and MPP2 cells. HSCs and MPP1 cells are molecularly highly similar cell 
subsets and in line we identified only 11 DAPAS in these populations. Usage of the different 
PASs was evaluated by calculating the ratio of the usage of a specific PAS against the sum of 
the usage of all the PASs for a specific transcript, defining the percentage of polyadenylation 
usage (PPAU). As HSCs and MPP2 cells showed the highest difference in APA, we decided 
to focus on these two populations. Analysis of the top 10 DAPAS genes exhibited a complex 
mixture of CR-APA as well as UTR-APA (Figure 3.21 B-C). For example, the genes Chd2, 
Ctsc and Ccnd3 displayed CR-/UTR-APA, while Hnrnpa3, Minos1 and Treml2 displayed UTR-
APA only. For all of these 3’-UTRs, we observed a switch from distal to more proximal PASs 
in MPP2 cells. To validate our DAPAS identification approach, we designed 3’-UTR- and 
isoform-specific primers and performed analysis of polyadenylation patterns in HSCs and 
MPP2 cells by qPCR analysis (Figure 3.21 D). RNA expression was normalized to Oaz1 (DCt), 
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and relative expression levels were determined as 2^-DCt. The proximal 2^-DCt value was 
divided by the distal 2^-DCt value, and the results were normalized to HSCs. Thus, values 
above 1 indicate a relative increase in proximal APA site usage, and values below 1 indicate 
a relative increase in distal APA site usage. For comparison to 3’-Seq data, proximal and distal 
raw read counts were added up (p+d), and the (p+d)/d ratio was calculated and normalized. 
This correction of proximal reads is necessary for comparison with qPCR data, as the proximal 
primer pair always amplifies the shortened as well as the lengthened transcript (p+d). For all 
DAPAS hits analyzed, we could confirm the APA patterns in HSCs and MPP2 cells by qPCR, 
independently validating our sequencing results and bioinformatic analysis pipeline. In 
summary, we generated a resource dataset of HSCs and MPP cells that enables analysis of 
DAPAS in primary hematopoietic cells. In addition, we showed for the first time that distinct 
APA patterns exist between HSCs and MPP cells. 
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Figure 3.21: Analysis of APA patterns in HSCs and MPP1-4 cells – DAPAS analysis.  
(A) Identification of DEGs (FDR < 0.1; -0.5 > Log2FC > 0.5) and DAPASs (FDR < 0.2) in MPPs compared to HSCs. 
(B) APA patterns of the top 10 DAPAS hits identified in MPP2 cells and HSCs. Usage of respective site in percent 
is shown (percentage of polyadenylation usage (PPAU), see methods section for details). DAPAS analysis: # 
significant. (C) Representative example of APA in MPP2 cells and HSCs. Exemplary IGV data of the gene Chd2 is 
shown. (D) DAPAS validation by qPCR analysis of selected hits identified in MPP2 cells vs HSCs. Heatmap 
represents normalized mean relative expression of the proximal to the distal mRNA isoform based on 3’-Seq (left 
panel) and qPCR (right panel) analysis. For all panels: 3’-Seq data is derived from libraries generated in 4 
independent experiments, representing 4 biological replicates per cell population, respectively. 
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3.2.2.4 3’-UTR shortening occurs upon HSC commitment and differentiation 
Further, we aimed to analyze global 3’-UTR length in HSC/MPP subsets. To this end, we 
analyzed 3’-UTR hits only. For 3’-UTRs containing more than one PAS, the percentage of 
usage of the most distal polyadenylation site (PDUI) was considered, and we calculated its 
differential usage between the conditions (dPDUI). Reduced usage indicates 3’-UTR 
shortening, while increased usage indicates 3’-UTR lengthening. We compared MPP1-4 cells 
to HSCs and observed significant progressive 3’-UTR shortening in MPP1-4 cells (Figure 3.22 
A-B). 3’-UTR shortening occurred upon HSC differentiation and commitment, which is tightly 
linked to increased cellular activity. Previously, shortening of 3’-UTRs has mainly been 
associated with increased protein output (Fu et al., 2018; Ji et al., 2011; Jia et al., 2017; Pai et 
al., 2016; Sandberg et al., 2008; Zheng et al., 2018). Therefore, we were interested in gene 
functions that were significantly enriched in MPPs compared to HSCs. Thus, we performed 
gene ontology (GO) term and REVIGO analysis on the 3’-UTR shortened gene list for MPP2 
cells compared to HSCs (Figure 3.22 C). We considered only genes with a relative shortening 
of more than 10% in the distal PAS. Shortened genes were mainly associated with processes 
like cell division, cell-cell signaling, stem cell division and glutamine metabolism. Interestingly, 
some of these processes (e.g. cell division) have previously been shown to be characteristic 
for MPP2 cells compared to HSCs (Cabezas-Wallscheid et al., 2014). Considering that 3’-UTR 
shortening is linked to an increase in protein expression, it seems feasible that these MPP-
related processes are enriched in the shortened gene sets. Overall, HSC commitment and 
differentiation are associated with global 3’-UTR shortening in vivo. In addition, shortened gene 
lists are enriched for MPP-specific processes.  
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Figure 3.22: 3’-UTR shortening occurs upon HSC commitment and differentiation.  
(A) Analysis of 3’-UTR shortening/lengthening. Only changes in 3’-UTRs belonging to the same exon in the 
respective populations were considered (UTR-APA only). Binomial test. (B) Length of 3’-UTRs in MPP populations 
in percent normalized to HSCs. (C) GO term and subsequent REVIGO (Supek et al., 2011) analysis of genes 
exhibiting 3’-UTR shortening in MPP2 cells compared to HSCs is shown. Bubble color indicates p-value; bubble 
size indicates frequency of the GO term. For all panels: 3’-Seq data is derived from libraries generated in 4 
independent experiments, representing 4 biological replicates per cell population, respectively. 
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3.2.3 PABPN1 regulates APA in primary hematopoietic cells  
After showing that KD of the APA regulator Pabpn1 impairs HSC function (see 3.2.1) and 
performing analysis of APA patterns in HSCs and MPP cells (see 3.2.2), we aimed to show 
that PABPN1 regulates APA in in vivo-derived hematopoietic cells. Thus, we performed 3’-Seq 
analysis of Scr control and Pabpn1 KD cells. GFP+ LSK cells were sorted 72 h after 
transduction, and libraries were generated (Figure 3.23 A). Unfortunately, analysis of 
transplanted HSC or LSK cells was not possible, as only few Pabpn1 KD cells were found in 
recipient animals. As previously described (see 3.2.2.2), we filtered the generated datasets 
(Figure 3.23 B). For Scr control as well as Pabpn1 KD conditions, the majority of reads was 
localized in the 3’-UTR region. Again, we could confirm reliability and robustness of our dataset 
by observing the expected usage patterns of conserved PASs (Figure 3.23 C). We then 
performed in-depth analysis and observed slightly decreased intronic polyadenylation in KD 
conditions (Figure 3.23 D). In addition, we observed a decrease in the number of genes 
showing usage of at least 3 PASs per gene (Figure 3.23 E). When considering our previous 
results (see 3.2.2.3), this indicates that Pabpn1 KD LSK cells exhibit less HSC-like 
polyadenylation patterns. This observation is in line with the decreased HSC potential of the 
KD cells observed in vivo. 
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Figure 3.23: Pabpn1 regulates APA in primary hematopoietic cells – 3’-Seq analysis.  
(A) Workflow of 3’-Seq data generation of Scr control and Pabpn1 KD cells. (B) Read annotation before and after 
filtering of the 3’-Seq dataset. Number of peaks per population is shown. (C) Usage of different conserved PASs in 
Scr control and Pabpn1 KD cells. Percentage of PAS usage is shown. (D) Read classification in percent of Scr 
control and Pabpn1 KD cells. Chi-square test. (E) PAS number per gene in percent for Scr control and Pabpn1 KD 
cells. Chi-square test. For all panels: 3’-Seq data is derived from libraries generated in 3 independent experiments, 
representing 3 biological replicates per cell population, respectively. 
Again, we called DAPAS and identified 40 APA switches in Pabpn1 KD cells already 72 h after 
transduction (Figure 3.24 A). We found a mixture of CR-APA (e.g. Cbx5, Cstf3, Ak2) and UTR-
APA (e.g. Slc25a19, Parg, Cab39l) (Figure 3.24 B). Pabpn1 KD has previously been 
associated with overall 3’-UTR shortening in cell lines (Jenal et al., 2012). As described (see 
3.2.2.4), we performed 3’-UTR shortening/lengthening analysis (Figure 3.25). We identified 
436 genes with 3’-UTR shortening and 456 with 3’-UTR lengthening, indicating no preference 
in Pabpn1 KD cells in our experimental conditions. Collectively, we were able to show that 
Pabpn1 does not only regulate APA in established cell lines and disease models (Jenal et al., 
2012) but also in primary in vivo-derived hematopoietic cells.  
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Figure 3.24: Pabpn1 regulates APA in primary hematopoietic cells – DAPAS analysis.  
(A) Identification of DAPAS in shRNA-mediated Pabpn1 KD cells compared to Scr control cells. LSK cells were 
sorted and transduced, GFP+ LSK cells were resorted and used for library generation. (B) APA patterns of the top 
10 DAPAS hits identified in shRNA-mediated Pabpn1 KD cells and Scr control cells. Usage of respective site in 
percent is shown (Percentage of polyadenylation usage (PPAU), see methods section for details). DAPAS analysis, 
#: significant. For all panels: 3’-Seq data is derived from libraries generated in 3 independent experiments, 
representing 3 biological replicates per cell population, respectively. 
 
Figure 3.25 Pabpn1 regulates APA in primary hematopoietic cells – 3’-UTR length analysis.  
Analysis of 3’-UTR shortening/lengthening. Only changes in 3’-UTRs belonging to the same exon in the respective 
population were considered (UTR-APA only). Binomial test. For all panels: 3’-Seq data is derived from libraries 
generated in 3 independent experiments, representing 3 biological replicates per cell population, respectively. 
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3.2.4 APA and 3’-UTR shortening occur in HSCs in response to inflammation-
induced activation 
3.2.4.1 3’-Seq analysis of quiescent and proliferating HSCs 
APA has been linked to the proliferative status of cells (Tian and Manley, 2017). In addition, 
we observed APA and 3’-UTR shortening upon HSC differentiation, which is tightly linked to 
an increase in cell cycle progression (Figure 3.26 A). Thus, we wondered if activation of HSCs 
induces APA changes and 3’-UTR length modifications. To this end, we injected mice with pIC, 
a dsRNA analog, inducing an interferon response leading to HSC activation 16h post injection 
(Figure 3.26 A) (Essers et al., 2009). Homeostatic steady-state HSCs (sHSC; LK CD150+ 
CD48- CD34-) and proliferating HSCs (pHSCs; LK CD150+ CD48- CD34-) were sorted in 
independent biological quadruplicates (Figure 3.26 B-C). Sca-1 was excluded as a marker as 
this surface protein is upregulated on different cell populations during inflammation-induced 
activation (Essers et al., 2009; Haas et al., 2015). 
 
Figure 3.26: 3’-Seq analysis of quiescent and proliferating HSCs – gating strategy.  
(A) Flow cytometry-based cell cycle analysis of homeostatic and activated HSCs and MPP cells. Gated on LSK 
CD150+/- CD48+/- CD34+/-. N = 4-6, mean + SD. (B) Workflow and study design of 3’-Seq analysis of 
homeostatic/proliferating HSCs (steady state HSC: sHSC; proliferating HSC: pHSC). (C) Representative flow 
cytometry dot plots of the homeostatic and proliferating HSC sorting approach.  
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As previously described (see 3.2.2.1), we used paired-end data to evaluate the quality of our 
generated 3’-Seq dataset. PCA showed robust clustering of biological replicates, again 
underlining the reliability of our sequencing approach (Figure 3.27 A). Next, we used the single-
end read dataset to evaluate APA (see also 3.2.2.2 and 3.2.2.3). Filtering of the dataset led to 
the expected exclusion of most hits annotated in non-3’-UTR regions (Figure 3.27 B). Again, 
we observed no differences in PAS motif usage between conditions and observed the 
polyadenylation signal AAUAAA to be used in more than 50% of polyadenylation events, 
further underlining the quality of the generated data (Figure 3.27 C). Analysis of read 
localization revealed a decrease in intronic polyadenylation events in pHSCs (Figure 3.27 D). 
In addition, we observed a decrease in the number of genes using at least 3 PASs per gene 
upon activation of HSCs (Figure 3.27 E). Taking our previous results into account (see 3.2.2.3), 
this indicates that activated pHSCs exhibit a polyadenylation pattern that is more MPP-like 
compared to homeostatic sHSCs. In summary, we generated a 3’-Seq resource dataset of 
sHSCs and pHSCs and observed less HSC-like polyadenylation patterns upon cellular 
activation.    
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Figure 3.27: 3’-Seq analysis of quiescent and proliferating HSCs – QC.  
(A) PCA of the sHSC/pHSC 3’-Seq dataset. (B) Read annotation before and after filtering of the 3’-Seq dataset. 
Number of peaks per population is shown. (C) Usage of different conserved PASs. Percentage of PAS usage is 
shown. (D) Read classification in percent. Chi-square test. (E) PAS number per gene in percent for HSCs and MPP 
cells. Chi-square test. For all panels: 3’-Seq data is derived from libraries generated in 4 independent experiments, 
representing 4 biological replicates per cell population, respectively. 
3.2.4.2 Identification of distinct APA patterns and 3’-UTR shortening upon HSC 
activation  
In the following, we performed DAPAS analysis (see also 3.2.2.3). 69 significant DAPAS events 
were identified upon activation of HSCs by pIC (Figure 3.28 A). Again, APA events were highly 
complex and consisted of CR-APA (Helz, Kansl3, Ern1) as well as UTR-APA (Rps6kb1, 
Cops2) (Figure 3.28 B). We conclude that APA is regulated in response to HSC activation and 
exit of G0. 
In line with our expectations, analysis of 3’-UTR length (see 3.2.2.4) revealed 3’-UTR 
shortening upon activation of HSCs and exit of quiescence (Figure 3.29 A). Over 1300 
transcripts exhibited shortening of 3’-UTR length, corresponding to approximately 60% of 
shared sHSC/pHSC transcripts (Figure 3.29 A-B). Collecitvely, we show that activation of 
HSCs is linked to APA changes and 3’-UTR shortening in vivo.  
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Figure 3.28: Identification of distinct APA patterns upon HSC activation.  
(A) Identification of DAPAS in proliferating vs homeostatic HSCs by 3’-Seq analysis. (B) APA patterns of the top 10 
DAPAS hits identified in proliferating and homeostatic HSCs. Usage of respective site in percent is shown 
(Percentage of polyadenylation usage (PPAU), see methods section for details). DAPAS analysis, #: significant. 
For all panels: 3’-Seq data is derived from libraries generated in 4 independent experiments, representing 4 
biological replicates per cell population, respectively. 
 
Figure 3.29: Identification of 3’-UTR shortening upon HSC activation.  
(A) Analysis of 3’-UTR shortening/lengthening. Only changes in 3’-UTRs belonging to the same exon in the 
respective populations were considered (UTR-APA only). Binomial test. (B) Length of 3’-UTRs in pHSCs in percent 
normalized to sHSCs. For all panels: 3’-Seq data is derived from libraries generated in 4 independent experiments, 
representing 4 biological replicates per cell population, respectively. 
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3.2.5 The protease Ctsc and the immune cell surface receptor Treml2 are 
regulated by APA 
With robust 3’-Seq datasets at hand, we aimed to identify DAPAS hits with potentially functional 
importance for HSC differentiation and activation. To this end, we generated a Venn diagram 
to identify DAPAS overlaps between MPP1-4 cells compared to HSCs (Figure 3.30 A). The 
RNA-binding protein Hnrnpa3 exhibited differential APA in MPP1-4 cells versus HSCs, while 
Imp4, involved in RNA processing, and the protease Cathepsin C (Ctsc) showed differential 
APA in MPP2-4 cells versus HSCs. Ctsc belongs to the papain enzyme family and encodes a 
protease (Pham and Ley, 1999). This gene caught our interest, as CTSC is important for 
cleavage and activation of Granzyme A and B in vivo, which have been linked to the LPS-
induced stress response in HSCs (Carnevalli et al., 2014; Pham and Ley, 1999). We observed 
that expression of full-length Ctsc was significantly increased by CR-APA in MPP2-4 cells 
compared to HSCs (Figure 3.30 B-C). HSCs mainly express a shortened Ctsc version lacking 
functional domains. The same trend was observed for sHSCs compared to pHSCs. We 
confirmed these expression patterns by qPCR (Figure 3.30 D). It has been shown that CTSC 
secretion is increased in response to LPS (Hamon et al., 2016). Analysis of in vivo LPS-treated 
HSCs revealed a significant APA-mediated switch from the shortened to the functional full-
length Ctsc isoform (Figure 3.30 D). In summary, differentiation as well as pIC- and LPS-
induced activation of HSCs leads to an APA-mediated switch to the full-length Ctsc isoform. 
This switch might be important for Granzyme A and B activation during hematopoietic stress 
response. 
In addition to CR-APA, we also identified UTR-APA only events. For example, we observed a 
significant switch to the more proximal PAS in MPP2 cells and pHSCs of the gene triggering 
receptor expressed on myeloid cells-like 2 (Treml2) (Figure 3.31 A-B). This switch leads to a 
decrease in 3’-UTR length of more than 1000 bp. Previously, Treml2 expression has been 
shown to be upregulated and re-localized in response to inflammation in myeloid cells (King et 
al., 2006; Thomas et al., 2016). Similar processes could occur upon HSC differentiation and 
activation and might be mediated by UTR-APA.  
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Figure 3.30: The protease Ctsc is regulated by APA.  
(A) Venn diagram depicting overlap of DAPAS between HSCs and the respective MPP population. Numbers 
indicate DAPAS. (B) APA patterns of Ctsc in HSCs and MPP cells as well as sHSCs and pHSCs. Proliferation was 
induced by pIC injection. Usage of respective site in percent is shown (Percentage of polyadenylation usage 
(PPAU), see methods section for details). DAPAS analysis: # significant. (C) Representative example of APA 
between MPP2 cells and HSCs. Exemplary IGV data of the gene Ctsc is shown. (D) qPCR-based analysis of the 
DAPAS hit Ctsc in HSCs vs MPP2 cells; HSCs vs pHSCs; sHSCs vs in vivo LPS-treated HSCs. Normalized mean 
relative expression of the proximal to the distal mRNA isoform is shown. Values <1 indicate increase in relative 
usage of the full-length isoform in the respective population compared to HSCs. Gated on LSK CD150+/- CD48+/- 
CD34+/-. N = 3-6, unpaired student’s t-test. For panels A-C: 3’-Seq data is derived from libraries generated in 4 
independent experiments, representing 4 biological replicates per cell population, respectively. For panel D: *p < 
0.05, **p < 0.01, ***p < 0.001, ns: not significant; N indicates number of biological replicates; 3 or more independent 
experiments were performed; mean + SD is shown. 
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Figure 3.31: The immune cell surface receptor Treml2 is regulated by APA.  
(A) Alternative polyadenylation patterns of Treml2 in HSCs and MPP cells as well as sHSCs and pHSCs. Usage of 
respective site in percent is shown (Percentage of polyadenylation usage (PPAU), see methods section for details). 
DAPAS analysis: # significant. (B) Exemplary IGV data of the gene Treml2 is shown depicting APA between MPP2 
cells and HSCs. For all panels: 3’-Seq data is derived from libraries generated in 4 independent experiments, 
representing 4 biological replicates per cell population, respectively.  
3.2.6 APA-mediated Gls isoform switching occurs upon HSC activation, and 
GLS inhibition maintains stem cell potency 
3.2.6.1 Identification of Gls isoform switching mediated by APA in response to 
inflammation-induced HSC activation 
In addition to in-depth analysis of the HSC/MPP dataset, we also performed further analysis 
using the sHSC/pHSC 3’-Seq data. We observed a CR-APA switch in the gene Gls, leading to 
changes in Gls isoform expression (Figure 3.32 A-B). GLS is an enzyme metabolizing 
glutamine to glutamate, which in turn is used for energy production in the TCA cycle in the 
form of a-KG as well as amino acid and glutathione production (Figure 3.32 C) (Altman et al., 
2016). Two different GLS protein isoforms have been described, namely GAC and KGA 
(Figure 3.32 B) (Altman et al., 2016), and their expression is regulated by CR-APA. We 
detected a relative increase in GAC levels compared to KGA levels in pHSCs vs sHSCs and 
observed the same trend in MPP cells (Figure 3.32 A). We could confirm this switch to the 
GAC isoform upon HSC differentiation and activation by qPCR analysis (Figure 3.32 D). It has 
previously been reported that a relative increase in GAC levels is associated with higher overall 
GLS protein levels (van den Heuvel et al., 2012). To analyze the effect of the GAC:KGA ratio 
on GLS protein expression in HSC/MPP and sHSC/pHSC populations, we performed 
intracellular flow cytometry staining of GLS (Figure 3.32 E). Interestingly, we observed 
increased GLS levels in MPP cells and activated HSCs (Figure 3.32 F). In addition to the APA-
mediated Gls isoform switch, the process glutamine metabolism was enriched in the MPP2 
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shortened gene list (see 3.2.2.4). Thus, we decided to concentrate on the metabolic gene Gls 
and the reported isoform switch for functional validation of DAPAS hits.  
 
Figure 3.32: Identification of APA-mediated Gls isoform switching in response to inflammation-induced 
HSC activation.  
(A) APA patterns of Gls in HSCs and MPP cells as well as sHSCs and pHSCs. Usage of respective site in percent 
is shown (Percentage of polyadenylation usage (PPAU), see methods section for details). DAPAS analysis, #: 
significant. (B) Representative example of APA between pHSCs and sHSCs. Exemplary IGV data of the gene Gls 
is shown. (C) Schematic representation of glutaminolysis. (D) qPCR-based analysis of the DAPAS hit Gls in HSCs, 
MPP2 cells and pHSCs. Normalized mean relative expression of the proximal to the distal mRNA isoform is shown. 
Values >1 indicate increased relative usage of the GAC isoform in MPP2 cells/pHSCs compared to HSCs. Gated 
on LSK CD150+/-CD48+/- CD34+/-. N = 5-8, unpaired student’s t-test. (E) Representative histogram plots of GLS 
expression in HSCs and MPP2 cells as well as sHSCs and pHSCs. (F) Flow cytometry-based analysis of GLS 
protein expression in HSCs/MPP cells (LSK CD150 +/- CD48+/- CD34+/-) and in sHSCs/pHSCs (LK CD150+ 
CD48- CD34-). Fold change (FC) of the mean fluorescent intensity (MFI) is shown. Normalized to HSCs/sHSCs. N 
= 12-14, left panel: paired student’s t-test, right panel: unpaired student’s t-test. For panels A-B: 3’-Seq data is 
derived from libraries generated in 4 independent experiments, representing 4 biological replicates per cell 
population, respectively. For panel D-F: *p < 0.05, **p < 0.01, ***p < 0.001, ns: not significant; N indicates number 
of biological replicates; 3 or more independent experiments were performed; mean + SD is shown.  
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3.2.6.2 Short-term inhibition of GLS in vitro maintains HSC potency 
We observed an isoform switch of the gene Gls to the metabolically more active GAC isoform, 
leading to an overall increase in GLS protein levels. Therefore, we hypothesized that these 
findings might be indicative of a metabolic reprogramming towards glutaminolysis upon HSC 
differentiation and activation. This reprogramming might be a prerequisite for HSC activation. 
To test our hypothesis, we first made use of the GLS inhibitor CB-839, currently in clinical trials. 
We aimed to investigate the effects of GLS inhibition on cell cycle status and colony forming 
potential of HSPCs (Figure 3.33 A). Initially, we performed depletion of Lin+ cells to enrich for 
HSCs and MPP cells. Depleted cells were cultured in vitro for 48 h and treated with different 
concentrations of CB-839 or DMSO. Subsequently, we performed cell cycle analysis by Ki-
67/DAPI staining and viability analysis using 7AAD/Annexin (Figure 3.33 B-C). In these dose 
escalation studies, we observed the most prominent effects using 5 µM CB-839 (Figure 3.33 
B). This concentration did not affect cell viability if compared to untreated or DMSO-treated 
controls (Figure 3.33 C). For cell cycle analysis, BM cells were lineage-depleted and cultured 
in vitro in the presence of 5 µM CB-839 or DMSO (Figure 3.33 A). 48 h later, we performed 
cell cycle analysis by flow cytometry and gated HSCs and MPP1-4 cells (Figure 3.33 D-E). In 
general, culture of HSCs and MPP cells leads to exit from the G0 state and active proliferation 
due to the differentiation-inducing in vitro conditions. This effect was observed in DMSO- and 
CB-839-treated MPP cells. Interestingly, analysis of HSCs exhibited an increase in the 
frequency of cells in G0 upon GLS inhibition, indicating that activation and repression of 
glutaminolysis are critical for controlling the balance between proliferation and quiescence of 
HSCs. To test if this cell cycle effect is also functionally relevant, we performed CFU assays 
(Figure 3.33 A). LSK cells were sorted and cultured in presence of CB-839 or DMSO. 72 h 
later, pre-treated cells were harvested and used for standard CFU assays in the absence of 
CB-839 (Figure 3.33 F). In primary platings, we observed reduced colony-forming potential in 
CB-839 pre-treated conditions. However, in secondary platings, CB-839 pre-treated cells 
formed significantly more colonies compared to DMSO pre-treated, controls indicating higher 
maintenance of HSC function. In CFU assays, HSC potential is assessed in secondary 
platings, as colony formation in primary platings is mainly dependent on MPP cells. Thus, we 
conclude that in vitro treatment of HSCs with the GLS inhibitor CB-839 prevents glutaminolysis, 
thereby limiting HSC proliferation. In turn, limited HSC proliferation leads to increased 
maintenance of HSC potential in the otherwise HSC-exhausting in vitro culture conditions.  
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Figure 3.33: Short-term inhibition of GLS in vitro maintains HSC potency.  
(A) Workflow of CB-839 in vitro treatment. (B) Flow cytometry-based cell cycle analysis for titration of the GLS 
inhibitor CB-839. HSCs were gated and analyzed 48 h after treatment. Greater than or equal to 1 independent 
experiment was performed. N = 2-7. (C) Flow cytometry-based viability analysis upon CB-839-treatment. N = 5-7, 
two-way ANOVA. (D) Representative flow cytometry density plots of cell cycle analysis in control and CB-839 
treated HSCs. Gated on LSK CD150+ CD48- CD34-. (E) Flow cytometry-based cell cycle analysis of in vitro CB-
839 treated HSPCs gated on HSCs and MPP cells (LSK CD150+/- CD48+/- CD34+/-). Analysis performed after 48 
h. N = 7, two-way ANOVA. (F) CFU assay of control and CB-839-treated LSK cells represented as fold change 
(FC) in colony numbers for first and second plating. Plating was performed 72 h after start of culture and treatment. 
N = 5, unpaired student’s t-test. For all panels: *p < 0.05, **p < 0.01, ***p < 0.001, ns: not significant; N indicates 
number of biological replicates; 2 or more independent experiments were performed, unless otherwise indicated; 
mean + SD is shown. 
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3.2.6.3 NUDT21 mediates Gls isoform switching in hematopoietic cells 
The APA regulator NUDT21, also called CFIM25, has previously been reported to control Gls 
isoform switching in HeLa cells (Masamha et al., 2016). Masamha et al. could show that 
relative expression of KGA is increased upon KD of Nudt21, while the GAC isoform gets 
downregulated. We aimed to investigate if NUDT21 regulates Gls isoform switching in 
hematopoietic cells. To this end, we sorted LSK cells and performed lentiviral Nudt21 KD 
(Figure 3.34 A) (see also 3.2.1.2). Successfully transduced cells express GFP and were 
resorted to perform KD validation and in vitro functional analysis. First, we performed KD 
validation by qPCR analysis (Figure 3.34 B). Using three different shRNAs (IDs: 10, 4, 2), we 
observed significant downregulation (~50%) of Nudt21 48 h after transduction. Next, we aimed 
to analyze the effect of Nudt21 KD on Gls isoform expression. To this end, we analyzed GAC 
and KGA levels by using isoform-specific TaqMan probes for qPCR analysis (Figure 3.34 C). 
Normalized proximal (GAC)/distal (KGA) expression levels were analyzed. A relative increase 
in GAC levels is indicated by elevated numbers of proximal transcripts (GAC) leading to 
relative expression values above 1, while values below 1 indicate a relative increase in distal 
transcripts (KGA) (see also 3.2.2.3). Analysis of Scr control samples revealed a relative 
increase in GAC levels upon in vitro culture of LSK cells. These results suggest that the 
differentiation- and activation-inducing in vitro culture conditions lead to a Gls isoform switch 
to the active GAC isoform, indicating enhanced glutaminolysis. These observations are in line 
with our previous experiments in which we observed inhibition of glutaminolysis to be beneficial 
for maintaining HSCs by limiting exit of the G0 cell cycle state. In our Nudt21 KD conditions, 
we observed a diminished increase in relative GAC expression, indicating that Nudt21 is 
needed for Gls isoform switching and GAC expression in hematopoietic cells. Taken together, 
we showed that Nudt21 mediates Gls isoform switching in the HSC/MPP compartment and 
reduced NUDT21 levels lead to decreased relative GAC expression. 
 Results  
 
 98 
 
 
Figure 3.34: NUDT21 mediates Gls isoform switching in hematopoietic cells.  
(A) Workflow of Nudt21 KD and subsequent in vitro analysis. (B) qPCR-based analysis of Nudt21 expression in Scr 
control and KD cells after 48 h. N = 5-7, unpaired student’s t-test. (C) qPCR-based analysis of Gls expression in 
LSK cells (0h), Scr control cells (48 h in vitro, resorted GFP+ cells) and KD cells (48 h in vitro, resorted GFP+ cells). 
Normalized mean relative expression of the proximal to the distal mRNA isoform is shown. Values >1 indicate 
increase in relative usage of the GAC isoform in cultured cells compared to LSK cells in vivo. Significance levels 
compared to LSK 0h unless otherwise indicated. N = 3-11, unpaired student’s t-test. For all panels: *p < 0.05, **p 
< 0.01, ***p < 0.001, ns: not significant; N indicates number of biological replicates; 3 or more independent 
experiments were performed; mean + SD is shown. 
3.2.6.4 Nudt21 KD inhibits glutaminolysis by restricting GLS levels and impairs HSC 
function 
In a next step, we aimed to investigate the functional importance of NUDT21-mediated Gls 
isoform switching. First, we analyzed the effect of decreased isoform switching on GLS protein 
levels by intracellular flow cytometry analysis 72 h after LSK transduction (Figure 3.35 A-B). In 
vitro cultured Scr control cells exhibited an overall increase in GLS protein levels compared to 
freshly isolated LSK cells. This is in line with the relative increase in GAC expression levels we 
reported (Figure 3.34 C). KD of Nudt21 led to a diminished increase in relative GAC levels 
and, accordingly, we observed only a declined increase in GLS protein levels. Thus, NUDT21 
seems to be essential for mediating Gls isoform switching to GAC, thereby leading to an 
increase in GLS protein levels in hematopoietic cells. These increased levels are needed, as 
glutaminolysis seems to be key for complete HSC activation. In turn, prevention of Gls 
switching should lead to impaired HSC function. To proof this hypothesis, we performed serial 
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CFU assays using Scr control and Nudt21 KD cells 48 h after LSK transduction (Figure 3.35 
C). Nudt21 KD cells formed significantly less colonies and exhausted in serial platings. Flow 
cytometry analysis after the first plating revealed maintenance of LSK cell frequency in Nudt21 
KD compared to Scr control settings, indicating that lack of colony formation is caused by a 
block in differentiation (Figure 3.35 D). In summary, irreversible prevention of Gls switching by 
KD of Nudt21 maintains LSK cells, which, however, are not able to form colonies. The block 
of differentiation might be caused by prevention of progenitor proliferation and expansion. This 
block is potentially caused by inhibited metabolic switching supported by our observation of 
reduced GLS protein levels.  
 
Figure 3.35: Nudt21 KD inhibits glutaminolysis by restricting GLS levels and impairs HSC function.  
(A) Representative flow cytometry plots of GLS expression in LSK cells (0h), Scr control (72 h in vitro) and Nudt21 
KD (72 h in vitro) cells. (B) Flow cytometry-based analysis of GLS protein expression in LSK cells (0h), Scr control 
cells (72 h in vitro, resorted GFP+ cells) and KD cells (72 h in vitro, resorted GFP+ cells). Fold change (FC) of the 
mean fluorescent intensity (MFI) is shown. Normalized to LSK in vivo cells. Significance levels compared to LSK 
0h unless otherwise indicated. N = 5-6, unpaired student’s t-test. (C) CFU assay of Scr control and Nudt21 KD cells 
showing fold change (FC) in colony numbers for first, second and third plating. N = 3-5, unpaired student’s t-test. 
Significance levels compared to Scr control. (D) Flow cytometry-based analysis of the LSK content in cells from 
CFU assays after primary plating. Percent of LSK cells of all GFP+ cells is shown. N = 4-5, unpaired student’s t-
test. Significance levels compared to Scr control. For all panels: *p < 0.05, **p < 0.01, ***p < 0.001, ns: not 
significant; N indicates number of biological replicates; 2 or more independent experiments were performed; mean 
+ SD is shown. 
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Overall, we show in this study that the APA regulator PABPN1 is essential for HSC function 
using extensive in vitro and in vivo functional assays (Figure 3.36). The advancement in ultra-
low input 3’-Seq techniques enabled us to analyze APA globally in rare BM populations, 
generating a 3’-UTR/APA resource dataset of HSPCs. We report APA upon HSC commitment 
and activation. 3’-UTR shortening occurs upon stem cell differentiation and upon exit of G0. In 
addition, we also demonstrate the functional importance of APA in vivo by reporting an APA 
switch in the metabolic gene Gls to be essential for HSC activation. 
 
Figure 3.36: A model of the role of APA in the HSC/MPP compartment.  
Schematic model of 3’-UTR shortening in the hematopoietic system upon HSC commitment/differentiation and 
activation during inflammatory response induced by pIC. Interfering with APA by KD of the APA regulator Pabpn1 
leads to loss of HSC function. During stress response, HSCs become activated and switch to the Gls isoform GAC 
by APA. This leads to a metabolic shift and dependency on glutaminolysis. Pab: PABPN1. 
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3.3 Generation of Pabpn1flox mice 
In order to facilitate functional research on APA and the APA regulator PABPN1, we aimed to 
generate an inducible Pabpn1 KO mouse model. Such a model has the advantage that it can 
be used in combination with tissue-specific Cre drivers and in disease models, for example 
leukemia. Thereby, analysis of impaired APA in different cell types in vivo and in different 
functional contexts is feasible.  
3.3.1 Design of a Pabpn1flox mouse model and gRNA testing 
3.3.1.1 Pabpn1 targeting approach 
First, we designed our targeting approach. Deletion of the floxed Pabpn1 region should lead 
to complete loss of Pabpn1 expression from the targeted allele. To this end, we checked 
Pabpn1 isoforms and functional domains using Ensembl (www.ensembl.org). Several isoforms 
are reported, and all of them share expression of exon 3 and 4 of the most common Pabpn1 
isoform (ENSMUST00000022808.13). In addition, the functionally important RNA binding 
domains are localized in these exons. Therefore, we decided to introduce loxP sites flanking 
exon 3 and 4. We aimed to use the CRISPR/Cas9 method as described by Miura et al. and 
Quadros et al. (Miura et al., 2018; Quadros et al., 2017). Briefly, long ssDNA donor templates 
are injected together with pre-assembled crRNA-tracrRNA:Cas9 ribonucleoprotein complexes 
into mouse zygotes. Excision and recombination take place in the 1-cell or early 2-cell state. 
As recombination occurs directly in vivo, we aimed to increase efficiency by pre-testing our 
gRNA efficiency in vitro. To this end, we collaborated with Dr. Kai Schönig (ZI Mannheim). 3 
gRNAs per targeting locus were designed (upstream of exon 3: gRNAs A1-3; downstream of 
exon 4: gRNAs B1-3) using CRISPOR (http://crispor.tefor.net/) (Haeussler et al., 2016) (Figure 
3.37 A). The potential targeting sequence was at least 250 bp upstream or downstream of the 
respective exon to exclude interference of the introduced loxP sites with splicing.  
3.3.1.2 gRNA testing in vitro 
To test gRNA efficiency, we used a disrupted lacZ reporter gene with the respective targeting 
sequence (gRNAs A1-3 or gRNAs B1-3) and measured reporter signal after in vitro targeting 
(Figure 3.37 B). First, we ordered gRNA oligonucleotides and reporter oligos. The reporter 
oligos correspond to the Pabpn1 introns that should be targeted by the respective gRNAs. The 
gRNA oligonucleotides were annealed and cloned into the px330 Cas9 vector, enabling 
gRNA/Cas9 expression. The targeting sequences were inserted between the lacZ fragments 
in the pCRISPR report vector (targeting sequence oligo A or B). HeLa cells were transfected 
with the px330 Cas9 vector encoding for gRNA A1, A2, A3, B1, B2 or B3. Co-transfection with 
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the respective pCRISPR reporter plasmid and a luciferase-encoding control plasmid 
(pUHC131.1) was performed. 24 h later, cells were lysed and LacZ as well as luciferase activity 
were measured. The luciferase signal was used for normalization to correct for differences in 
transfection efficiency and cell number. The normalized LacZ signal ((LacZ signal/luciferase 
signal) x mean luciferase signal) of the respective tested gRNA is a direct indicator of gRNA 
targeting efficiency. Testing revealed the highest efficiency for gRNAs A3 and B2 (Figure 3.37 
C).  
 
Figure 3.37: Testing of gRNA efficency.  
(A) gRNA design based on Pabpn1 isoforms and PAM localization. gRNAs were designed using CRISPOR 
(http://crispor.tefor.net/) (Haeussler et al., 2016). (B) Schematic representation of the lacZ fragments in the 
pCRISPR report vector containing targeting sequence oligo A or B. This vector is used to test gRNA efficiency. (C) 
Testing of gRNA efficiency. Normalized LacZ signal is shown. N = 6. N indicates number of biological replicates; 2 
independent experiments were performed; mean + SD is shown. 
3.3.2 Generation of Pabpn1flox mouse generation 
3.3.2.1 Pronucleus injections 
Initially, we injected two px330 Cas9 vectors encoding gRNA A3 and B2, respectively, together 
with Cas9 mRNA and a circular 6 kb plasmid containing the targeting sequence with integrated 
loxP sites flanked by ~1300 homology arms on both sides. This approach, however, failed to 
generate transgenic mice. In a next step, we decided to use the CRISPR/Cas9 method as 
described by Miura et al. and Quadros et al. (Miura et al., 2018; Quadros et al., 2017). We 
ordered crRNA and tracrRNA for in vivo injections corresponding to gRNA A3 and B2, as these 
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have been shown to be more efficient than single-molecule guide RNAs (Miura et al., 2018; 
Quadros et al., 2017). In addition, we ordered a long ssDNA megamerâ. In this 1126 
nucleotide (nt) long megamer, a 60 nt homology arm was followed by the upper loxP site, exon 
3 and 4 including intronic sequences, the lower loxP site and a 60 nt downstream homology 
arm. crRNA/tracrRNAs were annealed to obtain active gRNAs and mixed with Cas9 protein 
and the ssDNA template. This mix was injected into one of the pronuclei of C57Bl6/J zygotes, 
which were subsequently transplanted into pseudo-pregnant foster mice. Injections were 
performed by the transgenic service of the DKFZ.  
3.3.2.2 Genotyping of transgenic mice 
From two rounds of injections, 17 mice were born. In order to identify potential founder mice, 
we developed a stringent genotyping strategy. In a first step, integration of the upstream (us) 
and the downstream (ds) loxP site was evaluated by PCR1 and PCR2, respectively. 
Successful integration of loxP sites leads to a band shift of 36 bp. This size difference can be 
difficult to detect in gel analysis. Thus, in addition to loxP sites, we also introduced restriction 
enzyme sites during design of the ssDNA template. Only PCR products generated by 
amplification of the floxed sequence can be digested. Analysis revealed 7 animals with 
integration of both loxP sites (Table 3.1; Appendix Figures 1-2). Only 7 of these animals 
showed integration of upper and lower loxP and were used for further analysis (IDs: 3, 5, 7, 
11, 14, 15, 16). Next, PCR3 and subsequent digestion was performed to check if both loxP 
sites were localized on the same allele (Table 3.1; Appendix Figure 3). Only four animals 
passed this QC (IDs: 5, 11, 14, 15). To check for targeted integration in contrast to random 
integration, we designed and performed PCR4 (upper loxP) and PCR5 (lower loxP) and 
subsequent digestion (Table 3.1; Appendix Figures 4-5). All four animals passed this QC step. 
To exclude the presence of point mutations, we performed amplicon sequencing of PCR2 and 
4 (Table 3.1). In total, 3 animals (IDs: 5, 11, 15) passed this final QC. The mouse with ID5 was 
crossed to C57Bl6/J wildtype animals to generate heterozygous offspring. These mice were 
again extensively genotyped, and loxP integration was verified (data not shown). 
Heterozygous mice were crossed, generating homozygous Pabpn1flox/flox mice. These mice are 
currently being crossed to Cre drivers (e.g. VavCre, MxCre) to validate the function of the 
integrated loxP sites. In summary, we successfully generated transgenic Pabpn1flox mice by 
CRISPR/Cas9-based targeting of zygotes.  
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Table 3.1: Genotyping of transgenic mice.  
Overview of Pabpn1flox mouse generation and genotyping results. (us: upstream; ds: downstream; ND: not 
determined; Het: heterozygous; Hom: homozygous; WT: wildtype) 
ID Sex Birthdate PCR 1 
+ digest  
(us 
loxP) 
PCR 2 
+ digest  
(ds 
loxP) 
PCR 3 + 
digest 
(loxP on 
same allele) 
PCR 4 + 
digest  
(us 
localization 
correct) 
PCR 5 + 
digest  
(ds 
localization 
correct) 
Seq 
PCR 2 
Seq 
PCR 4 
1 M 23.04.18 WT ? ND ND ND ND ND 
2 F 23.04.18 WT WT ND ND ND ND ND 
3 M 23.04.18 Hom Hom failed ND failed ND ND 
4 M 02.05.18 WT WT ND ND ND ND ND 
5 M 02.05.18 Het Het passed passed passed passed passed 
6 M 02.05.18 WT WT ND ND ND ND ND 
7 M 02.05.18 Het Het failed ND failed ND ND 
8 F 02.05.18 WT WT ND ND ND ND ND 
9 F 02.05.18 WT Het ND ND ND ND ND 
10 M 02.05.18 WT Het ND ND ND ND ND 
11 M 02.05.18 Het Het passed passed passed passed passed 
12 M 02.05.18 WT WT ND ND ND ND ND 
13 F 02.05.18 WT WT ND ND ND ND ND 
14 F 02.05.18 Het Het passed passed passed passed failed 
15 F 02.05.18 Het Het passed passed passed passed passed 
16 M 02.05.18 Het Hom failed ND failed ND ND 
17 F 02.05.18 WT WT ND ND ND ND ND 
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4 Discussion 
4.1 The role of the lncRNA Meg3 in HSCs 
In recent years, multiple studies could show that specific lncRNAs play crucial roles in HSCs 
and the hematopoietic compartment (Alvarez-Dominguez and Lodish, 2017; Luo et al., 2015; 
Yildirim et al., 2013). As Meg3 was very highly and specifically expressed in HSCs, we aimed 
to unravel the function of Meg3 in hematopoiesis. In our experiments, we could not detect any 
impairments upon loss of Meg3 expression in the hematopoietic compartment.  
4.1.1 Meg3 is dispensable for HSCs 
Several KO mouse models were described in the past, showing that Meg3 is important for 
embryonic development (Lin et al., 2003; Takahashi et al., 2009; Zhou et al., 2010). Depending 
on the targeting strategy, different developmental phenotypes were observed (see also 1.2.4). 
Deletion of IG-DMR (Lin et al., 2003) and deletion of the Meg3 promoter, part of the Meg3-
DMR and exon 1-5 (Zhou et al., 2010) exhibited highly similar phenotypes. In both models, 
maternal inheritance of the deletion was embryonically lethal and led to loss of imprinting. 
Inheritance of the deletion from the paternal side, however, was only associated with minor 
phenotypes. In contrast, the model of Takahashi et al., harboring a deletion of a 10 kb region 
including the Meg3-DMR, the Meg3 promoter and exon 1-5, presented a very different 
developmental phenotype (Takahashi et al., 2009). In this model, no loss of imprinting was 
observed. Mice that inherited the deletion from the maternal side died 4 weeks after birth, while 
paternal inheritance led to partial embryonic lethality. This phenotype is presumably caused 
by residual activity of the Neomycin promoter, still present from the mouse targeting approach, 
which drives expression of the other ncRNA clusters in the Dlk1-Meg3 locus in paternal and 
maternal deletion mice, respectively (Takahashi et al., 2009; Zhou et al., 2010).  
Qian et al. recently used the Lin and Takahashi mouse models to analyze the effects of loss 
of Dlk1-Meg3 imprinting on fetal liver HSCs (Qian et al., 2016). Using this approach, they 
reported impaired fetal liver HSC function in the IG-DMR (Lin et al., 2003) and Meg3 
(Takahashi et al., 2009) knockout mouse models. Functionally, they linked the observed 
phenotype to loss of expression of the miRNA cluster localized on the maternal allele. These 
miRNAs suppress the PI3K-mTOR pathway in healthy HSCs. Loss of this suppression led to 
activation of the PI3K-mTOR pathway and in turn increased OXPHOS and ROS production. 
ROS presumably induced HSC apoptosis, thereby causing the reported phenotype. These 
findings are significantly different to our findings. We neither observed impaired hematopoiesis 
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in adult HSCs nor during development. In the mouse models used by Qian et al., whole-body 
deletion of the locus takes place. Thus, all cells of the developing embryo are affected, and 
Meg3 is known to be important during development (Lin et al., 2003; Takahashi et al., 2009; 
Zhou et al., 2010). Consequently, the observed reduced numbers of fetal liver HSCs and 
impaired liver HSC function could be secondary effects caused by defective HSC niche 
development. Importantly, Qian et al. showed impaired HSC development in the Lin and 
Takahashi model and linked it to loss of imprinting and loss of miRNA expression. Functional 
studies on the PI3K-mTOR and miRNA pathways were only performed using the Lin model. In 
the Takahashi model, however, imprinting is not affected, and expression patterns of the 
miRNA cluster in knockout animals are only reduced and not lost, especially in liver tissue 
(Takahashi et al., 2009). Thus, it seems reasonable that the functional impairment of fetal liver 
HSCs in the Takahashi model were caused by other mechanisms than those observed and 
described in the Lin model.  
In our study, we use an inducible deletion approach, and loss of Meg3 and the associated 
miRNA cluster do not impair adult hematopoiesis and HSCs, independently of the deletion 
time point. Using this strategy, we were able to directly analyze knockout effects on adult 
hematopoiesis, excluding potential developmental and microenvironmental impairments that 
could eventually affect HSCs. Adult HSCs are deeply quiescent, and Meg3 is known to be 
involved in cell cycle regulation via the p53- and Rb-pathways (Passegue et al., 2005; Wilson 
et al., 2008; Zhang et al., 2010c; Zhou et al., 2007). Thus, we employed straight and 
competitive transplantation assays to challenge HSCs and to further investigate HSC function 
over time. We did not observe any biologically relevant impairment of Meg3 KO HSCs under 
homeostatic or stress conditions.  
As Qian et al. focused on fetal liver HSCs and we observed strikingly different results in the 
adult system, we aimed to additionally address the role of the Meg3 locus during development. 
Of note, fetal liver HSCs greatly differ from adult HSCs, as they are actively cycling and 
expanding (Bowie et al., 2006; Nygren et al., 2006; Wilson et al., 2008). Thus, we deleted 
Meg3 in CD45+ cells in the murine embryo by using Vav1 as a Cre driver. Surprisingly, mice 
were viable, and we did not observe signs of hematopoietic impairments in adult mice. We 
conclude that Meg3 is dispensable for embryonic establishment of hematopoiesis and HSC 
function after the endothelial-cell-to-HSC transition. We cannot exclude that Meg3 might play 
an important role for this transition step during development, leading to the defects in fetal liver 
HSCs observed by Qian et al. (Qian et al., 2016).  
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4.1.2 Deletion of imprinted loci – targeting strategy matters 
In our model, we target exon 1-4 of the Meg3 locus, leading to loss of expression of both Meg3 
and the miRNA cluster. However, we do not target DMRs. Importantly, imprinting is not 
affected in our model (Zhou and Klibanski; unpublished observation). A broader disruption of 
the imprinted locus by targeting DMRs could potentially lead to globally altered gene 
expression patterns, which in turn could affect hematopoiesis – independently of Meg3 and 
the miRNA cluster itself. It is possible that the effects observed by Qian et al. are related to 
such broader disruptions of gene regulation. Future studies will need to shed light on the 
effects of specific DMR targeting in hematopoietic cells, affecting the entire Meg3-Dlk1 locus 
in adult mice. However, additional inducible mouse models are needed to answer these 
questions.  
Further, special care has to be taken when interpreting results generated in knockout mouse 
models of imprinted regions. By altering imprinting or KO of imprinted regions, not only 
maternal genes are silenced or deleted, but paternal expression patterns are often reactivated 
on the maternal allele and vice versa. Thus, observed biological effects could be caused by 
loss of expression or increased expression of the maternal/paternal genes, respectively.  
4.1.3 Loss of Meg3 in the hematopoietic compartment does not cause 
development of leukemia 
Meg3 has been reported to act as a tumor suppressor lncRNA in several cancer entities 
(Benetatos et al., 2011; Zhou et al., 2012). Interestingly, aberrant methylation patterns of 
DMRs in the Meg3 locus were reported in MM, MDS and AML patients (Benetatos et al., 2008; 
Benetatos et al., 2010; Khoury et al., 2010). Meg3 promoter methylation was associated with 
decreased overall survival (Benetatos et al., 2010) and increased Dlk1 expression, which was 
further associated with silencing of the maternal expression patterns observed in the majority 
of AML patients (Khoury et al., 2010). Functionally, Meg3 also has a tumor suppressor function 
in AML cells and was reported to act via a p53-dependent and -independent axis (Lyu et al., 
2017). In this thesis, we show that loss of Meg3 and the associated miRNA cluster alone does 
not cause the development of leukemia or myeloproliferative diseases even in long-term 
experiments such as tertiary transplantations. In addition, we did not observe any proliferative 
advantages of Meg3 mat KO cells. We conclude that loss of the tumor suppressor Meg3 alone 
is not sufficient for cell transformation in the hematopoietic system. Interestingly, loss of Meg3 
in cancer cells mostly occurs by epigenetic silencing (Benetatos et al., 2011; Zhou et al., 2012). 
Taken together, Meg3 dysregulation might result as a secondary event during the development 
of leukemia but is unlikely to be an early event during leukemogenesis. 
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4.1.4 The role of the lncRNA Meg3 in HSCs – summary 
In this study, we show by inducible deletion of Meg3 and the associated maternal miRNA 
cluster that this locus is dispensable for HSCs in the adult organism. We did not observe 
impaired hematopoiesis during homeostatic conditions, upon serial transplantation or in 
response to inflammation-induced stress. In addition, embryonic deletion of the locus after the 
endothelial-cell-to-HSC transition step did not affect hematopoiesis. These findings are 
surprising, as the lncRNA Meg3 is highly and specifically expressed in the HSC compartment 
and strongly downregulated in early progenitors. Future studies are needed to understand why 
the locus is specifically expressed in the HSC compartment, even though it is functionally 
dispensable.  
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4.2 HSC function, differentiation and activation are regulated by APA 
Different layers regulating HSC self-renewal, function and differentiation in health and disease 
have been discovered. These mechanisms include regulation of DNA methylation, chromatin 
accessibility and modifications, enhancer usage, gene expression, RNA editing, protein 
translation and stability as well as alternative splicing (Bahr et al., 2018; Cabezas-Wallscheid 
et al., 2014; Goldstein et al., 2017; Ji et al., 2010; Lipka et al., 2014; Luo et al., 2015; Signer 
et al., 2014; Zipeto et al., 2016). These regulatory layers act in a synergistic fashion to tightly 
control HSC fate and function. Perturbations in this precisely equilibrated system can lead to 
stem cell failure or cause development of hematological malignancies. In this thesis, we 
demonstrate that the RNA regulatory mechanism APA is dynamically regulated within the 
HSPC compartment and that correct APA is essential for proper HSC function. 
4.2.1 3’-Seq of highly purified cell subsets using ultra-low input approaches 
Multiple studies have used different approaches to analyze 3’-UTR length variations and 
occurrence of APA in vivo in health and disease, including EST databases, microarray 
approaches and 3’-enriched sequencing methods. Different developmental stages and mature 
tissues, including testis, muscle and brain tissue, as well as mature immune cells have been 
analyzed (Boutet et al., 2012; Jereb et al., 2018; Ji et al., 2009; Jia et al., 2017; Lau et al., 
2010; Mueller et al., 2016; Singh et al., 2018). Most studies focused on the characterization of 
whole tissues, not taking cellular heterogeneity within organ structures into account. 
Alternatively, analysis of pre-defined APA events was performed in specific cell subsets 
(Boutet et al., 2012; Cesana et al., 2018; Mueller et al., 2016). Global APA analysis of cellular 
subsets in vivo is rare. Jereb et al., for example, investigated APA patterns in different neuronal 
cell types, including Purkinje and granule cells. They used specific mouse models that enabled 
pulldown of RNA from defined cell types (Jereb et al., 2018). In addition, a recent study 
reported 3’-Seq analysis of human in vivo-derived B cells (Singh et al., 2018). The so far 
unsolved problems of 3’-enriched sequencing analysis are caused by the prerequisites of the 
different techniques. Most published protocols and available kits depend on high amounts of 
RNA input, which can be achieved by using cell lines, whole tissues or frequent cell subsets. 
However, these techniques do not enable global analysis of sporadic cell subsets like stem 
and progenitor cells. Thus, the extent and functional relevance of APA in rare, but highly 
functional in vivo cell subsets, like stem cells, remains elusive.  
Here, we were able to solve this problem. Sorting schemes and isolation of low amounts of 
high-quality total RNA from sorted HSC and MPP subsets were previously accomplished by 
our laboratory (Cabezas-Wallscheid et al., 2017; Cabezas-Wallscheid et al., 2014). We could 
use this approach to derive high-quality total RNA from homeostatic as well as activated HSCs 
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and MPP1-4 subsets. The QuantSeq 3’-mRNA Library Prep Kit REV (Lexogen) enables 
generation of libraries for 3’-Seq analysis using as little as 10 ng of total RNA. However, 
analysis of APA in HSCs and MPP subsets using 10 ng of total RNA is not feasible. Sorting of 
10,000 HSCs requires pooling of 3 mice, and total RNA isolation leads to recovery of only 3 
ng of total RNA. Thus, to enable time- and cost-effective APA analysis in in vivo-derived 
specific cell subsets, we further lowered the input needed for library generation by introducing 
an additional RNA denaturation step before random priming and reverse transcription. We 
think that this denaturation step leads to a higher efficiency of random priming and reverse 
transcription, enabling library generation from as little as 3 ng of total RNA (see also methods 
section). Thus, we developed a workflow that enables global analysis of 3’-UTRs in rare in vivo 
cell populations by combining widely used sorting approaches and adaptations of commercially 
available kits. Therefore, our approach can be broadly adapted to enable analysis of other 
cellular subsets in different in vivo systems. Here, we present the first global APA analysis of 
the rare in vivo cell subsets HSCs and MPPs. 
The Rev version of the QuantSeq 3’-mRNA Library Prep Kit (Lexogen) is advantageous for 
APA analysis. In this approach, a custom sequencing primer is used to generate read1 during 
sequencing. This primer covers the residual part of the poly(A) tail, which is part of the 
sequencing libraries. Thereby, the read starts directly upstream of the cleavage site, facilitating 
detection of the utilized PAS 15 to 40 nt upstream. Using this technique, the employed PAS, 
the length of the 3’-UTR and the associated exon can be identified by annealing read 1 to the 
genome and performing bioinformatic analysis. This approach solves an issue typically 
occurring in 3’-UTR analysis using other sequencing methods: The base calling quality 
severely drops downstream of the T stretch generated during sequencing of the residual 
poly(A) tail (Chen et al., 2017; Wilkening et al., 2013). This is caused by polymerase slippage 
during library amplification, clustering or sequencing. Thus, reads within one cluster become 
desynchronized, and no clear fluorescent signal is detectable and the sequence cannot be 
identified. Other methods for 3’-enriched sequencing try to solve this issue by using so-called 
RNA manipulation-based approaches for library generation. In these methods, for example, 
splint digestion and digestion of the residual poly(A) tail (3P-Seq) or RNA fragmentation and 
capturing are used (3’READS) (Hoque et al., 2013; Jan et al., 2011). However, these methods 
are not yet feasible for analysis of ultra-low RNA inputs.  
One drawback of our sequencing approach compared to 3P-Seq and 3’READS is the internal 
priming issue. Internal priming describes a process occurring during oligo(dT)-mediated 
reverse transcription. The oligo(dT) primer does not only anneal to the poly(A) tails but also to 
internal A stretches present in RNA molecules. During library generation, this leads to library 
molecules that seem to represent cleavage and polyadenylation events but, in reality, only 
represent genomic A stretches. In our sequencing approach, we deal with the internal priming 
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issue by using very strict bioinformatic filtering steps prior to APA analysis. We only include 
reads in our analysis that lie downstream of a conserved PAS and that do not harbor genomic 
poly(A) stretches downstream of the read start site. Thereby, we ensure that only real cleavage 
and polyadenylation events are considered in our APA analysis.  
Recently, many groups have focused on the re-analysis of RNA-seq datasets for APA analysis 
(Ha et al., 2018; Xia et al., 2014; Ye et al., 2018). These approaches are of high interest as 
they allow analysis of APA without the need to generate new sequencing data. However, it has 
to be kept in mind that these tools depend on bioinformatic and statistical reconstruction of 
PAS usage. Cleavage site identification is less precise, and de novo PAS discovery is limited. 
In addition, only a fraction of reads is located in 3’-UTR regions. Thus, RNA-seq data with a 
higher sequencing depth is needed to enable APA analysis as compared to 3’-enriched 
sequencing methods. Re-analysis of RNA-seq data is a fast approach to identify APA events 
that occur frequently in the respective setting. However, global in-depth analysis and de novo 
identification of APA events remains dependent on 3’-enriched sequencing methodologies.  
Lately, also single-cell approaches have been used for APA analysis (Velten et al., 2015; Ye 
et al., 2019). Library generation and sequencing of single cells frequently uses methods relying 
on 3’-end methods. Therefore, APA analysis and analysis of cell heterogeneity is possible 
using these datasets. However, sequencing depth in single cell approaches is limited (Liu and 
Trapnell, 2016). Hence, many low to medium expressed genes cannot be detected, and APA 
analysis is restricted to highly expressed genes. While highly expressed genes are useful to 
identify intercellular heterogeneity and cellular trajectories, APA often occurs in very specific 
non-housekeeping genes. Thus, for a general understanding of the prevalence and relevance 
of APA, bulk sequencing approaches are better suited. Single-cell approaches can be used in 
addition to understand to which extent APA contributes to intercellular heterogeneity.  
In summary, we provide a novel 3’-Seq resource dataset enabling APA analysis in the HSPC 
compartment in vivo. The bioinformatic analysis workflow enables identification of high-
confidence PAS usage patterns and allows analysis of differential APA on a single gene level 
and analysis of global 3’-UTR length regulation. Our library generation and bioinformatic 
analysis approach is applicable to other biological questions and model systems. The dataset 
allows us for the first time to analyze APA quantitatively and investigate the role of this RNA 
regulatory mechanism in stem cell hierarchies. 
Previously, the role of APA in stem cells has mainly been studied in ESCs and in iPSC 
generation (Brumbaugh et al., 2018; Ji and Tian, 2009; Lackford et al., 2014). In vivo analysis 
was focused on germ cells and specific genes exhibiting APA in muscle stem cells and HSCs 
(Cesana et al., 2018; Liu et al., 2007; Mueller et al., 2016). Using our adapted sequencing 
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approach, we can now globally analyze APA within stem cell hierarchies. Our data provides 
evidence that regulation of 3’-UTR length and APA represent a novel hub to target and control 
stem cell function in vivo. 
4.2.2 APA patterns identified in HSC/MPP populations are versatile 
Using our 3’-Seq approach, we could identify differential APA upon HSC differentiation and 
activation on a single gene level. We observed differential CR-APA as well as UTR-APA in 
MPP1-4 cells and pHSCs compared to HSCs and sHSCs, respectively. In fact, a mixture of 
CR- and UTR-APA was detected for a given gene in most cases. These results indicate that 
APA patterns are highly versatile and that CR- and UTR-APA are tightly connected. Complex 
APA regulation patterns have been reported: APA is regulated by intrinsic PAS strength (Hu 
et al., 2005; Tian et al., 2005), the presence of 3’-processing factors (Lackford et al., 2014; Li 
et al., 2015; Takagaki and Manley, 1998; Takagaki et al., 1996; Xia et al., 2014; Yao et al., 
2013), epigenetic marks (Spies et al., 2009; Wood et al., 2008), transcription regulators and 
transcription itself (Ji et al., 2011; Nagaike et al., 2011; Pinto et al., 2011; Rosonina et al., 
2003) and other regulatory layers. All of these different regulatory mechanisms can be 
expected to work synergistically and antagonistically at any given time point. Thus, in a single 
cell, not only one PAS is used per actively transcribed gene. The different mechanisms 
controlling PAS selection slightly vary for every transcript, even if transcribed from the same 
gene with only minutes between start of transcription initiation. Thus, an equilibrium of PAS 
usage for a distinct gene is reached in a defined cellular status, e.g. in HSCs. In this status, 
the different PASs are used in a certain ratio, as we could observe in HSC analysis. Changes 
in the cellular status, in our case for example differentiation towards MPP2, do not lead to 
complete loss of usage of one PAS but instead to a more complex gradual shift towards usage 
of other PASs. PAS usage is increased at some sites, whereas a pronounced decrease in 
usage is observed at other sites. In addition, usage of some PASs for the same gene remain 
unchanged. Our data indicates that complex processes like HSC activation and differentiation 
are accompanied by distinct changes in APA patterns that are characterized by versatile 
mixtures of CR- and UTR-APA affecting PASs in different genomic locations, including introns, 
exons and annotated 3’-UTRs.  
Interestingly, we observed enhanced intronic polyadenylation and usage of higher numbers of 
PASs per gene in HSCs compared to MPP cells and pHSCs. Of note, Pabpn1 KD cells, which 
harbor decreased HSC function, also exhibited a decrease in intronic polyadenylation and PAS 
number per gene. Thus, intronic polyadenylation patterns and high PAS numbers per gene 
seem to be characteristic for functional quiescent HSCs. This APA status might be indicative 
of the highest HSC potency. However, we do not yet understand why intronic polyadenylation 
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and PAS selection in general are increased in the HSC compartment. Previously, intronic 
polyadenylation has been shown to mediate IgM switching in activated B cells from the 
membrane-bound to the secreted version by exclusion of the transmembrane domain 
(Takagaki and Manley, 1998; Takagaki et al., 1996). Thus, intronic polyadenylation in HSCs 
could be important to regulate localization and secretion of certain proteins. Further, specific 
intronic polyadenylation events have been described in resident muscle stem cells for the gene 
Pdgfra (Mueller et al., 2016), and immune cells have been shown to exhibit globally enhanced 
intronic polyadenylation (Singh et al., 2018). Hence, intronic polyadenylation seems to occur 
in different biological settings, but additional research is needed to understand the relevance 
of these events. Singh et al. could already show that mRNAs generated by intronic 
polyadenylation are not subject to nonsense-mediated decay, as they harbor stop codons and 
standard 3’-UTR structures (Singh et al., 2018). In our analyses, we also observe intronic 
polyadenylation at sites harboring common 3’-UTR motifs, including the PAS, hinting at the 
generation of functional proteins. 
It has to be considered that in-depth analysis of 3’-UTR regions has only recently become 
available. Therefore, the annotation of all expressed 3’-UTRs is not yet complete. We think 
that intronic polyadenylation observed in many studies should rather be considered as CR-
APA. The presence of the typical 3’-UTR sequences, including the PAS and other motifs, as 
well as the presence of stop codons in the last exon of transcripts generated by most intronic 
polyadenylation events should help to differentiate between “CR-APA intronic polyadenylation” 
and “real intronic polyadenylation”, which in turn leads to the generation of truncated non-
functional proteins. Allocation to intronic structures might be caused by incomplete 3’-UTR 
annotation. “CR-APA intronic polyadenylation” seems to be a mechanism to modulate 
secretion of specific proteins and is specifically regulated during cellular differentiation 
processes (Singh et al., 2018). These reports are in line with our observations. Conclusively, 
intronic polyadenylation and enhanced PAS usage are characteristic for HSCs and become 
downregulated in response to HSC activation and differentiation. The functional relevance of 
this pattern and the effects on the proteome and individual protein function remain to be 
determined. 
4.2.3 DAPAS reflect molecular distances between HSCs and MPP populations 
Previous reports showed that differential gene expression analysis can be used to identify 
molecular differences between HSCs and MPP populations (Cabezas-Wallscheid et al., 2017; 
Cabezas-Wallscheid et al., 2014). In addition, cellular trajectories and molecular distances 
between these populations could be identified. We could validate these findings by performing 
differential gene expression analysis using our 3’-Seq dataset and by performing PCA. Only 
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few differences were identified between HSCs and MPP1 cells by differential gene expression 
analysis, while MPP2, MPP3 and MPP4 cells were more distinct compared to HSCs on a gene 
expression level. These differences also reflect functional differences between HSCs and the 
different MPP populations (Cabezas-Wallscheid et al., 2014; Pietras et al., 2015). Only HSCs 
are capable of long-term multilineage engraftment, while MPP1 cells exhibit short-term 
multilineage engraftment. Engraftment potential of MPP2 cells is further reduced, but remains 
multilineage. In contrast, MPP3 and MPP4 cells exhibit lineage-biased engraftment (Cabezas-
Wallscheid et al., 2014; Pietras et al., 2015). Interestingly, DAPAS analysis reflected the earlier 
observations made by us and others in DEG analysis. Only few DAPAS hits were identified 
between HSCs and MPP1 cells, reflecting their high molecular identity. However, a greater 
number of DAPAS was identified in HSCs compared to MPP2-4 cells. These cells also 
exhibited greater differences in PCA and DEG analysis. Thus, the number of DAPAS between 
defined cellular populations can be used to estimate their molecular and functional distance. 
These differences might be caused mainly by the cell cycle status, as HSCs are highly 
quiescent and MPP cells are more active (see also 4.2.4).  
4.2.4 APA patterns and 3’-UTR length in HSCs depend on the activation status  
HSC differentiation towards progenitors as well as inflammation-mediated HSC activation rely 
on increased HSC proliferation (Essers et al., 2009; Wilson et al., 2008). Analysis of our 3’-
Seq dataset of HSCs and MPPs revealed that HSC activation and exit of G0 is accompanied 
by APA switches and overall 3’-UTR shortening.  
Interestingly, 3’-UTR shortening has been observed in a number of biological settings including 
immune cell activation (Gruber et al., 2014b; Jia et al., 2017; Pai et al., 2016; Sandberg et al., 
2008), cellular transformation (Lee et al., 2018; Xia et al., 2014; Xiang et al., 2018) and during 
cellular stress response (Hollerer et al., 2016; Zheng et al., 2018). All of these cellular settings 
are accompanied by increased cell cycle progression. In line, we observed 3’-UTR shortening 
in activated HSCs. This shortening response was induced by cellular activity of HSCs, 
independently of the cause of activation, in our case differentiation or inflammation-induced 
stress response. 3’-UTR shortening seems to be an intrinsic cellular response observed upon 
increased cellular activity.  
Especially during the activation of HSCs and exit of the quiescent state, the demand for 
functional proteins is high, as overall protein content in quiescent HSCs is extremely low. 
Interestingly, Signer et al. showed that an increase in protein synthesis in progenitors as well 
as upon HSC activation is critical for proper HSC function (Signer et al., 2014). Furthermore, 
we recently identified a biosynthetic shutdown as a hallmark of HSC dormancy (Cabezas-
Wallscheid et al., 2017). Based on our results, HSCs might evade miRNA targeting of mRNAs 
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by global shortening of 3’-UTRs, potentially leading to an increase in overall protein production 
during differentiation and stress-induced activation processes. This increase in protein content 
is a prerequisite for HSC function and activation and might be influenced by APA. 3’-UTR 
shortening has so far mainly been analyzed in cell lines and was linked to evasion of miRNA-
based regulation and increased protein output (Fu et al., 2018; Ji et al., 2011; Jia et al., 2017; 
Pai et al., 2016; Sandberg et al., 2008; Zheng et al., 2018); but also unchanged protein 
expression was observed (Gruber et al., 2014b). Studies performed by Fu et al. could partially 
resolve these contradictory results (Fu et al., 2018). Enhanced protein expression caused by 
3’-UTR shortening seems to be characteristic for actively cycling cells, especially in the G2/M 
phase. These observations support our hypothesis that HSCs entering the cell cycle depend 
on APA-mediated 3’-UTR shortening to generate protein output, which is needed for HSC 
function during activation (Signer et al., 2014). In the future, the link between APA and changes 
in protein expression patterns in HSPCs should be further investigated. As HSPCs are 
extremely rare and protein content in general is low, standard analysis of protein expression 
of APA hits, e.g. by western blot analysis, is not feasible. Proteome analysis can be performed, 
however the number of detectable proteins is limited due to the low input. Thus, only 
intracellular flow cytometry analysis and immunofluorescence approaches are practicable to 
analyze protein expression, although technically challenging for a global identification 
approach.  
How these APA adaptations are achieved in proliferating HSCs remains to be determined. In 
the past, mTOR signaling and E2F, two common mediators of cellular activity, have been 
shown to regulate APA in response to cellular activation for example by increasing levels of 3’-
processing factors (Chang et al., 2015; Elkon et al., 2012). Both factors have also been shown 
to be important for HSC function and to mediate HSC activation, making them potential 
regulators of APA during HSC activation (Gan and DePinho, 2009; Julian and Blais, 2015; 
Kalaitzidis et al., 2012; Kim et al., 2017). Further, mTOR-mediated 3’-UTR shortening has been 
reported to augment protein synthesis by enhancing polysome formation (Chang et al., 2015).  
We previously observed expression of many biosynthetic processes to be upregulated in HSCs 
upon commitment and exit of the dormant state, including transcription, mRNA processing and 
translation (Cabezas-Wallscheid et al., 2017). Increased levels of 3’-processing factors 
(Lackford et al., 2014; Li et al., 2015; Takagaki and Manley, 1998; Takagaki et al., 1996; Xia 
et al., 2014; Yao et al., 2013) and enhanced transcription (Ji et al., 2011; Pinto et al., 2011) 
have previously been linked to APA regulation. Thus, enhanced mRNA processing and 
transcription could be additional mechanisms regulating APA upon HSC activation. The exact 
mechanisms that regulate the observed changes in APA patterns upon HSC differentiation 
and activation remain to be elucidated.  
 Discussion  
 116 
4.2.5 PABPN1 regulates APA in the hematopoietic system and is required for 
HSC function 
In our study, we demonstrate that the APA regulator PABPN1 is essential for HSC self-renewal 
and multipotency in vitro and in vivo. Initially, PABPN1 was described to be important for 
efficient poly(A) tail generation and regulation of poly(A) tail length (Kerwitz et al., 2003; Kuhn 
et al., 2009; Wahle, 1991, 1995). However, multiple recent studies could show that PABPN1 
additionally acts as an important regulator of APA (Banerjee et al., 2017; de Klerk et al., 2012; 
Jenal et al., 2012; Riaz et al., 2016). First, Jenal et al. identified PABPN1 as an APA regulator 
in U2OS cells and reported 3’-UTR shortening upon Pabpn1 KD (Jenal et al., 2012). In 
addition, they and others showed that mutated Pabpn1 causes the development of the 
myopathic disease OPMD by deregulated APA (de Klerk et al., 2012; Jenal et al., 2012). In 
recent years, these initial observations were extended by studies focusing on deregulated 
Pabpn1 and APA in muscle cells and during muscle wasting (Banerjee et al., 2017; Riaz et al., 
2016). Our data extends these findings by showing that PABPN1 also acts as an important 
APA regulator in an independent, unperturbed stem cell hierarchy in vivo. We show that 
Pabpn1 is essential for HSC function and we observed deregulated APA patterns upon 
Pabpn1 KD. Of note, APA profiles, including PAS localization and PAS number per gene, were 
less HSC-like in Pabpn1 KD cells, hinting that HSC-characteristic APA patterns are partially 
lost upon Pabpn1 KD.  
Most studies reported shortening of 3’-UTRs in response to loss of Pabpn1 (de Klerk et al., 
2012; Jenal et al., 2012). We, however, did not observe global changes in 3’-UTR length, but 
a decrease in the total number of detected PASs. Interestingly, Banerjee et al. reported 3’-
UTR lengthening upon Pabpn1 KD for some of their main targets (Banerjee et al., 2017). Thus, 
the influence of PABPN1 on global 3’-UTR length appears to depend on the cell type and the 
cellular status. Importantly, de Klerk et al. reported dose-dependent effects of Pabpn1 KD on 
3’-UTR length (de Klerk et al., 2012). KD of Papbn1 that reduced protein levels by 40% did not 
consistently change 3’-UTR length, while a KD of 70% led to the reported 3’-UTR shortening 
effect. In our setting, we observed an approximately 50% KD of Pabpn1, raising the possibility 
that a stronger KD might induce global 3’-UTR shortening. In addition, we performed 3’-Seq 
analysis of KD cells 72 h after viral transduction. This approach was necessary to derive 
enough material for analysis. However, it would be interesting to analyze APA patterns in in 
vivo-derived Pabpn1 KD HSCs. As these HSCs, however, harbor cellular defects, we were 
unable to derive enough cells to perform 3’-Seq analysis. While we observed deregulated APA 
in hematopoietic Pabpn1 KD cells, technical challenges prevented us from performing 
encompassing 3’-UTR length analysis, e.g. in HSC populations.  
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Intriguingly, Pabpn1 expression levels and associated APA patterns have been shown to act 
as prognostic factors in lung cancer (Ichinose et al., 2014). Additionally, global analysis of APA 
patterns in published datasets and cell lines showed that 3’-UTR shortening is a hallmark of 
cancer cells (Xiang et al., 2018). In this study, PABPN1 was identified as the master regulator 
of APA disruption in transformed cellular states. Thus, future studies should focus on the role 
of PABPN1 as a regulator of APA in hematological malignancies. This research is of major 
interest, as highly potent small molecules that modulate APA by targeting PABPN1 have 
recently been identified (Araki et al., 2018). These inhibitors lead to global 3’-UTR shortening, 
mimicking Pabpn1 KD phenotypes. In the future, restoring tissue-specific APA patterns might 
be a novel therapeutic approach for cancer therapy. 
4.2.6 Ctsc and Treml2 are regulated by APA in HSPCs 
We identified individual genes that dynamically undergo APA during HSC differentiation and 
pIC-mediated activation. For example, the papain family protease-encoding gene Ctsc 
exhibited significant DAPAS in MPPs compared to HSCs. In our analysis, we observed that a 
shortened, presumably enzymatically non-functional (Turk et al., 2001), CTSC version is 
expressed in HSCs during homeostasis. Expression of the functional full-length version is 
enhanced upon HSC differentiation and pIC- as well as LPS-induced activation. Interestingly, 
CTSC activates the proteases Granzyme A and B, and Granzyme B has been shown to play 
an important role in the LPS stress response in HSCs (Carnevalli et al., 2014; Pham and Ley, 
1999). In addition, LPS has been shown to enhance CTSC secretion (Hamon et al., 2016). We 
speculate that pIC- and LPS-induced activation of HSCs leads to APA-mediated switching to 
the full-length Ctsc version. In the following, CTSC might be secreted or act intracellularly and 
in turn activates Granzyme A and B. Activation and secretion of granzymes in response to LPS 
has been reported in HSCs (Carnevalli et al., 2014). It is hypothesized that Granzymes modify 
the stem cell niche to allow HSC mobilization or induce cell death. In summary, we identified 
an APA switch in Ctsc, potentially coordinating Granzyme activation within the HSC/MPP 
compartment upon activation. Additional research is needed to functionally verify this 
hypothesis.  
In addition, UTR-APA affecting the gene Treml2 was identified. APA in Treml2 led to a 
decrease in 3’-UTR length of more than 1000 nt in MPP2 cells and pHSCs. Interestingly, 
TREML2 upregulation and re-localization to the surface in response to inflammation has been 
reported in myeloid cells (King et al., 2006; Thomas et al., 2016). Changes in surface 
expression upon pIC-induced inflammatory activation and cellular commitment might occur in 
HSCs. This process might be regulated by APA and could thereby regulate TREML2 function 
in HSCs. It has been shown that modulation of 3’-UTR length alone, namely UTR-APA, alters 
CD47 localization (Berkovits and Mayr, 2015). The shorter 3’-UTR version mediates retention 
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of the CD47 protein in the ER, while the longer 3’-UTR version mediates transport to the cell 
membrane. This is achieved by interaction of the longer 3’-UTR with HuR and Set, which in 
turn mediate CD47 protein localization. A similar mechanism could regulate TREML2 
localization. However, further studies are needed to functionally understand the role of DAPAS 
in Treml2 and the general function of TREML2 in hematopoietic biology.  
4.2.7 NUDT21-mediated metabolic reprogramming towards glutaminolysis is 
essential for HSC activation and differentiation 
Another highly interesting finding of this thesis is that the metabolic enzyme GLS exhibits 
isoform switching by CR-APA upon HSC activation and differentiation and that the process 
glutamine metabolism is enriched in genes exhibiting 3’-UTR shortening. GLS is the first 
enzyme in glutaminolysis, generating glutamate from glutamine (Altman et al., 2016). 
Glutaminolysis provides building blocks for amino acid, nucleotide and lipid biosynthesis. In 
addition, it can be used for glutathione production and as a fuel for the TCA cycle by conversion 
to aKG (Altman et al., 2016). 
Two different GLS enzymes are known: The kidney-type glutaminase (GLS) and the liver-type 
glutaminase (GLS2) (Aledo et al., 2000; Elgadi et al., 1999). Expression patterns of these two 
enzymes are highly tissue-specific (Aledo et al., 2000; Elgadi et al., 1999). In HSPCs, we 
observe high expression of Gls, while Gls2 is not robustly expressed (Cabezas-Wallscheid et 
al., 2014). The Gls gene encodes two different protein isoforms, GAC and KGA. In the study 
at hand, we observed a Gls isoform switch favoring expression of GAC in HSCs exiting G0 or 
upon differentiation. This switch was accompanied by an overall increase in GLS protein levels. 
While both GLS isoforms are enzymatically functional, KGA contains additional ankyrin repeats 
at the C-terminus compared to GAC. Cassago and colleagues could show that the GLS 
isoform GAC, but not KGA, is found in mitochondria (Cassago et al., 2012). In addition, they 
could show that GAC harbors superior enzymatic kinetics for glutamine to glutamate 
conversion in presence of the activator phosphate compared to KGA and GLS2. Due to its 
localization, GAC seems to convert glutamine to glutamate preferably for mitochondrial 
processes like the TCA cycle. In contrast, KGA, and also GLS2, seem to be more active in the 
cytosol or even the nucleus (Cassago et al., 2012; Olalla et al., 2002). KGA harbors ankyrin 
repeats at the C-terminus enabling additional protein-protein interactions. Thus, KGA could be 
involved in process that are independent of glutaminolysis (Cassago et al., 2012). Transferred 
to our observations, this indicates that activation of HSCs is accompanied by a relative 
increase in GAC for metabolic adaptations, allowing increased utilization of the TCA cycle and 
in turn OXPHOS or glutathione production.  
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Different cancer entities, including leukemia, have been reported to be addicted to 
glutaminolysis (Gallipoli et al., 2018; Jacque et al., 2015; McBrayer et al., 2018). Interestingly, 
this metabolic addiction has been linked to isoform switching of Gls towards GAC and has 
been shown to be essential for cancer cell growth (Jacque et al., 2015; van den Heuvel et al., 
2012; Xia et al., 2014). In our study, we found this metabolic adjustment initially identified in 
cancer cells to be a physiological property of untransformed HSCs in response to cellular 
activation. Malignant cells as well as stem cells seem to rely on glutaminolysis during 
enhanced cellular proliferation. Thus, cancer cells might hijack this metabolic switch providing 
pro-proliferative metabolic conditions usually present upon stem cell activation.  
Remarkably, the oncogenic transcription factor c-Myc has been shown to be involved in 
regulating Gls expression in cancer cells (Gao et al., 2009). c-Myc transcriptionally represses 
miR-23a/b, which in turn leads to upregulation of Gls, a target of miR-23a/b. Thereby, c-Myc 
seems to enhance glutaminolysis in tumor cells (Gao et al., 2009). However, additional studies 
could show that some cancer entities rather depend on the GAC isoform, which is not targeted 
by miR-23a/b (Xia et al., 2014). Thus, the Gls isoform switch towards GAC enhances 
glutaminolysis and uncouples it from c-Myc. Upon HSC activation and commitment, c-Myc 
protein levels are known to increase, mediating cellular activation (Ehninger et al., 2014). In 
addition, c-Myc expression is low in dormant HSCs, and Myc-depleted ESCs are characterized 
by a quiescent state and low biosynthesis (Cabezas-Wallscheid et al., 2017; Scognamiglio et 
al., 2016). Interestingly, analysis of miRNA-seq data generated by us showed that miR-23a/b 
is significantly upregulated in MPP2 cells (data not shown). Thus, we consider miR-23a/b to 
have important roles during HSC activation and commitment. In HSCs and MPPs, enhanced 
c-Myc levels do not correlate with repression of miR23a/b. Therefore, HSCs seem to rely on 
the alternative pathway, namely switching to the more active GAC isoform, to increase 
glutaminolysis during stress response.  
In response to stress-induced HSC activation, we observe a switch to the GAC isoform of Gls 
and enhanced total GLS protein levels. However, it remains elusive which metabolic pathways 
are supported by these metabolic adaptations, as glutamine and glutamate contribute to many 
metabolic routes (Altman et al., 2016). After conversion of glutamine to glutamate, glutamate 
can be used to generate glutathione, which is important to neutralize ROS. Alternatively, 
glutamate dehydrogenase or aminotransferases use glutamate for aKG production. aKG is 
used for energy generation via the TCA cycle and OXPHOS. Glutamate, glutamine and aKG 
are source materials to generate nucleotides, amino acids or lipids. Of note, aKG is also a very 
important co-substrate for many dioxygenases involved in, for example, protein hydroxylation 
and epigenetic modifications, e.g. Tet1/2 enzymes involved in DNA demethylation (Zdzisinska 
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et al., 2017). Thus, these processes could also be affected by enhanced glutaminolysis. 
Quiescent HSCs are biosynthetically silenced, exhibiting low cellular activity and protein 
translation (Cabezas-Wallscheid et al., 2017; Signer et al., 2014; Wilson et al., 2008). Thus, 
when HSCs become activated, these cells are in need of biomass, including amino acids and 
lipids. At the same time, an increased energy demand has to be met. By metabolizing 
glutamine to glutamate, HSCs are able to meet all of these metabolic needs, as glutamate can 
enter all of these biosynthetic fates. In addition, HSCs need to control ROS levels during 
increased cellular activity to limit DNA damage (Flach et al., 2014; Walter et al., 2015). Thus, 
enhanced glutathione levels are beneficial. Glutamate also provides the means to increase 
glutathione production. In summary, we consider increased glutaminolysis to be highly 
beneficial for HSCs undergoing cellular activation as it facilitates increased energy production 
and generation of biomass, while at the same time preventing DNA damage by producing ROS 
scavengers. In line, activated HSCs have been reported to switch to OXPHOS (Ito and Ito, 
2018; Ito and Suda, 2014; Yu et al., 2013), which can be driven by glutaminolysis. Additional 
experiments are needed to understand which pathways are used to metabolize glutamate in 
activated HSCs.  
Standard cultivation protocols for HSCs induce differentiation and loss of stem cell potential. 
In this thesis, I could show that short-term prevention of glutaminolysis by GLS inhibition leads 
to increased HSC maintenance in culture by limiting the number of HSCs exiting G0. In vivo, 
HSCs are maintained in a quiescent state, limiting for example DNA damage (Flach et al., 
2014; Walter et al., 2015). HSCs seem to lose stem cell potential with every round of division, 
presumably to protect individuals from blood contribution of HSCs harboring DNA mutations 
that could eventually develop into leukemia (Ito and Suda, 2014). In vitro, this intrinsic HSC 
“clock” limits stem cell maintenance. By inhibiting GLS, we observed less HSCs exiting G0 and 
in turn increased stem cell maintenance as shown by CFU assay. Thus, HSC potential is 
indeed maintained if proliferation is prevented. In addition, these experiments show that 
efficient HSC proliferation is dependent on enhanced glutaminolysis as indicated by our in vivo 
discoveries. In vivo, glutaminolysis is enhanced by APA upon enforced HSC proliferation by 
pIC. Collectively, enhanced glutaminolysis is a prerequisite for HSC proliferation and 
activation, and in vitro inhibition of this pathway enhances HSC maintenance, presumably by 
limiting HSC cell division.  
APA-mediated Gls isoform switching from the KGA to the GAC isoform is controlled by 
NUDT21 (Masamha et al., 2016). Nudt21 KD has been shown to enhance relative KGA 
expression (Masamha et al., 2016). As we observed enhanced relative GAC expression upon 
HSC activation, we wondered if this switch is also mediated by and dependent on NUDT21. 
Strikingly, Nudt21 KD limited the APA-mediated switch to the GAC isoform, leading to a 
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diminished increase in GLS protein levels in activating culture conditions compared to control 
cells. Therefore, NUDT21 is essential to mediate GAC/KGA isoform switching in HSPCs during 
stress response. I could additionally show that HSPC function is impaired when preventing the 
isoform switch. We observed a differentiation block in Nudt21 KD cells, presumably caused by 
inhibition of metabolic adaptations. Without the biomass and energy provided by enhanced 
glutaminolysis, HSPCs seem to be incapable of undergoing differentiation. Intriguingly, and in 
line with our findings, Brumbaugh et al. could show that Nudt21 KD in ESCs and myeloid cells 
impairs differentiation (Brumbaugh et al., 2018). In this study, the authors linked the observed 
phenotype to changes in APA patterns that lead to enhanced protein levels of chromatin 
modifiers. These chromatin modifiers in turn maintain stem cell-like chromatin states, and 
NUDT21 was reported to influence APA patterns of multiple additional genes (Brumbaugh et 
al., 2018; Masamha et al., 2014). In our study, we did not focus on the broader influence of 
Nudt21 KD on APA patterns other than Gls. Thus, we cannot exclude that the observed 
inhibition of differentiation is caused by other effects of NUDT21 depletion or an interplay of 
different processes. Future experiments will focus on the detailed role of GAC and KGA in 
mediating HSC stemness and activation, for example by specific targeting of the different 
isoforms. Overall, we present data indicating that APA-mediated Gls isoform switching is 
important for metabolic reprogramming of HSCs and required for HSC activation.  
Although the importance and prevalence of glutaminolysis in HSCs has long been discussed, 
functional studies are lacking (Ito and Suda, 2014). Previously, it has been shown that 
glutamine metabolism is essential for de novo nucleotide synthesis during erythroid lineage 
specification (Oburoglu et al., 2014). In addition, GLS has been reported to be important for T 
cell differentiation and proliferation, promoting Th17 while restricting Th1 cells (Johnson et al., 
2018). Only recently, it was reported that skeletal stem cells depend on GLS and glutamine 
metabolism to regulate osteoblast and adipocyte differentiation and to enable bone formation 
(Yu et al., 2019). In this setting, glutaminolysis was critical for aKG production, and aKG in 
turn was essential for the proliferation, specification and differentiation of skeletal stem cells. 
Taken together, our results and the reported studies indicate that hematopoietic cells and stem 
cells depend on GLS and glutamine metabolism for differentiation and stem cell proliferation. 
We extend these findings by showing that HSCs residing at the top of the hematopoietic 
hierarchy depend on GLS for stem cell proliferation and differentiation as well. We further link 
these metabolic adaptations to changes in APA. Future studies will investigate the related 
metabolic pathways in depth.  
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4.2.8 HSC function, differentiation and activation are regulated by APA – 
summary 
In this study, we show that the process of APA and 3’-UTR choice is tightly regulated and 
functionally important for hematopoiesis. We demonstrate that the APA regulator PABPN1 is 
essential for HSC function in vitro and in vivo. Furthermore, the advancement in ultra-low input 
3’-Seq techniques enabled us to analyze APA globally in rare BM populations and to generate 
a 3’-UTR/APA resource dataset of all genes expressed in HSPCs. Using this novel resource, 
we report APA upon HSC commitment and activation. We observed 3’-UTR shortening upon 
stem cell differentiation and upon exit of G0. In addition, we also demonstrate the functional 
importance of APA by reporting an APA switch in the metabolic gene Gls to be essential for 
HSC activation. 
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4.3 Generation of a Pabpn1flox mouse model  
Using the Easi-CRISPR technique (Miura et al., 2018; Quadros et al., 2017), we generated a 
mouse model in which exon 3 and 4 of Pabpn1 are floxed. Using this approach, efficiencies of 
8.5-100% have been reported for generation of transgenic mice. In comparison to other 
CRISPR/Cas9 techniques for the generation of transgenic animals, Easi-CRISPR is more 
efficient (Miura et al., 2018). In most published techniques, dsDNA donor templates are used, 
leading to a reduction in targeting efficiency (Aida et al., 2016; Raveux et al., 2017). However, 
these methods are better suited for integrating large inserts, as Easi-CRISPR can only be used 
for inserts up to 1.5 kb (Miura et al., 2018; Quadros et al., 2017). In our initial approach, we 
tried to generate transgenic mice using a dsDNA plasmid as the template. However, no 
transgenic mice were obtained. By using Easi-CRISPR, 3 of 17 animals were correctly targeted 
(~18%). Thus, in our hands, Easi-CRIPSR was a quick and reliable approach to generate 
floxed transgenic animals.  
A common issue with CRISPR-Cas9 targeting are off-target effects (Sander and Joung, 2014). 
To increase specificity, we chose gRNAs that are predicted to have a low number of off-targets. 
gRNA A3 was predicted to have 90 potential off-targets, all presenting at least 3 mismatches 
compared to the target site. gRNA B2 presented 100 anticipated off-targets, all with at least 2 
mismatches. Due to the high number of mismatches, the likelihood of off-target mutations is 
low. In any case, as homology regions are not found in other parts of the genome, an off-target 
event would induce a mutation but not lead to loxP site integration. In addition, all of the 
predicted off-targets were localized on other chromosomes than Pabpn1, which is localized on 
chromosome 14. Thus, mutations caused by off-target effects would be lost during further 
crossing of the generated mice. We therefore did not systematically screen for off-target 
events. In summary, the likelihood of off-targets is low due to gRNA choice and backcrossing 
of mice.  
Using one founder animal, we generated homozygous Pabpn1flox mice. We are now crossing 
these mice to Cre drivers, including Vav1 and Mx1, to first check if our targeting strategy leads 
to Pabpn1 KO upon Cre induction. After the functional validation, we will apply our transgenic 
mouse model to answer different biological questions. For example, it could be used to analyze 
the effects of complete loss of Pabpn1 on the hematopoietic system. This would also open up 
the possibility to perform additional 3’-Seq experiments and APA analysis of Pabpn1 KO cells, 
including HSCs, in vivo. Our mouse model can of course also be used in additional 
experimental settings to analyze the role of Pabpn1 and APA in different tissues and disease 
settings. For example, the mice can be used to study the role of Pabpn1 and deregulated APA 
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in cancer. Pabpn1 is downregulated in cancer cells and associated with globally deregulated 
APA (Ichinose et al., 2014; Xiang et al., 2018). Thus, we aim to use the generated mouse 
model in the future to generate leukemic mice, for example by employing the MLL-AF9 
oncogene by lentiviral transduction. After initiation of leukemia, Pabpn1 could be deleted by 
Cre induction, and the effects on disease progression and APA patterns could be analyzed.  
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4.4 Outlook 
By combining transgenic knockout and conditional knockout mouse models, and novel 
sequencing approaches, I could show that regulatory RNAs like lncRNAs and RNA regulation 
itself, such as APA, are important players in HSC biology. In addition, the generation of a novel 
mouse model will enable further research on the role of APA in HSCs and other cellular 
systems.  
I could show that Meg3 and the associated miRNA cluster are dispensable for adult HSCs and 
during HSC development after the endothelial-cell-to-HSC transition by performing analysis of 
MxCre Meg3 mat flox/pat wt and VavCre Meg3 mat flox/pat wt mice. Additional experiments could be 
performed to better understand the role of the Meg3 locus during embryonic development of 
the hematopoietic system. To this end, Meg3 mat flox/pat flox mice could be crossed to additional 
Cre drivers, for example VEC-Cre. VEC-Cre enables analysis of the effects of gene deletion 
on HSC formation from the vasculature including the dorsal aorta, vitelline and umbilical 
arteries and the placenta (Chen et al., 2009). In addition, broader disruptions of the Dlk1-Meg3 
locus by targeting DMRs could be used to investigate the effects on hematopoiesis. This 
approach, which would not only affect Meg3 and the miRNA cluster but also imprinting itself, 
could help to understand the different observations made by Qian et al. (Qian et al., 2016) and 
us. In addition, we could use ROSA26 Cre mice for global Meg3 deletion in the Meg3 mat flox/pat 
flox mice and check if we observe similar effects as described in the Qian et al. paper. All of 
these experiments could help to unravel why Meg3 is so highly and specifically expressed in 
HSCs. Furthermore, to better understand the role of Meg3 in leukemia, MxCre Meg3 mat flox/pat 
wt LSK cells could be transduced with the MLL-AF9 or MLL-ENL oncogene. Subsequent 
transplantation of transduced cells and Cre-mediated deletion could be performed to analyze 
the impact of Meg3 loss on leukemia development and maintenance. As Meg3 functions as a 
tumor suppressor, we would expect faster disease progression. 
I could show for the first time that APA is differentially regulated upon HSC differentiation and 
activation in vivo. In addition, I could show that APA is also important for HSC function in mice. 
Future studies are needed to understand exactly how APA is regulated in HSCs and MPP cells 
and upon inflammation-induced HSC activation. Different experimental setups are needed to 
understand if an increase in 3’-processing factors, enhanced transcription, epigenetic 
modifications or signaling pathways mediate APA changes upon HSC commitment and 
proliferation. In the future, we aim to link APA profiles in HSPCs to miRNA expression profiles. 
To this end, we have established an ultra-low input small RNA-seq approach that allows us to 
globally asses miRNA expression profiles in HSCs, MPPs, sHSCs and pHSCs. We already 
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generated the sequencing data in all of these populations, and analysis is currently ongoing. 
We aim to understand if 3’-UTR shortening in MPPs and upon HSC activation is induced to 
evade miRNA targeting. Using our novel miRNA datasets, we can compare the expression of 
miRNAs with their associated 3’-UTR targets and analyze if expression patterns in HSPCs are 
correlated. Further, the effect of APA on protein levels of different hits in HSPCs will be 
analyzed using microscopy-based immunofluorescence and flow cytometry analysis. In 
addition to Gls, we intend to functionally validate additional APA hits identified in our dataset. 
For example, we aim to understand if the longer 3’-UTR version of Treml2 influences protein 
localization. Initial flow cytometry- and microscopy-based analysis of intracellular and plasma 
membrane expression of TREML2 in HSCs and MPP2 cells indicates that the longer 3’-UTR 
version could indeed mediate plasma membrane localization of TREML2. Additional 
experiments using fluorescent reporter constructs linked to the respective 3’-UTR will help to 
understand the impact of the different Treml2 3’-UTRs on protein localization. Besides, we also 
aim to understand how APA affects protein translation in hematopoietic cells. We crossed 
Rpl22-HA mice, which express the HA-tagged ribosomal subunit Rpl22 (Sanz et al., 2009), to 
CMV-Cre mice. Thereby, we generated mice, that express the tagged ribosome subunit in all 
body cells. Initial experiments showed that we are able to sort HSCs and MPP populations and 
efficiently pull down ribosome-bound RNA from low inputs. RNA-seq and 3’-Seq analysis of 
this RNA will allow us to determine if 3’-UTRs of a certain length exhibit enhanced ribosome 
association, indicating active translation. A future study will also focus on the role of APA in 
hematopoietic malignancies. To this end, 3’-Seq analysis of patient samples will be performed. 
In addition to APA, we want to better understand the role of glutaminolysis in HSPCs. First, we 
aim to understand why proliferating HSCs depend on enhanced glutaminolysis and which 
metabolic pathways act downstream of glutamate. To this end, we aim to perform rescue 
experiments using Nudt21 KD cells together with different metabolites, including aKG, 
nucleotides and glutathione. In addition, we plan to perform Mito Fuel Flex Seahorse 
experiments. This approach will help us to understand if activated HSCs indeed depend on 
different metabolic pathways than resting HSCs. Further, this test will be performed using 
Nudt21 KD and control cells to analyze if glutaminolysis is indeed impaired in KD conditions. 
We also aim to establish metabolite tracing for low cellular input to investigate metabolic 
pathways in HSCs, activated HSCs and in response to Nudt21 KD. Moreover, we want to focus 
on the specific role of the GLS isoforms GAC and KGA in HSCs. We already generated 
lentiviral vectors for overexpression of the GAC and the KGA isoform, respectively. We will 
use these for lentiviral transduction of HSCs. Afterwards, we plan to analyze functionality of 
GAC- and KGA-overexpressing HSCs in vitro and in vivo. Metabolic characterization of GAC-
/KGA-overexpressing HSCs will also be performed. Likewise, it would be interesting to 
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independently target GAC and KGA in HSCs by CRISPR/Cas9 or isoform-specific KD. 
Functional analysis of GAC- or KGA-only HSCs will help to understand the specific roles of the 
isoforms in hematopoiesis. Metabolic analysis of these cells could also be performed to 
investigate if GAC is the isoform driving glutaminolysis in HSCs as indicated by reports in other 
cellular systems.  
With regard to our newly generated Pabpn1flox mouse model, we first aim to functionally test 
the generated mouse line by crossing it to different Cre drivers, including Mx1 and Vav1. After 
confirming their functionality, the floxed mice can be used to interfere with APA patterns in 
different tissues and disease models. Thereby, analysis of the importance of APA and Pabpn1 
as an APA regulator in different settings is feasible. 
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5 Materials and Methods 
5.1 Materials 
5.1.1 Chemicals, reagents, cytokines and cell culture medium 
Table 5.1: Chemicals, reagents, cytokines and cell culture medium 
Item Catalog No.  Manufacturer 
2-Mercaptoethanol  M6250  Sigma-Aldrich Co. LCC  
ACK Lysing Buffer 10-548E Lonza BioWhittakerTM  
Agarose Standard  3810.3  Carl Roth GmbH & Co. KG 
Amplicillin  10835242001  Roche Diagnostics GmbH  
Boric acid  B6768 Sigma-Aldrich Co. LCC 
Bromphenol blue  B0126 Sigma-Aldrich Co. LCC 
CB-839 S7655 Selleckchem 
Chloroform 28830L Sigma-Aldrich Co. LCC 
Chloroquine diphosphate salt  C6628  Sigma-Aldrich Co. LCC 
DAPI D1306 Thermo Fisher Scientific Inc. 
Deoxyribonucleotide triphosphate 
(dNTP)  18427013 Thermo Fisher Scientific Inc. 
Dimethyl sulfoxide (DMSO) 276855 Sigma-Aldrich Co. LCC 
Direct PCR Tail Lysis Reagent 31-102-T Peqlab 
DMEM (1x)+GlutaMAXTM-I  31966-021  Thermo Fisher Scientific Inc. 
Dulbecco’s Phosphate Buffered Saline  D8537 Sigma-Aldrich Co. LCC  
Ethanol BP2818-100 Thermo Fisher Scientific Inc. 
Ethidium bromide solution 2218.4  Carl Roth GmbH & Co. KG 
Ethylenediamine tetra-acetic acid-
disodium salt (EDTA)  E6635 Sigma-Aldrich Co. LCC 
Fetal Calf Serum (FCS)  10082147  Thermo Fisher Scientific Inc. 
GeneRuler 1kb Plus DNA Ladder  SM1331  Thermo Fisher Scientific Inc. 
GeneRuler 100 bp Plus DNA Ladder SM0321 Thermo Fisher Scientific Inc. 
Glycerol  A1123,1000  Applichem  
GlycoBlueTM Coprecipitant AM9515 Thermo Fisher Scientific Inc. 
HEPES Buffer (1M)  H0887  Sigma-Aldrich Co. LCC 
Hoechst 33342  H3570  Thermo Fisher Scientific Inc. 
Isopropanol 33539 Sigma-Aldrich Co. LCC 
KCl P9541 Sigma-Aldrich Co. LCC 
L-Glutamine 200 mM (100x)  25030-024  Thermo Fisher Scientific Inc.  
LB Broth (MILLER) for microbiology  110285 Merck Millipore 
LB-Agar (MILLER) for microbiology  110283 Merck Millipore 
MethoCultTM GF M3434 03434 Stemcell Technologies 
MgSO4 M2643 Sigma-Aldrich Co. LCC 
Na2HPO4.7H2O S9390 Sigma-Aldrich Co. LCC 
NaH2PO4.H2O S5011 Sigma-Aldrich Co. LCC 
NaOH 795429 Sigma-Aldrich Co. LCC 
ONPG N1127 Sigma-Aldrich Co. LCC 
Opti-MEM I 31985062 Thermo Fisher Scientific Inc. 
Passive Lysis 5X Buffer E1941 Promega 
Penicillin-Streptomycin  P4458  Sigma-Aldrich Co. LCC  
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Poly(I:C) HMW tlrl-pic-5 InvivoGen 
Polybrene TR-1003-G Sigma-Aldrich Co. LCC 
QIAzol Lysis Reagent 79306 Qiagen Ltd. 
Recombinant Human Flt3  300-19  PeproTech GmbH 
Recombinant Murine Stem Cell Factor  250-03  PeproTech GmbH 
Recombinant Murine Thrombopoietin  315-14  PeproTech GmbH 
RetroNectin® GMP grade  T201  Takara Bio Inc.  
Roti®-Fect P001 Carl Roth GmbH & Co. KG 
StemPro-34 SFM (1X)  10639011 Life TechnologiesTM 
tris(hydroxymethyl)aminomethane 
(Tris)  252859 Sigma-Aldrich Co. LCC 
Tris HCl 10812846001 Sigma-Aldrich Co. LCC 
Trypsin-EDTA Solution  T3924  Sigma-Aldrich Co. LCC  
Ultrapure Water with 0.1% Gelatin  ES-006-B  Merck Millipore  
UltraPureTM Distilled Water  10977-035  Life TechnologiesTM 
Xylencyanol X4126 Sigma-Aldrich Co. LCC 
 
5.1.2 Enzymes 
Table 5.2: Enzymes 
Enzyme Manufacturer 
BbsI New England BioLabs Inc. 
BstBI New England BioLabs Inc. 
DNase I Qiagen Ltd. 
EcoRI New England BioLabs Inc. 
Fisher BioReagentsTM Taq DNA Polymerase Thermo Fisher Scientific Inc. 
HindIII-HF New England BioLabs Inc. 
NruI New England BioLabs Inc. 
Proteinase K Peqlab 
SnaBI New England BioLabs Inc. 
T4 DNA Ligase New England BioLabs Inc. 
XmnI New England BioLabs Inc. 
 
5.1.3 Buffer composition 
Table 5.3: Buffer composition 
Buffer Composition 
10x TBE  
890 mM Tris 
890 mM boric acid 
20 mM EDTA pH 8.0 
pH 8.0  
DNA gel loading buffer  
0.25% bromophenol blue 
0.25% xylencyanol 
15% glycerol 
in 10 ml dH2O  
DNase I stock solution  Lyophilized DNase I (1500 Kunitz units) dissolved in 550 µl RNase-free H2O, aliquoted and stored at -20°C  
DNase treatment  5 µl DNase solution 35 µl buffer RDD (provided in the RNase-free DNase set)  
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Microinjection buffer 
10 mM TrisHCl 
1 mM EDTA  
pH 7.5  
in dH2O 
ONPG solution 0.55 g ONPG in 100 ml dH2O 
Z-buffer 
1.60 g Na2HPO4.7H2O 
0.55 g NaH2PO4.H2O 
0.075 g KCl 
0.012 g MgSO4 
pH 7.0 
in 100 ml dH2O 
 
5.1.4 Oligonucleotides 
See Table 5.18, Table 5.22, Table 5.29, Table 5.30, Table 5.33, Table 5.35 and Table 5.36 for 
sequences. Sequences are always indicated 5’ – 3’. 
Table 5.4: Oligonucleotides 
Oligonucleotide Manufacturer 
crRNA Integrated DNA Technologies (IDT) 
Oligonucleotides for CRISPR/Cas9 cloning Sigma-Aldrich Co. LCC 
Primer for qPCR analysis Sigma-Aldrich Co. LCC  
Primer for qPCR genotyping Sigma-Aldrich Co. LCC  
ssDNA template Integrated DNA Technologies (IDT) 
tracrRNA (1072534) Integrated DNA Technologies (IDT) 
 
5.1.5 Plasmids, recombinant DNA and recombinant proteins 
Table 5.5: Plasmids, recombinant DNA and recombinant proteins 
Item Catalog No.  Manufacturer 
Alt-R S.p. Cas9 Nuclease 3NLS 1074181 Integrated DNA Technologies (IDT) 
Packaging Plasmid pMD2.g  12259 Addgene 
Packaging Plasmid pSPAX2 12260 Addgene 
pCRISPR-Report pTAL-Rep (Wefers et al., 2013) 
px330 Cas9 42230 Addgene 
Scr Ctrl (pSMARTvector Non-
targeting mEF1a/TurboGFP 
Glycerol Stock) 
VSC11710 GE Helathcare Dharmacon, Inc. 
shRNA Nudt21_1 (10) 
(pSMARTvector mEF1a/Turbo 
GFP Glycerol Stock; 
CAAATTACCTGGTGGGGAA) 
V3SM11241-
230917780 GE Helathcare Dharmacon, Inc. 
shRNA Nudt21_2 (2) 
(pSMARTvector mEF1a/Turbo 
GFP Glycerol Stock; 
ACCATTAATCTGTACCCGC) 
V3SM11241-
234316681 GE Helathcare Dharmacon, Inc. 
shRNA Nudt21_3 (4) 
(pSMARTvector mEF1a/Turbo 
V3SM11241-
237221737 GE Helathcare Dharmacon, Inc. 
 Materials and Methods  
 132 
GFP Glycerol Stock; 
TCATTAGCTTTTGGTTCTA) 
shRNA Pabpn1_2 
(pSMARTvector mEF1a/Turbo 
GFP Glycerol Stock; 
TAGTTATAGGATTCTCCCC) 
V3SM11241-
233531280  GE Helathcare Dharmacon, Inc. 
shRNA Pabpn1_3 
(pSMARTvector mEF1a/Turbo 
GFP Glycerol Stock; 
AATACCATGATGTCGCTCT) 
V3SM11241-
232142176  GE Helathcare Dharmacon, Inc. 
 
5.1.6 Kits 
Table 5.6: Kits 
Item Catalog No.  Manufacturer 
Agencourt AMPure XP A63881 Beckman Coulter 
Agilent High Sensitivity DNA Kit 5067-4626 Agilent Technologies 
Agilent RNA 6000 Pico Kit 5067-1513 Agilent Technologies 
BD Cytofix/Cytoperm  554722 BD Biosciences  
Calcium Phosphate Transfection 
Kit K2780-01 Thermo Fisher Scientific Inc. 
DNeasy Blood & Tissue Kits 69504 Qiagen Ltd. 
DreamTaq Green PCR Master 
Mix (2X)  K1081 Thermo Fisher Scientific Inc. 
DynabeadsTM UntouchedTM 
Mouse T Cells Kit 11413D  Thermo Fisher Scientific Inc.  
FITC Annexin V Apoptosis 
Detection Kit I 556547 BD Biosciences 
GAC/KGA TaqMan Assay 
Mm01257297_m1 Mm01257297_m1 Thermo Fisher Scientific Inc. 
Gapdh TaqMan Assay 
Mm99999915_g1 Mm99999915_g1 Thermo Fisher Scientific Inc. 
KGA TaqMan Assay 
Mm01257298_m1 Mm01257298_m1 Thermo Fisher Scientific Inc. 
NucleoBond® Xtra Midi 740410 Macherey-Nagel 
NucleoSpin® Plasmid  740588 Macherey-Nagel 
OneComp eBeads  01-1111-41  Thermo Fisher Scientific Inc. 
PCR Add-on Kit for Illumina SKU: 020.96. Lexogen GmbH 
PE Annexin V Apoptosis 
Detection Kit I 559763 BD Biosciences 
PicoPureTM RNA Isolation Kit  KIT0204 Thermo Fisher Scientific Inc.  
Power SYBR® Green PCR 
Master Mix  4367659  Thermo Fisher Scientific Inc.  
QIAEX II Gel Extraction Kit 20021 Qiagen Ltd. 
QIAGEN® Plasmid Maxi Kit  12163  Qiagen Ltd. 
QIAquick PCR Purification Kit 28104 Qiagen Ltd. 
QuantSeq 3′ mRNA-seq Library 
Prep Kit REV for Illumina SKU: 016.96. Lexogen GmbH 
SMARTer® smRNA-seq Kit for 
Illumina® 635031 Takara Bio Inc. 
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SuperScriptTM VILOTM Master 
Mix 11755050 Thermo Fisher Scientific Inc.  
SUPREMERUN Tube - 
Supreme Sanger Sequencing  SUPREMERUN tube  Eurofins Genomics 
TaqMan Fast Advanced Master 
Mix 4444963 Thermo Fisher Scientific Inc. 
 
5.1.7 Cells and bacteria 
Table 5.7: Cells and bacteria 
Item Catalog No.  Manufacturer 
293FT cell line R70007 Thermo Fisher Scientific Inc. 
HeLa Cells ATCC® CRM-CCL-2TM ATCC 
One ShotTM Stbl3TM 
Chemically Competent E. coli  C7373-03  Life Technologies
TM 
 
5.1.8 Consumables 
Table 5.8: Consumables 
Item Manufacturer 
0.45 µm HV Durapore® Membrane  Merck Millipore 
18G Needles Neoject Neomedic 
25G Needles Neoject Neomedic 
384-well PCR plates Thermo Fisher Scientific Inc. 
96 Well Solid Polystyrene Microplate white Sigma-Aldrich Co. LCC 
Cell Strainer 40 µm, EASYStrainer Greiner Bio One International GmbH  
Conical Vials 15 ml TPP Techno Plastic Products AG 
Conical Vials 50 ml Greiner Bio One International GmbH 
Corning® tissue-culture treated culture dishes Sigma-Aldrich Co. LCC 
Disposable Scalpel Feather Safety Razor Co Ltd. 
ERSTA TBC-Syringe 1 ml Codan 
FACS tubes conical 4.5 ml Greiner Bio One International GmbH 
FACS tubes round bottom, REF 55.1579 Sarstedt AG & Co 
MCT-175-C-S RNase free tubes Axygen Inc. 
Microvette® 500 K3E  Sarstedt AG & Co 
Pasteur Capillary Pipettes  Wilhelm Ulbrich GdbR  
PCR SingleCap 8er-SoftStrips Biozym Scientific GmbH 
Petri Dish 35 mm Falcon Brand Products 
Safe Lock Tubes Eppendorf AG 
Serological Pipettes Corning Inc. 
Stericup Quick Release-HV Sterile Vacuum 
Filtration System Merck Millipore 
Thinwall Polypropylene Tubes Beckman Coulter 
TipOne Filter Pipet Tips (10 µL, 20 µL, 200 µL, 
1000 µL) Starlab International GmbH 
Tissue culture 6/12 well plate Falcon Brand Products 
Tissue Culture Flask 150  TPP Techno Plastic Products AG  
Ultra Low Attachment 6/24/96 Well Plates Corning Inc. 
Ultra-FineTM Needle 12.7 mm x 30 G 0.5 ml BD Biosciences 
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5.1.9 Equipment 
Table 5.9: Equipment 
Equipment Type  Manufacturer 
2100 Bioanalyzer 
Instrument G2939BA Agilent Technologies 
Cell Sorter  
BD FACSAria I, 
BD FACSAria II, 
BD FACSAria III, 
BD FACSAria Fusion  
BD Biosciences  
Cell Viability Analyzer  Vi-CellXR  Beckman Coulter 
Centrifuge 5415D  Eppendorf AG 
Centrifuge 5810R  Eppendorf AG 
Centrifuge 5427R Eppendorf AG 
Chip Priming Station 5065-4401 Agilent Technologies 
CO2 Incubator  Forma Steri-Cycle  Thermo Fisher Scientific Inc.  
Digital Tube Roller SRT9D Stuart Bibby Scientific Limited 
Electrophoresis power 
supply  PowerPac Basic Power Supply Bio-Rad Laboratories  
Flow Cytometer  BD LSRII, BD LSRFortessa  BD Biosciences  
Gel Imaging System UV-Transluminator and video system  Intas  
Heating block MHR23 Ditabis 
Hemicytometer Neubauer counting chamber Braun 
Incubation Shaker Multitron Infors HT 
Luciferase 
Measurement Device 
Perkin Elmer Wallac 1420 
Victor2 Microplate Reader GMI Inc. 
Magnetic Separator DYNAL Invitrogen Bead Separator 
Thermo Fisher Scientific 
Inc. 
Magnetic Separator FastGene MagnaStand 0.2 Nippon Genetics Europe GmbH 
Microscope 
Zeiss Primo Vert inverted 
microscope equipped with an 
AxioCam Erc 5s  
Zeiss  
PCR Workstation AirClean 600 Starlab International GmbH 
Pipetboy Pipetboy2  INTEGRA Biosciences AG 
Pipettes Research plus Eppendorf AG 
Real-Time PCR 
System  ViiA
TM 7  Applied BiosystemsTM 
Refrigerator Refrigerator 4°C  Liebherr 
Refrigerator Refrigerator -20°C  Liebherr 
Refrigerator Refrigerator -80°C  SANYO Electric Co. 
Sequencer HiSeq 2000 Sequencing System Illumina 
Spectrophotometer  NanoDrop 2000  Thermo Fisher Scientific Inc. 
Thermocycler  T3000 Biomet Inc.  
Tissue Culture Hood  Safe 2020  Thermo Fisher Scientific Inc.  
Ultracentrifuge Optima L90-K Beckman Coulter 
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Vortex Mixer  IKA MS 3 S36 Basic Chip Vortex IKA-Werke 
Vortex Mixer  Vortex Mixer 7-2020  neoLab Migge GmbH  
Weighing balance Precision weighing balance ALC-110.4  Acculab 
 
5.1.10 Computer and software 
Table 5.10: Computer and software 
Computer/Software Company 
2100 Expert Software Agilent Technologies 
Adobe Acrobat Reader  Adobe Systems 
Adobe Illustrator CS6 Adobe Systems 
Endnote X8.2 Clarivate Analytics 
FACSDiva Software BD Biosciences 
FlowJo 10.4.1  FlowJo, LCC 
GraphPad Prism 8 for Mac  GraphPad 
Integrative Genomics Viewer Broad Institute and the Regents of the University of California 
MacBookPro notebook Apple 
Microsoft Excel 2016 for Mac  Microsoft 
Microsoft PowerPoint 2016 for Mac  Microsoft 
Microsoft Word 2016 for Mac  Microsoft 
R R Core Team 
RStudio RStudio, Inc. 
SnapGene Viewer Version 4 GSL Biotech LLC 
ViiA7 Software  Thermo Fisher Scientific Inc. 
 
5.1.11 Internet resources 
Table 5.11: Internet resources 
Resource Website 
Ensembl genome browser 95 https://www.ensembl.org/ 
National Center for Biotechnology Information https://www.ncbi.nlm.nih.gov/ 
REViGO http://revigo.irb.hr/ 
 
5.1.12 Mouse strains 
Table 5.12: Mouse strains 
Strain Sex 
C57Bl6/J (CD45.1, CD45.2, CD45.1/.2) m/f 
MxCre m/f 
MxCre Meg3 mat flox/pat wt m/f 
Meg3 mat flox/pat wt m/f 
VavCre m/f 
VavCre Meg3 mat flox/pat wt m/f 
Pabpn1flox m/f 
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5.1.13 Antibodies 
Anti-PABPN1 and anti-GLS antibodies were purchased from abcam. All other antibodies were 
purchased from eBioscience and/or BD Biosciences.  
Table 5.13: Antibodies 
Antigen Label Clone 
B220 AF700, PE-Cy7, PE-Cy5, biotin, PB, APC RA3-6B2 
CD117 (c-Kit) BV-711, PE, APC 2B8 
CD11b APC-Cy7, PE-Cy7, AF700, biotin, PB, APC M1/70 
CD127 PE A7R34 
CD135 PE RAM34 
CD150 PE-Cy5 TC15-12F12.2 
CD16/32 APC 93 
CD25 APC PC61 
CD34 FITC, AF700 RAM34 
CD4 PE-Cy7, AF700, PE, PE-Cy5, biotin, PB, APC-Cy7, APC GK1.5 
CD44 PE-Cy5 IM7 
CD45.1 PE-Cy7, PE A28 
CD45.2 PB 104 
CD48 PB, PE-Cy7, PE, AF700 HM48-1 
CD71 PE R17217 
CD8a PE-Cy7, PB, AF700, PE, PE-Cy5, biotin, PB, APC 53-6.7 
GLS AF488  EP7212  
Gr1 APC, PE-Cy7, AF700, biotin, PB RB6-8C5 
IgM PE-Cy5 II/41 
Ki-67 AF647 B56 
Ly-6A/E (Sca-1) APC-Cy7 D7 
PABPN1 AF647  EP3000Y  
Streptavidin  PE-TxRed - 
Ter119 PB, PE-Cy7, AF700, FITC, biotin, APC TER-119 
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5.2 Methods 
5.2.1 Methods – results part 3.1 
Most of this methods section (5.2.1) has been published as part of an article in Scientific 
Reports (Sommerkamp et al., 2019). 
5.2.1.1 Animals 
All mice were kept under specific pathogen-free (SPF) conditions in individually ventilated 
cages (IVC) at the animal facility of the German Cancer Research Center (DKFZ, Heidelberg). 
Meg3 flox mice were generated by Klibanski et al., loxP sites flank exon 1 to 4 (Klibanski et 
al., unpublished). Female Meg3 flox mice were crossed to male MxCre driver mice (Kuhn et 
al., 1995), generating MxCre Meg3 mat flox/pat wt mice. Cre+ animals were used in experiments. 
MxCre mice or Meg3 mat flox/pat wt mice were used as controls. All animals were intraperitoneally 
injected 5 times over 10 days with pIC (100 µg pIC in PBS) 6-18 weeks after birth. Analysis or 
further experiments were started 6-12 weeks after injections. Female Meg3 flox mice were 
crossed to male VavCre driver mice (Georgiades et al., 2002) for analysis of embryonic Meg3 
deletion, generating VavCre Meg3 mat flox/pat wt mice. Mice were analyzed 9-15 weeks after birth. 
Meg3 mat flox/pat wt littermates were used as controls. C57BL/6J mice, 11-17 weeks old (CD45.2, 
CD45.1 or CD45.2/CD45.1) were either purchased from Harlan Laboratories (now Envigo) (the 
Netherlands) or Janvier Labs (France) or bred in-house. Mice were sacrificed by cervical 
dislocation, and all animal procedures were performed according to protocols approved by the 
German authorities, Regierungspräsidium Karlsruhe (Nr. A-23/17, Z110/02, DKFZ299 and G-
149/16). To reduce animal numbers, remaining bone marrow/cDNA samples generated in this 
and previous studies were used whenever possible. Generation of miRNA-seq data was 
performed using residual material from Meg3 KO and control mice generated during the 
reported experiments under the test number G-149/16.  
5.2.1.2 Genotyping 
For genotyping of mouse lines housed in the DKFZ animal core facility, tails were cut (approx. 
3 mm length) and incubated with 100 µl Direct PCR tail lysis reagent containing 0.2 mg/ml 
proteinase K at 55°C for 3-16 h. Subsequently, proteinase was inactivated by incubation at 
85°C for 45 min. Samples were stored for further PCR analysis (1 µl/reaction) at 4°C.  
Genotyping of mutant mouse strains was performed by PCR. PCRs were performed according 
to a standard protocol (Table 5.14, Table 5.15, Table 5.16 and Table 5.17) with the primers 
listed in Table 5.18.  
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Genotyping PCR products were separated based on their length using gel electrophoresis. 
Gels were prepared by boiling a suspension of 1-2% agarose in 1x TBE buffer. After addition 
of 30 µg ethidium bromide per 100 ml, the solution was filled in a gel tray containing a comb. 
PCR products were loaded without addition of loading dye, as this is already included in the 
DreamTaq Green PCR Mastermix. PCR fragments were separated by applying 120V. Finally, 
DNA fragments were visualized using an UV transilluminator, and gels were documented using 
a camera system.  
Table 5.14: Genotyping PCR mastermix  
Component Amount  
DreamTaq Green PCR Mastermix 12.5 µl 
Fwd primer (10 µM) 0.6 µl 
Rev primer (10 µM) 0.6 µl 
DNA 1 µl 
H2O 11.3 µl 
 
Table 5.15: Genotyping PCR program MxCre  
Step Temperature Time Number of cycles 
Denaturation 95°C 2 min  
Amplification 
94°C 
62°C 
72°C 
45 s 
45 s 
45 s 
40 
Final elongation 72°C 5 min  
Storage 4°C ∞  
 
Table 5.16: Genotyping PCR program VavCre 
Step Temperature Time Number of cycles 
Denaturation 95°C 2 min  
Amplification 
94°C 
70°C 
72°C 
45 s 
45 s 
45 s 
40 
Final elongation 72°C 5 min  
Storage 4°C ∞  
 
Table 5.17: Genotyping PCR program Meg3 flox 
Step Temperature Time Number of cycles 
Denaturation 95°C 2 min  
Amplification 
95°C 
62°C 
72°C 
45 s 
30 s 
60 s 
40 
Final elongation 72°C 10 min  
Storage 4°C ∞  
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Table 5.18: Genotyping primers 
Genotype Primer Sequence Amplicon 
MxCre 
Mx1 
 
Cre2L21 
GGCAGGGCTCCTCAGTGATTC  
CTGGCGATCCCTGAACATGTC  
550 bp 
VavCre 
Vav-cre-
01MR9266 
 
Vav-cre-
01MR9267 
AGATGCCAGGACATCAGGAACCT 
ATCAGCCACACCAGACACAGAGA 
236 bp 
Upper 
Meg3 flox 
Lox1 
 
SDL2 
TAGTCCGTCAGAATCGGGGTAC  
CTATGACAAATTGCTGTAGCCGCAC 
wt: 419 bp 
 
flox: 481 bp 
Lower 
Meg3 flox 
NDEL1 
 
NDEL2 
CAGACTCCTGCAGCCCCTAT 
CACCATCCCTAAAGAGGTGATCTCA 
wt: 557 bp 
 
flox: 735 bp 
 
5.2.1.3 pIC-induced stress experiments 
Mice were intraperitoneally injected with 100 µg pIC (in PBS) or PBS either 8 days, 4 days or 
16 h prior to endpoint analysis. For serial stress experiments, mice were injected 2 times a 
week for a period of 4 weeks. Mice were analyzed 8 weeks after the last pIC injection.  
5.2.1.4 Cell suspension and flow cytometry 
Peripheral blood and BM analysis 
For isolation of BM, spleen and thymus cells, mice were sacrificed by cervical dislocation. 
Femur, tibia, hip and spine bones, spleen and thymus were isolated. Bones were cleaned from 
muscles and connective tissues using a scalpel and forceps and crushed in ice-cold PBS using 
pistil and mortar. The resulting cell suspension was filtered through a 40 µm cell strainer and 
pelleted by centrifugation. Total BM cells were used for colony forming unit or transplantation 
assays. For flow cytometry analysis and FACS, erythrocytes were lysed using ACK Lysing 
Buffer (5 min, RT, 3 ml/sample). Lysis was stopped by addition of 7 ml PBS. BM cells were 
counted using a Vi-CellXR Cell Viability Analyzer and used for flow cytometry stainings.  
PB was collected into EDTA-coated tubes. Erythrocyte lysis was performed before flow 
cytometry analysis using ACK Lysing Buffer (5 min, RT, 1 ml/sample). Lysis was stopped by 
addition of 1 ml PBS. White blood cells were pelleted by centrifugation (1,500 rpm at 4°C). 
Depending on lysis efficiency, erythrocyte lysis was repeated as described.  
For spleen and thymus, single cell suspensions were generated by passing thymus or spleen 
tissue through a 40 µm cell strainer. Cells were collected in PBS, and lysis of erythrocytes was 
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performed for spleen samples as previously described for BM samples. Afterwards, cell 
concentration was determined using a Vi-CellXR Cell Viability Analyzer.  
FACS 
For FACS, total BM cells were lineage depleted using the Dynabeads Untouched Mouse CD4 
Cells Kit. Total BM was stained with a 1:5 dilution of the lineage cocktail provided in the kit in 
PBS for 30 min (3 ml/mouse). Cells were washed with PBS and incubated for 20 min with 1.5 
ml washed Dynabeads per mouse. A magnet was used for cell depletion to enrich for the 
lineage-negative cell fraction. To purify HSCs, the depleted cells were stained for 30 min using 
the monoclonal antibodies indicated in Table 5.19. For isolation of transplanted HSCs, 
monoclonal antibodies were used as indicated in Table 5.19. Cell sorting was performed on a 
BD FACSAriaI, FACSAriaII, FACSAriaIII or FACSAria Fusion. Cell populations were identified 
and purified according to the cell surface phenotype listed in Table 5.20. Sorted cells were 
collected into RNA lysis buffer for qPCR analysis or QIAzol Lysis Reagent for small RNA-seq 
analysis and stored at -80°C.  
Table 5.19: Antibody combinations used for FACS stainings for results part 3.1 
Staining Surface marker Antibody clone (fluorophore) 
HSCs (BM) CD4 GK1.5 (PE-Cy7) 
  CD8a 53-6.7 (PE-Cy7) 
  CD11b M1/70 (PE-Cy7) 
  Gr1 RB6-8C5 (PE-Cy7) 
  Ter119 Ter-119 (PE-Cy7) 
  B220 RA3-6B2 (PE-Cy7) 
 c-Kit 2B8 (PE) 
 Sca-1 D7 (APC-Cy7) 
 CD48 HM48-1 (PB) 
 CD150 TC15-12F12.2 (PE-Cy5) 
 CD34 RAM34 (FITC) 
Transplanted HSCs (BM) Lin (CD4, CD8a, CD11b, 
Gr1, Ter119, B220) 
Clones see HSCs, all AF700 
  CD117 2B8 (APC) 
  Sca-1 D7 (APC-Cy7) 
  CD48 HM48-1 (PE) 
  CD150 TC15-12F12.2 (PE-Cy5) 
  CD34 RAM34 (FITC) 
  CD45.1 A28 (PE-Cy7) 
  CD45.2 104 (PB) 
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Table 5.20: Hematopoietic populations and corresponding cell surface markers 
Abbreviation Population name Cell surface phenotype 
Lin lineage CD11b+ Gr-1+ B220+ CD4+ CD8a+ Ter119+ 
LSK hematopoietic stem and progenitor cells  Lin- Sca-1+ c-Kit+ 
LS-K myeloid committed progenitors Lin- Sca-1- c-Kit+ 
HSC hematopoietic stem cell LSK CD150+ CD48- CD34- (CD135-) 
MPP1 multipotent progenitor 1 LSK CD150+ CD48- CD34+ (CD135-) 
MPP2 multipotent progenitor 2 LSK CD150+ CD48+ CD34+ (CD135-) 
MPP3 multipotent progenitor 3 LSK CD150- CD48+ CD34+ (CD135-) 
MPP4 multipotent progenitor 4 LSK CD150- CD48+ CD34+ (CD135+) 
MPP3/4 multipotent progenitor 3/4 LSK CD150- CD48+ CD34+  
sHSC steady-state HSC LK CD150- CD48+ CD34- 
pHSC proliferating HSC LK CD150- CD48+ CD34- 
CMP common myeloid progenitor LS-K IL7Rα- CD34+ CD16/32low 
GMP granulocyte macrophage progenitor  LS-K IL7Rα- CD34+ CD16/32high 
MEP megakaryocyte erythrocyte progenitor  LS-K IL7Rα- CD34- CD16/32low 
B cells B lymphocytes (CD11b-) (Gr1-) B220+ 
Pre/Pro B cells pre/pro B lymphocytes (CD11b-) (Gr1-) B220
low 
IgM- 
Immature B cells immature B lymphocytes (CD11b-) (Gr1-) B220
low 
IgM+ 
Mature B cells mature B lymphocytes (CD11b-) (Gr1-) B220
high 
IgM+ 
T cells T lymphocytes (CD11b-) (Gr1-) CD4+ or CD8a+ 
Myeloid cells myeloid cells CD11b+ Gr1+ 
DP double positive thymocytes  CD4+ CD8a+ 
DN1 double negative thymocytes 1 CD4- CD8a- CD44+ CD25-  
DN2 double negative thymocytes 2 CD4- CD8a- CD44+ CD25+ 
DN3 double negative thymocytes 3 CD4- CD8a- CD44- CD25+ 
DN4 double negative thymocytes 4 CD4- CD8a- CD44- CD25- 
 
Flow cytometry 
Ery-lysed peripheral blood, spleen cells, thymus cells and BM cells were used for flow 
cytometry stainings. Table 5.21 defines the monoclonal antibodies applied for the different 
surface staining approaches. Cells were stained for 30 min at 4°C. For cell cycle stainings, 
surface stainings were performed, and cells were fixed and permeabilized by using BD 
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Cytofix/Cytoperm buffer for 15 min at 4°C. Subsequently, intracellular Ki-67 (B56)-AF647 
staining was performed in PermWash solution for 30 min at 4°C. Then, cells were stained with 
Hoechst 33342 for 15 min at RT and subsequently analyzed on a BD LSRII or BD LSRFortessa 
flow cytometer. Cell populations were identified according to the cell surface phenotype listed 
in Table 5.21. 
Table 5.21: Antibody combinations used for stainings for flow cytometry analysis for results part 3.1 
Staining Surface marker Antibody clone (fluorophore) 
Differentiated Cells 
(PB, BM, Spleen) CD4 GK1.5 (PE-Cy7) 
  CD8a 53-6.7 (PE-Cy7) 
  CD11b M1/70 (APC-Cy7) 
  Gr1 RB6-8C5 (APC) 
  Ter119 Ter-119 (PB) 
  CD71 R17217 (PE) 
  B220 RA3-6B2 (AF700) 
  IgM II/41 (PE-Cy5) 
HSCs (BM) Lin (CD4, CD8a, CD11b, Gr1, Ter119, B220) 
Clones see differentiated cells, all PE-
Cy7 
  CD117 2B8 (BV-711) 
  Sca-1 D7 (APC-Cy7) 
  CD48 HM48-1 (PB) 
  CD150 TC15-12F12.2 (PE-Cy5) 
  CD34 RAM34 (FITC) 
  CD16/32 93 (APC) 
  CD127 A7R34 (PE) 
Thymus CD4 GK1.5 (PE-Cy7) 
  CD8a 53-6.7 (PB) 
  CD25 PC61 (APC) 
  CD44 IM7 (PE-Cy5) 
Cell Cycle (BM) Lin (CD4, CD8a, CD11b, Gr1, Ter119, B220) 
Clones see differentiated cells, all 
AF700 
  CD117 2B8 (PE) 
  Sca-1 D7 (APC-Cy7) 
  CD48 HM48-1 (PE-Cy7) 
  CD150 TC15-12F12.2 (PE-Cy5) 
  CD34 RAM34 (FITC) 
 Ki-67 (intracellular) B56 (AF647) 
Differentiated Cells 
Transplants (PB) CD4 GK1.5 (PE) 
  CD8a 53-6.7 (PE) 
  CD11b M1/70 (APC-Cy7) 
  Gr1 RB6-8C5 (APC) 
  B220 RA3-6B2 (PE-Cy5) 
  CD45.1 A28 (PE-Cy7) 
  CD45.2 104 (PB) 
Differentiated Cells 
Transplants (BM, 
Spleen) 
CD4 GK1.5 (PE-Cy5) 
  CD8a 53-6.7 (PE-Cy5) 
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  CD11b M1/70 (APC-Cy7) 
  Gr1 RB6-8C5 (APC) 
  Ter119 Ter-119 (FITC) 
  CD71 R17217 (PE) 
  B220 RA3-6B2 (AF700) 
  CD45.1 A28 (PE-Cy7) 
  CD45.2 104 (PB) 
HSCs Transplants 
(BM) 
Lin (CD4, CD8a, CD11b, 
Gr1, Ter119, B220) 
Clones see differentiated cells, all 
AF700 
  CD117 2B8 (BV-711) 
  Sca-1 D7 (APC-Cy7) 
  CD48 HM48-1 (PE) 
  CD150 TC15-12F12.2 (PE-Cy5) 
  CD34 RAM34 (FITC) 
  CD45.1 A28 (PE-Cy7) 
  CD45.2 104 (PB) 
Cell Cycle 
Transplants (BM)  
Lin (CD4, CD8a, CD11b, 
Gr1, Ter119, B220) 
Clones see differentiated cells, all 
biotin (2nd antibody Strepdavidin-PE-
TR) 
 CD117 2B8 (PE) 
 Sca-1 D7 (APC-Cy7) 
 CD48 HM48-1 (AF700) 
 CD150 TC15-12F12.2 (PE-Cy5) 
 CD34 RAM34 (FITC) 
 CD45.1 A28 (PE-Cy7) 
 Ki-67 (intracellular) B56 (AF647) 
 
5.2.1.5 Gene expression analysis by qPCR 
HSCs (MxCre or MxCre Meg3 mat flox/pat wt LSK CD150+ CD48- CD34-; fetal liver HSCs: E13.5 
CD48- CD41+ cKit+ CD34+; adult HSCs (8-12 weeks): LSK CD150+ CD48- CD34- CD135-; 
aged HSCs (24 months): LSK CD150+ CD48- CD34- CD135-) were sorted by FACS into RNA 
lysis buffer for qPCR analysis and stored at -80°C. RNA was isolated using the ARCTURUS 
PicoPure RNA Isolation Kit following the manufacturer’s instructions with a DNase digestion 
step. For cDNA synthesis, reverse transcription was performed using the SuperScript VILO 
cDNA Synthesis Kit according to manufacturer’s guidelines. cDNA samples were diluted in 
DNase- and RNase-free water (total volume of 200 µl per 10,000 sorted cells). Primers (Table 
5.22) were used with a final concentration of 0.5 µM in a total reaction volume of 10 µl. Fast 
SYBR Green Master Mix was used on a ViiA 7 Real-Time PCR System for qPCR analysis (see 
Table 5.23 for qPCR program). Fluorescent signal was detected at the end of every 
amplification step and continuously during the melting curve. Amplification curves were 
analyzed using the ViiA 7 software. RNA expression was normalized to the housekeeping gene 
Oaz1 and presented as relative quantification (ratio = 2^-DDCT). Primers were designed using 
the Universal ProbeLibrary Assay Design Center (Roche). 
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Table 5.22: qPCR primer for results part 3.1 (synthesis by Sigma-Aldrich) 
Primer Sequence 
Cdk6 fwd cgagtgcagaccagtgagg 
Cdk6 rev tgtgcacacatcaaacaacct 
c-Myc fwd caccagcagcgactctga 
c-Myc rev ggggtttgcctcttctcc 
Egr1 fwd agttccaacgccctctgac 
Egr1 rev acaggaacccgaaccaca 
Hoxa5 fwd agctgcacattagtcacgaca 
Hoxa5 rev gcggttgaagtggaattctt 
Hoxb4 fwd ctggatgcgcaaagttcac 
Hoxb4 rev gtgaaactccttctccaactcc 
Hoxb5 fwd gcttcacatcagccacgata 
Hoxb5 rev caggtagcgattgaagtggaat 
Meis1 fwd gacgctttaaagagagataaagatgc 
Meis1 rev catttctcaaaaatcagtgctaaga 
Meg3 fwd cgaggacttcacgcacaa 
Meg3 rev attccagatgatggctttg 
Oaz1 fwd tttcagctagcatcctgtactcc 
Oaz1 rev gaccctggtcttgtcgttaga 
Tgm2 fwd cctgaccctggatccctact 
Tgm2 rev cacccgctgtacttctcgtag 
 
Table 5.23: qPCR thermal cycling program 
Step Temperature Time Number of cycles 
Initial denaturation/ 
activation of polymerase 95°C 10 min  
Amplification 95°C 60°C 
15 s 
45 s 40 
Melting curve 65°C-95°C 0.5°C/s  
 
5.2.1.6 Small RNA sequencing 
Sample preparation and library generation 
Approximately 10,000-20,000 LSK SLAM cells (LSK CD150+ CD48-) were sorted by FACS 
into 100 µl QIAzol Lysis Reagent. Total RNA extraction was performed by adding 20 µl 
chloroform. Samples were incubated at RT for 3 min and centrifuged at 12,000 rpm for 5 min 
at RT. The aqueous phase was transferred into a new PCR tube and 0.4 µl glycoblue and 75 
µl isopropanol were added per sample. Samples were stored at -20°C for at least 5 days. 
Samples were centrifuged at 13,000 rpm for 1 h at 4°C. Samples were washed with 70% 
ethanol and centrifuged at 13,000 rpm for 15 min at 4°C. Supernatant was discarded and the 
 Materials and Methods  
 145 
pellet was dried for 1 min. The pellet was resuspended in 8 µl H2O. RNA quality was analyzed 
using the Agilent RNA 6000 Pico Kit according to manufacturer’s instructions. Libraries for 
small RNA-seq were generated using the SMARTer® smRNA-seq Kit for Illumina® according 
to manufacturer’s instructions. 23 ng of total RNA were used, and 15 cycles were applied for 
PCR amplification. Quality was checked using the Agilent High Sensitivity DNA Kit according 
to manufacturer’s instructions. Size selection was performed by using AMPure XP Beads 
according to manufacturer’s instructions. Sequencing was performed on an Illumina 
HiSeq2000 device. 
5.2.1.7 miRNA sequencing analysis 
Genomic mapping 
The adapter sequences ATGATCGGAAGAG, GATGAAGAACGCAG, 
AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT, GGTCTACG, 
TGGAATTCTCGGGTGCCAAGG, TCGTATGCCGTCTTCTGCTTG, 
AGATCGGAAGAGCACACGTCTGAACTCCAGTCA were removed with Trimmomatic (Bolger 
et al., 2014) (version 0.32, parameters: SE ILLUMINACLIP:adapter:2:30:10 HEADCROP:4 
TRAILING:3 MINLEN:17) from the fastq sequences. Additionally all reads containing N and all 
sequences <17 bases were removed. HomerTools (Heinz et al., 2010) (v3.18, trim -3 
AAAAAAAAA) for removing poly(A) tails and fastx_artifacts_filter (FASTX Toolkit 0.0.13 
http://hannonlab.cshl.edu/fastx_toolkit/) were used for further cleaning. Then, the clean fastq 
files were mapped against mouse genome 38 (NCBI) using Bowtie 2 version 2.2.4 (Langmead 
and Salzberg, 2012) (parameters -N 0 -L 8). The resulting SAM files were converted to BAM 
and sorted using samtools version 1.3.1. 
miRNA mapping and counting 
The clean fastq files were mapped with Bowtie version 0.12.9 (-f -v 1 -a --best -S) against an 
assembled ncRNA database consisting of a unique set of miRNAs of Ensembl version 95 
(http://www.ensembl.org/) and miRBase (v21, http://www.mirbase.org/). The resulting SAM 
files were parsed, and the number of reads for each mature miRNA was counted using Perl. 
Comparison of control Cre and KO samples 
For the comparison with DESeq2 (Love et al., 2014), the input tables containing the replicates 
for the groups to compare were created by a custom Perl script. In the count matrix, rows with 
an average count number < 5 were removed. Then, DESeq2 (version 1.4.1) was run with 
default parameters. 
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Data availability 
The small RNA-seq dataset generated and analyzed during the current study is available in 
the ArrayExpress repository, ArrayExpress accession E-MTAB-7519 
(http://www.ebi.ac.uk/arrayexpress/). 
5.2.1.8 Transplantation experiments and CFU assays 
Full chimeras 
1x10^6 total BM cells from induced MxCre control mice or induced MxCre Meg3 mat flox/pat wt mice 
were transplanted into fully irradiated (2x5 Gy) CD45.1 mice within 24 h after irradiation by tail 
vein injection. Approximately 4 months after transplantation, mice were euthanized and 3x10^6 
total BM cells were transplanted into fully irradiated (2x5 Gy) CD45.1 secondary recipient mice. 
Approximately 4 months after transplantation, mice were euthanized and 3x10^6 total BM cells 
were transplanted into fully irradiated (2x5 Gy) CD45.1 tertiary recipient mice. Contribution of 
CD45.2+ donor cells was monitored in peripheral blood approximately every 4 weeks by flow 
cytometry using the monoclonal antibodies indicated in Table 5.21.  
50/50 chimeras 
2x10^5 total BM cells from induced MxCre control mice or induced MxCre Meg3 mat flox/pat wt mice 
were transplanted into fully irradiated (2x5 Gy) CD45.1 mice within 24 h after irradiation by tail 
vein injection in competition to 2x10^5 total BM cells from CD45.1/.2 mice. Approximately 4 
months after transplantation, mice were euthanized and 3x10^6 total BM cells were 
transplanted into fully irradiated (2x5 Gy) CD45.1 secondary recipient mice. Approximately 4 
months after transplantation, mice were euthanized and 3x10^6 total BM cells were 
transplanted into fully irradiated (2x5 Gy) CD45.1 tertiary recipient mice. Contribution of 
CD45.2+ donor cells was monitored in peripheral blood approximately every 4 weeks by flow 
cytometry using the monoclonal antibodies indicated in Table 5.21. 
Colony forming unit assay 
40,000 freshly prepared BM cells were mixed with 3 ml of semi-solid MethoCult M3434 medium 
and plated on a 35 mm culture plate in technical duplicates (1 ml/replicate). Colonies were 
counted after 7 days using a Zeiss Primo Vert inverted microscope. For replating, cells were 
harvested by washing culture plates with PBS. Cells were counted using a hemocytometer, 
and 30,000 cells of each technical replicate were mixed with 1.5 ml of semi-solid MethoCult 
M3434 medium and plated on a 35 mm culture plate (1 ml/replicate). Colony number was 
determined after 8 days.  
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5.2.1.9 Statistical analysis 
Statistical analysis was performed by unpaired or paired student’s t-test or two- or one-way 
ANOVA without correction for multiple comparison (Fisher LSD test). All data are presented 
as mean + SD. Please see figure legends for detailed information. Significance levels were set 
at *p < 0.05, **p < 0.01 and ***p < 0.001. For statistical analysis, GraphPad Prism was used.  
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5.2.2 Methods – results part 3.2 
Most of this methods section (5.2.2) has been submitted as part of a paper draft. 
5.2.2.1 Animals 
C57BL/6J (CD45.2, CD45.1 or CD45.2/CD45.1) mice were either purchased from Envigo (the 
Netherlands) or Janvier Labs (France) or bred in-house. For 3’-Seq analysis, 6- to 12-weeks-
old female C57BL/6J (CD45.2) mice were used. All mice were bred in-house in the animal 
facility of the DKFZ under SPF conditions in IVCs. According to German guidelines, mice were 
euthanized by cervical dislocation, and all animal procedures were performed according to 
protocols approved by the German authorities, Regierungspräsidium Karlsruhe (Nr. A-23/17, 
Z110/02, DKFZ 299, G-183/17). To reduce animal numbers, remaining bone marrow/cDNA 
samples generated in this and previous studies were used whenever possible.  
5.2.2.2 pIC-induced inflammatory stress 
Mice were intraperitoneally injected with 100 µg pIC or PBS. 16 h later, mice were sacrificed, 
and bone marrow cells were used for subsequent experiments. 
5.2.2.3 Cell suspension and flow cytometry  
Mouse BM cells were isolated, and HSCs and MPP1-4 progenitors defined by their respective 
immunophenotype (Lineage- Sca1+ Kit+ CD135-/+ CD150-/+ CD48-/+ CD34-/+) or LSK 
(Lineage- Sca1+ Kit+) or sHSCs (PBS-injected control mice)/pHSCs (pIC-injected mice; after 
16h) (Lineage- Kit+ CD150+ CD48- CD34-; excluding Sca-1 as previously described (Haas et 
al., 2015)) were purified by FACS and subsequently subjected to 3’-Seq, qPCR analysis, in 
vitro CB-839 treatment, lentiviral transduction, CFU analysis or reconstitution assays. See also 
5.2.1.4 for further details. Briefly, BM was isolated from pooled femora, tibiae, ilia and vertebrae 
by gentle crushing in ice-cold PBS using a mortar and pistil. If no depletion of lineage-positive 
cells was done, lysis of erythrocytes was performed using ACK Lysing Buffer (see 5.2.1.4). To 
deplete lineage-positive cells, we used the Dynabeads Untouched Mouse CD4 Cells Kit (see 
5.2.1.4). To purify HSCs and MPP1-4 cells, the Lin- fraction was stained for 30 min using the 
monoclonal antibodies listed in Table 5.24. To purify LSK cells, the Lin- fraction was stained 
for 30 min using the monoclonal antibodies listed in Table 5.24. For some experiments, the 
fluorophore color panel was changed to enable analysis of additional markers. Cell sorting was 
performed on a BD FACS Aria I, II, III or FACS Aria Fusion. Cell populations were identified 
and purified according to the cell surface phenotype listed in Table 5.20. Cells were sorted into 
Complete Stem Cell Medium (see 5.2.2.9) for CFUs, lentiviral transduction, in vitro culture and 
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reconstitution experiments, or RNA lysis buffer for population 3’-Seq and qPCR analysis and 
stored at -80°C.  
Table 5.24: Antibody combinations used for FACS stainings for results part 3.2 
Staining Surface marker Antibody clone (fluorophore) 
HSC/MPP/sHSC/pHSC CD4 GK1.5 (PE-Cy7) 
  CD8a 53-6.7 (PE-Cy7) 
  CD11b M1/70 (PE-Cy7) 
  Gr1 RB6-8C5 (PE-Cy7) 
  Ter119 Ter-119 (PE-Cy7) 
  B220 RA3-6B2 (PE-Cy7) 
 c-Kit 2B8 (APC) 
 Sca-1 D7 (APC-Cy7) 
 CD135 RAM34 (PE) 
 CD48 HM48-1 (PB) 
 CD150 TC15-12F12.2 (PE-Cy5) 
 CD34 RAM34 (FITC) 
LSK Lin (CD4, CD8a, 
CD11b, Gr1, Ter119, 
B220) 
Clones see HSCs, all PB 
  CD117 2B8 (PE) 
  Sca-1 D7 (APC-Cy7) 
 
GLS stainings 
For flow cytometry analysis of GLS protein levels, homeostatic or pIC-treated BM cells were 
isolated from mice and stained for HSC/MPP markers as described using antibodies indicated 
in Table 5.25. Cells were fixed with BD Cytofix/Cytoperm buffer. Subsequently, intracellular 
GLS (AF488, clone EP7212, abcam) staining was performed using BD PermWash solution 
(see 5.2.1.4 for details on intracellular staining procedures). Cells were subsequently analyzed 
on a BD LSRII flow cytometer or BD LSRFortessa cell analyzer. For analysis of GLS 
expression in Nudt21 KD cells, GFP+ cells were resorted 48 h or 72 h after lentiviral 
transduction, and intracellular GLS staining was performed. The GFP is lost during the 
fixation/permeabilization step, therefore staining of GLS with anti-GLS -AF488 is possible.  
Table 5.25: Antibody combinations used for stainings for flow cytometry analysis of GLS for results part 3.2 
Staining Surface marker Antibody clone (fluorophore) 
GLS in HSCs/MPP Cells CD4 GK1.5 (PE-Cy7) 
  CD8a 53-6.7 (PE-Cy7) 
  CD11b M1/70 (PE-Cy7) 
  Gr1 RB6-8C5 (PE-Cy7) 
  Ter119 Ter-119 (PE-Cy7) 
  B220 RA3-6B2 (PE-Cy7) 
 c-Kit 2B8 (PE) 
 Sca-1 D7 (APC-Cy7) 
 CD48 HM48-1 (PB) 
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 CD150 TC15-12F12.2 (PE-Cy5) 
 CD34 RAM34 (AF700) 
  GLS (intracellular) EP7212 (AF488) 
 
PABPN1 stainings 
For analysis of knockdown efficiency, GFP+ cells were resorted 48 h or 72 h after lentiviral 
transduction. GFP+ cells were then fixed with BD Cytofix/Cytoperm buffer. Subsequently, 
intracellular PABPN1 (AF647, clone EP3000Y, abcam) staining was performed using BD 
PermWash solution (see 5.2.1.4 for details on intracellular staining procedures). Cells were 
subsequently analyzed on a BD LSRII flow cytometer or BD LSRFortessa cell analyzer. 
Cell cycle analysis 
HSC/MPP surface staining (LSK, CD150, CD48, CD34) was performed on BM cells or CB-
839-treated HSPCs (Table 5.26). Cells were fixed with BD Cytofix/Cytoperm buffer. 
Subsequently, intracellular Ki-67 staining was performed using BD PermWash solution. Prior 
to flow cytometry analysis, cells were stained with Hoechst 33342 or DAPI (see 5.2.1.4 for 
details on intracellular staining procedures). Cells were subsequently analyzed on a BD LSRII 
flow cytometer or BD LSRFortessa cell analyzer. 
Table 5.26: Antibody combinations used for stainings for flow cytometry analysis of cell cycle of CB-treated cells 
for results part 3.2 
Staining Surface marker Antibody clone (fluorophore) 
CC in CB-Treated Cells 
and HSCs/MPPs in BM 
CD4 GK1.5 (AF700) 
  CD8a 53-6.7 (AF700) 
  CD11b M1/70 (AF700) 
  Gr1 RB6-8C5 (AF700) 
  Ter119 Ter-119 (AF700) 
  B220 RA3-6B2 (AF700) 
 c-Kit 2B8 (PE) 
 Sca-1 D7 (APC-Cy7) 
 CD48 HM48-1 (PE-Cy7) 
 CD150 TC15-12F12.2 (PE-Cy5) 
 CD34 RAM34 (FITC) 
  Ki-67 (intracellular) B56 (AF647) 
 
Viability analysis 
Cells were harvested, and viability staining was performed using the FITC or PE Annexin V 
Apoptosis Detection Kit I (BD Biosciences) according to the manufacturer’s protocol. Cells 
were subsequently analyzed on a BD LSRII flow cytometer or BD LSRFortessa cell analyzer. 
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5.2.2.4 Lentiviral KD experiments 
shRNA-expressing plasmids were purchased from Dharmacon as bacterial glycerol stocks. 
Maxi-preps were performed to generate shRNA plasmids for transfection using Qiagen 
Plasmid Maxi Kit according to manufacturer’s instructions. Viruses were packaged by co-
transfection of shRNA plasmids (Scr GFP, Pabpn1 shRNA_2 and _3, Nudt21 
shRNA_1(10),_2(2),_3(4); Dharmacon; see Table 5.5 for details) with pSPAX2 and pMD2.g 
into 293T cells using the Invitrogen Calcium Phosphate Transfection Kit according to 
manufacturer’s guidelines and 25 µM chloroquine added additionally to the cells. After 12 h of 
transfection, cells were cultured in 0.1% gelatin-coated cell culture flasks in DMEM GlutaMAX 
(+10% FCS, 1% penicillin-streptomycin (P/S), 1% L-glutamine, 1% HEPES) at 37°C. Viral 
supernatants were collected 48 h post-transfection and filtered through a 45 µm filter and 
centrifuged at 22,000 rpm (2 h at 4°C). After centrifugation, the virus pellet was re-suspended 
in PBS and stored at -80°C. Viral titers were determined using 293T cells and subsequent flow 
cytometry analysis to quantify reporter fluorophore expression.  
For lentiviral transduction of LSK cells, BM cells were sorted as described (see 5.2.2.3). Sorted 
LSK cells were cultured in retronectin-coated (Takara; 4 µg/cm2) 96-/24-/6-well ultra-low 
attachment plates in Transduction Medium (StemPro-34 SFM, Life Technologies containing 
50 ng/ml SCF, 25 ng/ml TPO, 30 ng/ml Flt3-Ligand (all Preprotech), 100 u/ml 
penicillin/streptomycin, 2 mM L-glutamine, 8 µg/ml Polybrene (Sigma-Aldrich) and StemPro-
34 Supplement as recommended) and transduced with an MOI of 35. Medium was exchanged 
to Complete Stem Cell Medium (see 5.2.2.9) 24 h later. Cells were harvested 48 h or 72 h after 
transduction for sorting of GFP+ cells or flow cytometry analysis and viability analysis. GFP+ 
LSK cells were used for 3’-Seq analysis, and GFP+ cells were used for qPCR analysis, flow 
cytometry analysis and functional assays, including CFU and reconstitution experiments.  
5.2.2.5 Colony-forming unit assays using KD cells 
1,500 FACS-sorted GFP+ cells were resuspended 3 ml MethoCult M3434 (StemCell 
Technologies), and1 ml of Methocult was plated per technical replicate, respectively. Five days 
after plating of CFUs, colony formation was quantified. 20,000 cells of each replicate were 
used for replating and cultured in MethoCult M3434 (StemCell Technologies). Residual Cells 
were stained for flow cytometry analysis as described (Table 5.24, see also 5.2.2.3). 7 days 
after replating, colonies were quantified (for detailed procedure of CFU assays see 5.2.1.8).  
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5.2.2.6 Reconstitution experiments using KD cells 
Full chimeras and 50/50 chimeras 
For generation of full chimeras, 30,000 GFP+ cells (KD or Scr Ctrl, CD45.2) were sorted 48 h 
after lentiviral transduction of LSK cells per recipient mouse and injected intravenously. 
For generation of 50/50 chimeras, 15,000 GFP+ cells were sorted 48 h after lentiviral 
transduction of LSK cells per recipient mouse. We generated two sets of chimeras: CD45.1/.2 
Scr Ctrl + CD45.2 KD and CD45.1/.2 KD + CD45.2 Scr Ctrl. Always, 15,000 + 15,000 GFP+ 
cells were mixed. As CD45.2 cells are known to perform better in transplantation settings, we 
always compared contribution of CD45.2 KD and CD45.2 Scr Ctrl across our 50/50 chimeras 
to prevent over- or underestimation of our KD-related effects (Jafri et al., 2017).  
For all experiments, cells were transplanted into fully irradiated (2x5 Gy) C57Bl6/J mice 
(CD45.1). Contribution of CD45.2+ donor cells was monitored in peripheral blood 
approximately 4, 8, 12 and 16 weeks post-transplantation in primary and secondary recipients. 
Outcome was analyzed by flow cytometry using the monoclonal antibodies indicated in Table 
5.27. For endpoint analysis of chimeras, BM and thymus stainings were performed (Table 
5.27).  
For secondary transplantations, whole BM was isolated 16 weeks post-transplantation, and 
1x10^6 cells were retransplanted into fully irradiated (2x5 Gy) C57Bl6/J mice (CD45.1). 
Mice were only included in the 50/50 chimera analysis if >50 GFP+ cells were detected (>50 
GFP+ single cells for analysis of peripheral blood and peripheral organ/BM stainings; >50 
GFP+ cells of respective population or LSK cells for BM analysis). CD45-negative cells were 
excluded from the analysis.  
Homing analysis 
For analysis of homing capacity, 30,000 GFP+ cells (KD or Scr Ctrl, CD45.2) were sorted 48 
h after lentiviral transduction of LSK cells per recipient mouse. Cells were transplanted into 
fully irradiated (2x5 Gy) C57Bl6/J mice (CD45.1) and sacrificed 48 h later. HSC/MPP and 
CD45.1/.2 staining was performed (Table 5.27), and engraftment was analyzed by flow 
cytometry analysis.  
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Table 5.27: Antibody combinations used for flow cytometry stainings for Pabpn1 KD experiments in results part 3.2  
Staining Surface marker Antibody clone (fluorophore) 
Differentiated Cells 
Transplants (PB) CD4 GK1.5 (PE) 
  CD8a 53-6.7 (PE) 
  CD11b M1/70 (AF700) 
  Gr1 RB6-8C5 (APC) 
  B220 RA3-6B2 (PE-Cy5) 
  CD45.1 A28 (PE-Cy7) 
 CD45.2 104 (PB) 
Thymus 
Transplants CD4 GK1.5 (APC-Cy7) 
  CD8a 53-6.7 (PE) 
  CD25 PC61 (APC) 
  CD44 IM7 (PE-Cy5) 
  CD45.1 A28 (PE-Cy7) 
  CD45.2 104 (PB) 
HSCs/MPP Cells 
Transplants 
CD4 GK1.5 (APC) 
  CD8a 53-6.7 (APC) 
  CD11b M1/70 (APC) 
  Gr1 RB6-8C5 (APC) 
  Ter119 Ter-119 (APC) 
  B220 RA3-6B2 (APC)  
c-Kit 2B8 (BV-711)  
Sca-1 D7 (APC-Cy7)  
CD48 HM48-1 (PE-Cy7)  
CD150 TC15-12F12.2 (PE-Cy5) 
 CD34 RAM34 (AF700) 
  CD45.1 A28 (PE) 
  CD45.2 104 (PB) 
Homing 
Transplants  
Lin (CD4, CD8a, CD11b, 
Gr1, Ter119, B220) 
Clones see HSCs/MPP cells 
transplants, all APC 
  CD117 2B8 (BV-711) 
  Sca-1 D7 (APC-Cy7) 
  CD48 HM48-1 (PE-Cy7) 
  CD150 TC15-12F12.2 (PE-Cy5) 
  CD34 RAM34 (AF700) 
  CD45.1 A28 (PE) 
  CD45.2 104 (PB) 
 
5.2.2.7 3’-Seq library generation and bioinformatic analysis 
Library and data generation 
Total RNA isolation was performed using the ARCTURUS PicoPure RNA isolation kit 
(according to the manufacturer’s instructions). Total RNA was used for quality control and for 
normalization of the starting material. RNA quality was analyzed using the Agilent RNA 6000 
Pico Assay according to manufacturer’s guidelines. Sequencing libraries were generated with 
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3 ng of total RNA for HSCs/MPP cells, sHSCs (PBS-treated mice), pHSCs (pIC-treated mice) 
or Scr-/Pabpn1-KD LSK cells (72 h after viral transduction) using the QuantSeq 3’ mRNA-seq 
Library Prep Kit REV according to the manufacturer’s instructions except for adaptations 
(version 015UG009V0221: Do not skip step 2; 15 minute incubation time step 4; cycle number 
was adjusted to 19 using the PCR Add-on Kit for Illumina). Quality was checked using the 
Agilent High Sensitivity DNA Kit according to manufacturer’s instructions. A multiplex of 2 nM 
was generated, and sequencing was performed with an Illumina HiSeq2000 device in paired-
end mode reading 125 nucleotides. For sequencing, a custom sequencing primer was 
provided (5’ CCCTACACGACGCTCTTCCGATCTTTTTTTTTTTTTTTTTTT 3’) 
Downstream analysis 
Libraries were demultiplexed according to the barcodes, and quality control of the fastq files 
was performed using the fastqc package.  
For regular RNA-seq gene expression analysis, paired-end libraries were mapped against the 
mm10 mouse genome with the STAR package (Dobin et al., 2013) to generate sorted BAM 
files. Reads were annotated and counted against the GRCm38.p5 reference gene set 
(Ensembl) using the htseq-count package (Anders et al., 2015). Differentially expressed genes 
were identified with the DESeq2 package (Love et al., 2014) using the independent hypothesis 
weighting function of the IHW package for false discovery rate (FDR) calculation (Ignatiadis et 
al., 2016). Genes with FDR <0.1 and with log2 fold change higher than 0.5 or lower than -0.5 
were considered as differentially expressed. 
For APA analysis, we utilized only the Read1 of the two paired ends, since it originates from 
the custom sequencing primer of the Lexogen REV kit corresponding to the terminal end of 
the 3’-UTR. Sequencing adapters and polyadenylation tails were removed by trimming, and 
sequences containing less than 80% of A and T nucleotides were mapped against the mm10 
mouse genome using bowtie. Failed reads and reads with multiple hits to the genome were 
filtered out. Putative polyadenylation sites were clustered in a 50 bp half-window, and only 
polyadenylation sites present in all biological replicates for both conditions and with a minimum 
of 25 hits were considered for further analysis. Polyadenylation sites were annotated with the 
ChIPpeakAnno package (Zhu et al., 2010) using as reference the protein-coding genes 
reported in the GRCm38.p5 reference set. The flanking sequences were obtained with the 
BSgenome package (Bioconductor). High-confidence polyadenylation sites were identified as 
hits located within a gene or in the 3,000 bases downstream in the intergenic region that show 
at least one of the 12 identified consensus polyadenylation hexamers (Beaudoing et al., 2000) 
in the 40 bases upstream and that do not have more than seven As in the 10 bases 
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downstream. For each polyadenylation site, we calculated the Percentage of PolyAdenylation 
Usage (PPAU), defined as the ratio of its usage against the sum of the usage of all the 
polyadenylation sites for that specific transcript. ΔAPAS was identified using the DEXSeq 
package (Anders et al., 2012) using a FDR <20%. 
For analysis of APA shortening/lengthening, we considered only hits present in 3’-UTRs. For 
each 3’-UTR containing two or more polyadenylation sites, we considered the percentage of 
usage of the most distal polyadenylation site (PDUI) and calculated its differential usage 
between the conditions (dPDUI).  
GOterms (biological processes) were calculated for genes with a relative shortening or 
lengthening of the distal pA higher than 10% by using the topGO package (Bioconductor) with 
the classic Fisher statistics and using all the genes with at least one polyadenylation site in the 
3'-UTR as background. To visualize and summarize GO terms, REVIGO analysis 
(http://revigo.irb.hr/; GO terms of shortened genes MPP2 vs HSC classicFisher < 0.05; Allowed 
similarity: Tiny; p-values were provided; database: whole UniProt; semantic similarity measure: 
SimRel) was performed (Supek et al., 2011). 
Data availability 
The accession number for the 3’-Seq data of HSCs and MPP1-4 cells reported in this thesis is 
ArrayExpress: E-MTAB-7391. The accession number for the 3’-Seq data of sHSC and pHSCs 
reported in this thesis is ArrayExpress: E-MTAB-7390. The accession number for the 3’-Seq 
data of LSK Pabpn1 KD cells is ArrayExpress: E-MTAB-7392. 
5.2.2.8 qPCR analysis 
For real-time qPCR, total RNA of 5,000-10,000 cells was isolated as described (see also 
5.2.1.5) and reverse-transcribed using the SuperScript VILO cDNA Synthesis Kit according to 
the manufacturer’s guidelines (see also 5.2.1.5). For qPCR analysis, Fast SYBR Green Master 
Mix (see Table 5.23 for qPCR program) or TaqMan Probes and TaqMan Fast Advanced 
Master Mix (see Table 5.28 for TaqMan qPCR program) were used on a ViiA 7 Real-Time 
PCR System. RNA expression was normalized to Oaz1 or Gapdh housekeeping gene 
expression and presented as relative quantification (ratio = 2^-DDCT). For analysis of APA 
switches by qPCR, the 2^-DCT value was calculated. The proximal 2^-DCT value was divided 
by the distal 2^-DCT value, and results were normalized. For comparison to 3’-Seq data, the 
proximal raw read counts were added up (proximal + distal) and divided by the distal raw read 
counts, followed by normalization. Adding of proximal and distal counts of the 3’-Seq data is 
necessary for comparison with qPCR results, as the proximal primer pair always amplifies the 
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distal transcript as well. Results >1 indicate relative increase of the proximal transcript, 
whereas results <1 indicate relative increase of the distal transcript. Primers were designed 
using the Universal ProbeLibrary Assay Design Center (Roche) or NCBI Primer-BLAST 
(NCBI). TaqMan Probes were purchased from Thermo Scientific (Table 5.6). For list of primers 
for SYBR Green qPCR, see Table 5.29.  
Table 5.28: TaqMan qPCR thermal cycling program 
Step Temperature Time Number of cycles 
UNG* incubation 50°C 2 min  
Activation of polymerase 95°C 20 s  
Amplification 95°C 60°C 
1 s 
20 s 40 
*UNG: uracil-N-glycosylase; degradation of previous PCR amplifications or mis-primed, non-specific products, 
leaving native nucleic acid templates intended for amplification intact 
 
Table 5.29: qPCR primer for results part 3.2 (synthesis by Sigma-Aldrich) 
Primer Forward sequence Reverse sequence 
proximal 
CD84 GCCAGCCAAGGGATTTAGGA AGATCTGTGGGCCTGAGAGT 
distal 
CD84 GTAAGGCAGTGGCCTAGCTT AAGCCTTCACTGGTGTTCCA 
proximal 
Slc25a20 TGGCTGTGATGGTGAAACTGT CTCCAATTCTCTGGAAATCCTCT 
distal 
Slc25a20 GTCCCAGCCTCCTGGGATAA TGAGTGCTCTCATGGGGAAA 
proximal 
Minos1 ACAAACAGTGGCTGGAGTTGA AATACTGAAGTGCCCGGAGT 
distal 
Minos1 TCAGATTGAACCATGACAAGCA TAGGAAACAGACACTGGGCT 
proximal 
Rcc2 GCTCCGTTTCCAAGCGATTC AAAGGCAGGCTGGCTATGAG 
distal 
Rcc2 CAAAGGGTAACAGGAAGGGAGT AACAGCACTAAACCAGGCAC 
proximal 
Ogfrl1 TTTTCTGGGCTTTGCTTCGC GAGAGGAGAAAGCTCCTGCG 
distal 
Ogfrl1 TGTCATGTTACGAGGACGCA AGAGGAGTACACCCTGGCTT 
proximal 
Hnrnpa2b AGCTTCTTAACTCTACACACGCA AGCCAGGATCATGGTGTAATAAGA 
distal 
Hnrnpa2b TGATGTTACCCTTTACAATCAGCA AGTTCTTGTTGGTGCCTTCA 
proximal 
Hdlbp GTGCTGACTACATGCTGGGT CTCCTGATGCTGTGCTCTGG 
distal 
Hdlbp TCCACCCTCAACTCAATGGC TCATGTGGGTTAGTGCCACC 
proximal 
Treml2 ACAGAGCATGGAAAGGTCCC CAAGGCCCTAGCTGTGTCAG 
distal 
Treml2 CTCAGGGGACTCTAGGCTGT GCCATCATCACAGAACCCCA 
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proximal 
SSR1 ACGCAGGCAGAATATGGCTT CCTAGCGACTTCACTTGGCA 
distal 
SSR1 TTGTGACCATGACCCGCAAA GGGATGGAGCTCAGACGTAG 
proximal 
Ctsc AGGACTTCACTGGGGCTAAGA CCTCTGGGCTGGAATGTACC 
distal  
Ctsc TGCCTTTGAAGTCCACGATGA TTTGTCAGCTCGAAGGGGTT 
Oaz1 TTTCAGCTAGCATCCTGTACTCC GACCCTGGTCTTGTCGTTAGA 
Pabpn1 CGGAGCTAGAAGCGATCAAAG ATTGCCAACGTAGATAGAGCG 
 
5.2.2.9 CB-839 in vitro assays 
Enrichment of HSPCs  
To enrich HSPCs for in vitro assays, lineage marker-positive cells were depleted from BM as 
described in section 5.2.1.4. For bone marrow preparation, see 5.2.2.3. 
HSPC plating and treatment  
HSPCs were cultured in Complete Stem Cell Medium (StemPro-34 SFM, Life Technologies 
containing 50 ng/ml SCF, 25 ng/ml TPO, 30 ng/ml Flt3-Ligand (all Preprotech), 100 u/ml 
penicillin/streptomycin, 2 mM L-glutamine, StemPro-34 Supplement as recommended). Cells 
were cultured in 96-/24-/6-well ultra-low attachment plates and were treated with either CB-
839 (5 µM) or the respective amount of DMSO. After 48 h or 72 h of culture, cells were used 
for cell cycle and viability analysis (see also 5.2.2.3). 
CFUs of CB-839-treated cells  
1,000 FACS-sorted LSK cells were cultured in 100 µl Complete Stem Cell Medium (described 
in “HSPCs plating and treatment”) in 96-well ultra-low attachment plates and immediately 
treated with CB-839 (5 µM) or the respective amount of DMSO. 72 h after treatment, all cells 
of one well were harvested and cultured in MethoCult M3434 (see also 5.2.2.5 for more 
details). Five days after plating of CFUs, colony formation was quantified. 20,000 cells of each 
replicate were used for replating and cultured in MethoCult M3434 (StemCell Technologies). 
6-7 days after replating, colonies were quantified.  
5.2.2.10 Statistical analysis 
Statistical analysis was performed by unpaired or paired Student’s t-test or two- or one-way 
ANOVA without correction for multiple comparison (Fisher LSD test). All data are presented 
as mean + SD or ± 95% confidence interval. Please see figure legends for detailed information. 
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Significance levels were set at *p < 0.05, **p < 0.01 and ***p < 0.001. For statistical analysis, 
GraphPad Prism was used.   
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5.2.3 Methods – results part 3.3 
5.2.3.1 Animals 
C57BL/6J and generated Pabpn1flox mice were bred in-house in the animal facility of the DKFZ 
under specific-pathogen-free (SPF) conditions in individually ventilated cages (IVCs). All 
animal procedures were performed according to protocols approved by the German 
authorities, Regierungspräsidium Karlsruhe (Nr. A-23/17, Z110/02, DKFZ299, G-256/16).  
5.2.3.2 Testing of gRNA efficiency 
Cloning of the px330 Cas9 vector 
Oligos encoding the target-specific part of the crRNA were ordered for expression of full-length 
gRNAs (Table 5.30, Sigma-Aldrich; design gRNA A: 
http://crispor.tefor.net/crispor.py?batchId=aQ9aKiq6R1spZW5ypsBG; design gRNA B: 
http://crispor.tefor.net/crispor.py?batchId=idFOo1VhuwIGjPTeLMe3) in the px330 Cas9 
vector. The respective oligos were annealed for 2 h (starting at 95°C continuously cooled to 
RT). The px330 Cas9 vector was digested with BbsI enzyme for 2 h at 37°C. Annealed oligos 
and the digested px330 Cas9 vector were purified by agarose gel electrophoresis (2% for 
oligos; 1% for vector). Gels were prepared by boiling a suspension of 1-2% agarose in 1x TBE 
buffer. After addition of 30 µg ethidium bromide per 100 ml, the solution was filled in a gel tray 
containing a comb. Before loading, PCR products were mixed with loading buffer containing 
bromophenol blue. PCR fragments were separated by applying 120 V to the gel. Finally, DNA 
fragments were visualized using an UV transilluminator, and gels were documented using a 
camera system. Subsequently, gel extraction using the QIAEX II Gel Extraction Kit according 
to manufacturer’s guidelines (elution in 20 µl) was performed. 100 ng digested vector were 
ligated with 1.2 ng annealed oligos for 1.5 h at 22°C using T4 ligase. Bacterial (E. coli) 
transformation was performed with the ligated px330 Cas9 vectors encoding for Cas9 and the 
inserted oligos, which in the vector are fused to the residual gRNA sequence, leading to 
expression of a full-length single-molecule gRNA. Transformed bacteria were plated on agar 
plates (containing 100 µg/ml ampicillin) and incubated overnight at 37°C. The next day, 5 
colonies were picked per construct, and colony PCR (Table 5.31) was performed using the 
amplification program indicated in Table 5.32. Successful integration of target sequence oligos 
in the px330 Cas9 vector leads to a product of approximately 500 bp. Presence of this product 
was verified by agarose gel electrophoresis (1%). Positive clones were used for overnight 
culture and subsequent DNA plasmid Mini-prep using the Macherey Nagel NucleoSpin 
Plasmid Kit according to manufacturer’s protocols. Enzymatic digestion was used to test for 
oligo integration using the enzymes BbsI and EcoRI. Re-ligation of px330 Cas9 vector without 
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oligo integration leads to 2 products after the digestion step (3.2 kb and 5.3 kb). Successful 
oligo integration leads to abrogation of the BbsI restriction enzyme sites. Enzymatic digestion 
therefore leads to generation of only one 8.5 kb product. Digestion was performed for 2 h at 
37°C. Product size was analyzed by agarose gel electrophoresis (1%).  
Table 5.30: gRNA and reporter oligos  
Oligo Forward sequence Reverse sequence 
gRNA A1 CACCgagctgataatcgccccaaga AAACtcttggggcgattatcagctC 
gRNA A2 CACCgttcttggggcgattatcagc AAACgctgataatcgccccaagaaC 
gRNA A3 CACCgttcctaagtcctaactaaa AAACtttagttaggacttaggaac 
gRNA B1 CACCgttaaactgggattagacttc AAACgaagtctaatcccagtttaaC 
gRNA B2 CACCgtgactggcctaacttgagct AAACagctcaagttaggccagtcaC 
gRNA B3 CACCggcctaacttgagctgggcg AAACcgcccagctcaagttaggcc 
Reporter A 
cgGTCTGTACCCTTCTTGGGGC
GATTATCAGCTGGCATACgtaTG
GAGACCCTTTAGTTAGGACTTA
GGAACTGACTG 
CAGTCAGTTCCTAAGTCCTAACTAA
AGGGTCTCCAtacGTATGCCAGCTG
ATAATCGCCCCAAGAAGGGTACAG
AC 
Reporter B 
cgCTCAGAATTAAACTGGGATTA
GACTTCAGGTTTATACCACCAT
GACTGGCCTAACTTGAGCTGGG
CGTGGTGGaattcg 
cgaattCCACCACGCCCAGCTCAAGT
TAGGCCAGTCATGGTGGTATAAAC
CTGAAGTCTAATCCCAGTTTAATTC
TGAG 
 
Table 5.31: Colony PCR px330 Cas9 vector, Fisher BioReagentsTM Taq DNA Polymerase, Buffer B and MgCl2 
provided with polymerase 
Component Amount (µl) 
Buffer B  5 
MgCl2 (25 mM) 5 
Fwd primer (respective fwd gRNA oligo) 0.3 
Rev primer (px330_rev: gtactgccaagtaggaaagtcc) 0.3 
dNTPs (10 mM) 0.5 
TaqPol  0.5 
H2O 38.4 
 
Table 5.32: Colony PCR amplification program 
Step Temperature Time Number of cycles 
Denaturation 95°C 5 min  
Amplification 
95°C 
62°C 
72°C 
20 s 
30 s 
30 s 
30 
Final elongation 72°C 2 min  
Storage 4°C ∞  
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Cloning of the pCRISPR-Report vector 
In addition, oligos encoding for targeting sequences (Table 5.30, Sigma-Aldrich) were ordered 
for cloning into the pCRISPR-Report vector for gRNA testing. These oligos were annealed and 
purified by gel extraction as previously described (see “Cloning of the px330 Cas9 vector”). 
The pCRISPR-Report vector was digested using BstBI and NruI and purified by gel extraction 
as previously described (see “Cloning of the px330 Cas9 vector”). 100 ng digested vector were 
ligated with 1.2 ng annealed oligos for 1.5 h at 22°C using T4 ligase. Bacterial (E. coli) 
transformation was performed using the ligated pCRISPR-Report vectors encoding for lacZ 
fragments separated by targeting sequences that are equivalent to the mouse Pabpn1 
targeting sequences for upstream gRNAs A and downstream gRNAs B. Transformed bacteria 
were plated on agar plates (containing 100 µg/ml ampicillin) and incubated overnight at 37°C. 
The next day, 5 colonies were picked per construct, and colony PCR (Table 5.33) was 
performed using the amplification program indicated in Table 5.32. Successful integration of 
oligos in the the pCRISPR-Report vector leads to a product of approximately 900 bp length. 
Presence of this product was verified by agarose gel electrophoresis (1%). Positive clones 
were used for overnight culture and subsequent DNA plasmid Mini-prep using the Macherey 
Nagel NucleoSpin Plasmid Kit according to manufacturer’s protocols. Enzymatic digestion was 
used to test for oligo integration using the enzymes SnaBI (pCRISPR-Report for testing of A 
gRNAs) or EcoRI (pCRISPR-Report for testing of B gRNAs). Re-ligation of pCRISPR-Report 
vector without oligo integration leads to 1 product after the digestion step (7.4 kb). Successful 
oligo integration leads to presence of the respective restriction enzyme sites. Enzymatic 
digestion leads to generation of two products (A: 0.8 kb + 6.6 kb; B: 1.2 kb + 6.2 kb). Digestion 
was performed for 2 h at 37°C. Product size was analyzed by agarose gel electrophoresis 
(1%). Positive clones were selected and overnight culture and subsequent DNA plasmid Midi-
prep using the Macherey Nagel NucleoBond Xtra Midi Plasmid Kit according to manufacturer’s 
protocols was performed.  
Table 5.33: Colony PCR pCRISPR-Report vector, Fisher BioReagentsTM Taq DNA Polymerase, Buffer B and MgCl2 
provided with polymerase 
Component Amount (µl) 
Buffer B  5 
MgCl2 (25 mM) 5 
Fwd primer (respective fwd reporter oligo) 0.3 
Rev primer (lacZ_rev: ttacccgtaggtagtcacgca) 0.3 
dNTPs (10 mM) 0.5 
TaqPol  0.5 
H2O 38.4 
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Reporter assay 
25,000 HeLa cells/well were seeded in 12-well plates in DMEM GlutaMAX (+10% FCS, +1% 
Pen/Strep). A total of 27 wells were seeded (3 wells/condition, 6 gRNAs, 2 negative controls, 
1 positive control à 9*3 = 27). Cells were incubated for 2-3 h. Transfection mix was set up 
(Table 5.34) and mixed with 100 µl RotiFect mix (5 µl RotiFect in 100 µl Opti-MEM I) and 
incubated for 30 min at RT. 200 µl transfection mix were add per well, and cells were incubated 
overnight at 37°C. The next day, cells were washed with PBS and lysed using 1x passive lysis 
buffer in the wells for 3 min at RT. Plates were put on ice, and lysates were transferred to 
Eppendorf tubes. Lysates were centrifuged at 13,000 rpm for 5 min at 4°C. 30 µl supernatant 
per replicate and condition were transferred to a fresh Eppendorf tube, and 700 µl Z-buffer 
(0.35% 2-Mercaptoethanol) were added and mixed. Subsequently, 200 µl ONPG solution were 
added per tube and incubated at RT until a yellow color-shift was observed. Reaction was 
stopped using 500 µl 1 M NaOH per tube, and the signal was measured (420 nm). For 
luciferase measurements, 10 µl of lysate per replicate and condition were pipetted into a white 
96-well plate. This plate was measured in a luciferase detection instrument (Perkin Elmer 
Wallac 1420 Victor2 Microplate Reader). To calculate normalized signals, the following 
equation was used: LacZ/Luciferase*mean(Luciferase).  
Table 5.34: Transfection mix  
Component Amount  
pUHC131.1 (Luciferase Plasmid) 200 ng 
px330 Cas9 400 ng 
pCRISPR-Report 400 ng 
Opti-MEM I Fill up to 100 µl 
 
5.2.3.3 Easi-CRISPR 
crRNA, tracrRNA and ssDNA template molecules were ordered from IDT (Table 5.35). crRNA 
and tracrRNA were reconstituted in microinjection buffer to a final concentration of 100 µM. 
Cas9 protein was diluted in microinjection buffer to a final concentration of 500 ng/µl. The 
ssDNA template was reconstituted in 30 µl H2O. All stocks were aliquoted and stored at -80°C. 
crRNA and tracrRNA were diluted to 6.1 µM, and 15 µl crRNA + 15 µl tracrRNA were mixed 
and incubated for 2 min at 94°C and 10 min at RT. The generated 3.1 µM crRNA:tracrRNA 
mixes were aliquoted and stored at -80°C. For pronucleus injections, 1 µl crRNA_A3:tracrRNA 
(final 0.31 µM) was mixed with 1 µl crRNA_B2:tracrRNA (final 0.31 µM), 1 µl ssDNA template 
(final 10 ng/µl), 1 µl Cas9 protein (final 50 ng/µl) and 6 µl microinjection buffer. Injections were 
performed by the Transgenic Service of the DKFZ.  
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Table 5.35: IDT constructs  
Construct Sequence 
crRNA A3 GTTCCTAAGTCCTAACTAAA  
crRNA A3 TGACTGGCCTAACTTGAGCT 
ssDNA 
megamer 
GGCGATTATCAGCTGGCATTTGACCTTCAAGTCTTAACACTTTTCAGTT
GGAGACCCTTTATAACTTCGTATAGCATACATTATACGAAGTTATaAGcT
TAGGACTTAGGAACTGACTGGTGGCTGTAAGGGAGGGAGTTCTTTAAA
AATGTTAGATTTCAGTCCATTCTGTTTTGTTTGCTTTGAGGCATTTCAGC
TAAAGCTGAATAGAGACTCGACTTGAAAAACGTAAAATCTTAACACCGT
TTTTTATGGTCTTTTAAGAGGTAGTTTCTCTAATGTATATTGAAACCTAC
TATGTGCTAAACACTGTTATAGGTAATTGGTATAGTAGAAGTATACCCA
AAATTTAGCCTGCGGGTGGAAGTGTGTGTGTATTGATCGAGCAGAAGA
TGTGCTTGCCTAAGGTAATTTTTTTCCCCTCTAAAAGCTGGCCCAGTGA
TCATGTCTCTTGAGGAGAAGATGGAGGCTGATGCCCGCTCTATCTACG
TTGGCAATGTATGTATCAAGGAATAGTCTGCTTTGGGTTTTGGGGGGG
ACTTTTGTTTCTTATTCCTTACTTTGTTATGTGTTCAAATTGGAGTTTCC
CCAGTACTTGTCAAGTGTTCCTTTCCTTAGGTGGACTATGGTGCAACA
GCAGAAGAGCTGGAAGCCCATTTTCATGGCTGTGGTTCAGTCAACCGT
GTTACTATACTCTGTGACAAATTTAGTGGCCATCCCAAAGGGTAAGTAG
GAGGATAAGTTGAGATCATTTTACTCACATTTTAAAAATACGTGAAAAAT
ACATGAGCTCGGAATCGAACCTAGGACCTTGAACATGCTGATGTGTGC
TGTCAATCTAGTCAAAAGAGTGTTAACTCGTTTTAAAGGTTCTTATATAT
GTGGTCGGTTGGTTTTGTTTTCAAGTCAGAGTTTCTCTGTTTAACCCTG
GCTGTACTGGAATTACCTCTATAGACCAGGCTGGCCTTAAACTCAGAA
TTAAACTGGGATTAGACTTCAGGTTTATACCACCATGACTGGCtCTAgA
CTTGAATAACTTCGTATAGCATACATTATACGAAGTTATGCTGGGCGTG
GTGGTGCACGCCTTTAATCCCAGCACTTGGGAGACAGAGGCAGGGAT
TTC 
 
5.2.3.4 Genotyping 
For genotyping of offspring, tails were digested, and tail DNA was purified using the Qiagen 
DNeasy Blood and Tissue Kit following manufacturer’s instructions (elution in 100 µl). 5 
different PCR and digestion approaches were used to validate loxP integration (Table 5.36). 
DreamTaq Green PCR Mastermix was used for PCR amplification (Table 5.37, Table 5.38, 
Table 5.39). PCR products were analyzed by agarose gel electrophoresis (Table 5.40) and 
purified using the QIAquick PCR Purification Kit according to manufacturer’s guidelines. 
Enzyme digestion was performed at 37°C for 1.5 h and analyzed using agarose gel 
electrophoresis (Table 5.41). For mice exhibiting correct integration, PCR 2 and PCR 4 were 
repeated, and agarose gel electrophoresis was performed. The loxP band was excised and 
purified using the Qiagen QIAquick Gel Extraction Kit according to manufacturer’s guidelines. 
Purified PCR products were sent for sequencing by Eurofins together with the respective rev 
primer (PCR 2) and fwd primer (PCR 4) to exclude presence of point mutations. 
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 Table 5.36: Overview genotyping PCRs and digestion approaches (P: program) 
PCR Validation Forward primer Reverse primer P Enzyme  
PCR 1 Integration upper loxP 
CGATTATCAGCT
GGCATTTGACC 
GGCAAGCACATC
TTCTGCTCG P 1 HindIII-HF 
PCR 2 Integration lower loxP 
ACCTTGAACATG
CTGATGTGTGC 
GAGACACTTAACA
GGCAAAACCTAC P 1 XmnI 
PCR 3 
Upper and 
lower loxP on 
same allele 
CGATTATCAGCT
GGCATTTGACC 
GAGACACTTAACA
GGCAAAACCTAC P 2 
HindIII-HF 
+ XmnI 
PCR 4 
Upstream 
localization 
correct 
AAGCCGGGGAC
CTTGAATG 
GGCAAGCACATCT
TCTGCTCG P 2 HindIII-HF 
PCR 5 
Downstream 
localization 
correct 
ACCTTGAACATG
CTGATGTGTGC 
ACTCTCACTGCCA
CCAACTCC P 2 XmnI 
 
Table 5.37: Genotyping PCR mastermix  
Component Amount  
DreamTaq Green PCR Mastermix 25 µl 
Fwd primer (100 µM) 0.3 µl 
Rev primer (100 µM) 0.3 µl 
DNA 100 ng 
H2O up to 50 µl 
 
Table 5.38: PCR program 1 (P 1) 
Step Temperature Time Number of cycles 
Denaturation 95°C 2 min  
Amplification 
95°C 
62°C 
72°C 
30 s 
30 s 
45 s 
35 
Final elongation 72°C 5 min  
Storage 4°C ∞  
 
Table 5.39: PCR program 2 (P 2) 
Step Temperature Time Number of cycles 
Denaturation 95°C 2 min  
Amplification 
95°C 
62°C 
72°C 
30 s 
30 s 
1 min 
35 
Final elongation 72°C 5 min  
Storage 4°C ∞  
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Table 5.40: Expected amplicon sizes  
PCR Wildtype (bp) loxP (bp) 
PCR 1 365 401 
PCR 2 435 471 
PCR 3 1206 1278 
PCR 4 562 598 
PCR 5 1477 1513 
 
Table 5.41: Expected product sizes after digestion 
PCR Wildtype (bp) loxP (bp) 
PCR 1 365 95 + 306 
PCR 2 435 228 + 242 
PCR 3 1206 
Both alleles: 93 + 940 + 244 
Upstream only: 93 + 1184 
Downstream only: 1033 + 244 
PCR 4 562 254 + 308 
PCR 5 1477 231 + 1282 
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6 Appendix 
6.1 Appendix figures 
 
Appendix Figure 1: Gel images showing genotyping results for PCR 1 (A) and digestion of PCR 1 (B). 
 
 
Appendix Figure 2: Gel images showing genotyping results for PCR 2 (A) and digestion of PCR 2 (B). 
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Appendix Figure 3: Gel images showing genotyping results for PCR 3 (A) and digestion of PCR 3 (B). 
 
 
Appendix Figure 4: Gel images showing genotyping results for PCR 4 (A) and digestion of PCR 4 (B). 
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Appendix Figure 5: Gel images showing genotyping results for PCR 5 (A) and digestion of PCR 5 (B). 
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6.2 List of abbreviations 
Abbreviation Explanation 
% percent 
°C degrees Celsius 
AA amino acid 
aKG a-ketoglutarate 
AGM aorta-gonad-mesonephros 
AGO argonaute  
aHSC active HSC  
AML acute myeloid leukemia  
APA alternative polyadenylation  
APC allophycocyanin 
BM bone marrow 
c-Kit  v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog  
c-Myc cellular myelocytomatosis homologue 
CAR cells CXC-chemokine ligand 12-abundant reticular cells 
CD cluster of differentiation 
CDK  cycline-dependent kinase 
CFIIm cleavage factor IIm  
CFIm cleavage factor Im  
CFU colony forming unit  
CFU-S spleen colony forming unit  
Chr chromosome 
circRNAs circular RNAs  
CLL chronic lymphocytic leukemia 
CMP common myeloid progenitor 
CpG  cytosine phosphodiester bond guanine 
CPSF cleavage and polyadenylation specificity factor  
CR-APA coding region APA 
CRE cAMP response elements  
CREB cAMP response element binding protein  
CRISPR clustered, regularly interspaced, short palindromic repeat  
crRNA CRISPR RNA  
CstF cleavage stimulatory factor 
Ct cycle threshold 
Ctsc CathepsinC  
CXCL12 CXC-chemokine ligand 12  
CXCR4 CXC-chemokine receptor 4  
Cy5 cyanine 5 
Cy7 cyanine 7 
DAPAS differentially used APA sites  
DC dendritic cell 
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dCas9 dead-Cas9  
DEG differentially expressed gene 
dHSC dormant HSC  
DNA deoxyribonucleic acid 
Dnase  deoxyribonuclease 
dPDUI differential polyA site usage index  
DSB double-strand break 
Easi-CRISPR efficient additions with ssDNA inserts-CRISPR 
ESC embryonic stem cell  
EST expressed sequence tag 
FACS fluorescence-activated cell sorting  
FASN fatty acid synthase 
FAO fatty acid oxidation 
FOXO forkhead box protein O 
g gram 
GFP  green fluorescent protein 
Gln glutamine  
Gls glutaminase 
Glu glutamate  
GMP granulocyte-macrophage progenitor 
GO  gene ontology 
gRNA guide RNA 
Gy  Gray 
h hour(s) 
HDR homology-directed repair  
HIF hypoxia-inducible factor 
HSC hematopoietic stem cell 
HSPC hematopoietic stem and multipotent progenitor cell 
ICR imprinting control region 
IFN interferon 
IG-DMR intergenic differentially methylated region 
IGV integrative genomics viewer 
indel insertion-deletion  
iPSC induced pluripotent stem cell 
IVC individually ventilated cage 
kb kilo base pairs 
KD knockdown  
KO knockout  
LacZ b-galactosidase 
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